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NER plays an important role in remediating DNA damage. Latimer et al., have 
previously shown nucleotide excision repair (NER) to be intrinsically deficient in stage I 
sporadic BC by function and gene expression. Previous work performed on 12 
isogenically matched stage I tumors and non-tumor adjacent (NTA) samples identified 2 
types of NTA tissue with regard to functional NER. One type that represented 75% of the 
samples, had lower NER capacity, similar to the tumor (Low: Low pair). The other type 
had high NER relative to the tumor (High: Low pair). Two isogenic NTA/tumor cell line 
pairs representing these 2 types of NTA were identified by the UDS assay for 
downstream molecular analyses. Expression of the 20 canonical NER genes using 
microarray analysis was consistent with functional NER of the Low: Low and High: Low 
cell lines. Findings from expression microarray were validated using RNA sequencing, 
where 16/20 genes were significantly higher in the NTA line of the High: Low pair 
compared to the tumor line, but none of the 20 genes were significantly different in 
expression among the Low: Low pair. Protein expression was also evaluated for RPA3, 
XPC and RAD23B, however only RAD23B showed promising trends. We believe the 
mechanism of downregulation of NER genes was epigenetic based on downregulation in 
multiple genes and multiple patients. DNA methylation was explored as the mechanism 
of this phenomenon. Using MethylationEPIC array, analysis of promoter level, gene level 
and CpG island level methylation no correlation between methylation and gene 
expression in our cell line pairs. DDB1 showed differential methylation among the both 
High: Low and Low: Low pairs but in a direction opposite to gene expression, indicating 
possible inhibition of a repressor at its promoter region. RNA sequencing allowed us to 
explore the presence of single nucleotide variants in the 20 NER genes along with other 
BC genes. We discovered notable variants in ERCC2, ERCC5, ERCC6 as well as in 
BRCA1, CHK1 and ATR, which warrant further investigation using The Cancer Genome 
Atlas. Finally, we were able to construct person-specific maps or our own 
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1.1 Problem Background 
1.1.1 Breast Cancer 
Breast Cancer is the leading cause of mortality among women. In 2017, 40,610 
deaths and an additional 252,000 new incidences of invasive breast cancer have been 
estimated,  although earlier detection by regular mammograms has helped lower the stage 
at diagnosis (R. Siegel, Naishadham, & Jemal, 2013). The etiology of sporadic breast 
cancer cases, i.e., non-germline breast cancer, is still unknown and can be attributed to 
various lifestyle factors, environmental factors such as estrogenic chemicals in consumer 
products (e.g., bis-phenol A), as well as DNA-damage-causing agents (Ayyanan et al., 
2011). These factors are still not causatively correlated to breast cancer. Previous studies 
in our lab have shown intrinsic deficiency of nucleotide excision repair (NER) capacity in 
19/19 Stage I tumors compared to non-diseased breast reduction epithelium, as measured 
by the functional Unscheduled DNA Synthesis (UDS) assay (Latimer et al., 2010). This 
study has established a solid foundation of the role of NER in the etiology of sporadic 
breast cancer for the first time. Understanding the etiology of sporadic breast cancer is 
the ultimate objective of research at Dr. Latimer’s laboratory, and calls for further 
evidence on the etiology of mechanism of regulation of NER. 
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1.1.2 Non-tumor Adjacent Breast 
 The pathologically normal tissue surrounding a solid tumor (which we call the 
non-tumor adjacent or NTA) has been traditionally used as a ‘normal control’ for 
studying cancer etiology. Though the theory of field carcinogenesis is gaining acceptance 
among cancer researchers, some recent studies on breast cancer still used the seemingly 
normal tissue adjacent to the breast as a normal control (Faraglia et al., 2003; Fu, Mao, 
Wang, Ding, & Li, 2017). Therefore, solid evidence is needed to show the genetic non-
normalcy of the NTA breast, especially from an NER perspective which is unprecedented 
in literature to date to our knowledge. 
1.1.3 Model for breast carcinogenesis 
Carcinogenesis is an incremental process that results from accumulation of 
mutations or mutation-like events over decades (Vogelstein & Kinzler, 1993). This 
explains why majority of cancers develop later in life (with the exception of childhood 
cancers, which are more often than not, a result of an inherited germ line mutation). 
Breast cancer researchers in the past have illustrated a model of the events that are 
involved in the trajectory of transformation from normal breast to neoplastic (Bieche & 
Lidereau, 1995). However, this model is complicated and does not pinpoint specific 
driver events, unlike certain models like the one for colon cancer by Vogelstein et. al. 
(1993).  Therefore, further experimental evidence is necessary to link mutations and 
epigenetic changes to histopathological changes in breast cancer. 
1.1.4 Regulation of Nucleotide Excision Repair in breast cancer 
In 2010, Latimer et al., shown a correlation between NER and sporadic breast 
cancer.  Stage I breast tumor explants were shown to be intrinsically deficient in their 
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NER capacity compared to that of normal breast epithelium, as measured by the 
functional UDS assay. This intrinsic loss of NER capacity in early stage breast cancer is 
most likely epigenetic in nature, due to three major lines of observations - reduction in 
the expression of multiple genes (19/20), this phenomenon being observed in multiple 
patient samples and NER capacity being tissue specific (Latimer et al., 2003). The exact 
mechanism behind this epigenetic regulation of NER is unknown. 
Methylation of cytosine bases in the CpG-rich gene promoter regions has been 
known to be major mechanism of transcriptional regulation. Methylation is often 
associated with carcinogenesis by either inactivation of tumor suppressor genes or 
activation of proto-oncogenes (Wajed, Laird, & DeMeester, 2001). Although there have 
been studies showing the role of methylation in NER genes (Sabatino et al., 2010; A. 
Zhang et al., 2017; M. Zheng et al., 2017) as well as in breast cancer (Gao, 
Widschwendter, & Teschendorff, 2018; Nindrea, Harahap, Aryandono, & Lazuardi, 
2018; S. Zhang et al., 2018), the role of methylation has not been studied from an NER 
perspective in breast cancer etiology to date.  
1.2 Study Objective, Hypotheses and Aims 
Our long-term goal is to understand the etiology of sporadic breast cancer.  We 
hypothesize that reduction in NER capacity in early stage breast cancer occurs via 
epigenetic regulation of multiple NER genes. The objective of this study was to develop a 
scheme of the sequence of alterations (mutations as well as epimutations) leading to the 
formation of the tumor by studying tumor/NTA pairs. To accomplish this, we explored 
the existence of shared alterations between the NTA cell lines (NTALs) and their 
matched breast tumor cell lines (BTLs). Preliminary data on the primary NTA samples 
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and their matched stage I tumors showed 2 types of NTA. One type manifested low NER 
capacity similar to the tumor in 9/12 of the pairs (defined as Low NTAL: Low BTL pair 
or Low: Low). The second type showed a higher repair capacity than the tumor, which 
was not significantly different from the non-diseased breast tissue (hence defined as High 
NTAL: Low BTL pair or High: Low). 
 
Specific Aim 1: Assess the NER capacity of the available NTALs and their matched 
early-stage BTLs using a functional assay, the 3H-thymidine-based UDS assay, in order 
to identify representative Low: Low pairs and High: Low pairs. 
 
Hypothesis 2: The gene expression pattern of the 20 canonical NER genes will correlate 
with the UDS functional assay data. 
Specific Aim 2: Determine the expression pattern of the 20 canonical NER genes in the 
selected early-stage Low: Low pairs and High: Low pairs using gene expression 
microarray analyses and validate these results using RNA sequencing 
 
Hypothesis 3: The differences in expression levels for some of the 20 canonical NER 
genes between tumors and their matched NTA lines will be similar to the expression 
levels of their respective protein. 
Specific Aim 3: Examine expression of chosen NER proteins using Western Blotting 
 
Hypothesis 4: The underlying mechanism for the differences in NER capacity and gene 
expression patterns is epigenetic in nature. 
Specific Aim 4a: Perform methylation arrays on DNA derived from the Low: Low and 
High: Low pairs. 
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Aim 4b: Use RNA sequencing data on the selected Low: Low and High: Low pairs to find 
mutations, if they exist, in the 20 NER genes.  
1.3 Study Significance  
1.3.1 Studying early stage breast cancer for understanding etiology 
 Along with being the leading cause of mortality among women, breast cancer is 
also an expensive problem, manifested not only in terms of cost to families due to lost 
wages, but also in cost to treatment. These costs increase with each increase in stage of 
breast cancer (Blumen, Fitch, & Polkus, 2016). Although advancement in diagnostic 
technologies are now allowing for early detection of breast cancer and timely treatment 
increasing survival, there are still 3 million women walking with breast cancer in the US 
(Howlader et al., 2018). With screening mammography, we have been able to lower the 
average stage at diagnosis to stage I in the US within the past decade. This emphasizes 
the importance of studying early stage tumors, as it enables us to go a step closer to 
finding the etiology of sporadic breast cancer occurrence and allows us to determine the 
impact of treatment of early stage breast cancer. 
1.3.2 Importance of adjuvant radiation after lumpectomy 
 Breast conserving surgery or lumpectomy with adjuvant radiation is usually the 
treatment modality for early stage breast cancers (Gradishar et al., 2015). Clinical trials 
have shown that lumpectomy followed by radiation has similar outcomes and survival 
rates as compared to a total mastectomy upon treatment of early stage breast cancer (B. 
Fisher et al., 2002; Overgaard et al., 1999). However, there is still a debate as to the dose, 
area as well as duration of radiation therapy given to women undergoing tumor-removal 
surgery, where often times whole breast irradiation has been deemed either unnecessary 
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or as providing similar outcomes as partial irradiation (Livi et al., 2010; Vicini et al., 
2003; Whelan et al., 2002). Our study provides solid evidence regarding the pivotal role 
of adjuvant whole breast irradiation after lumpectomy, as we show that the NTA breast 
represents a pre-neoplastic stage in breast carcinogenesis. This indicates that patients with 
low DNA repair in their NTA breast might have a higher rate of recurrence owing to the 
genomic instability of the breast tissue that is left behind, if not taken care of by adjuvant 
radiation therapy. Our study also contributes towards settling the debate on the width of 
margins during tumor resection, as there is still a widespread practice of trying not to get 
wider margins for cosmetic and aesthetic purposes, with the preference of margin width 
depending on the hospital and/or surgeon chosen for surgery. 
1.4 Strengths of the Study 
1.4.1 Clinical relevance 
 One major strength of this study is that it is clinically relevant. This study could 
provide the rationale for a test for recurrence in breast cancer patients treated with 
lumpectomy. After validation with a large study, patients could be screened for the NER 
capacity or NER gene expression of their NTA breast sample. Patients’ risk of recurrence 
could be predicted based on the functional NER capacity detected in the NTA breast, 
where lower NER capacity would indicate higher risk of recurrence. This study will 
contribute towards treatment strategies for increasing overall survival in breast cancer 
patients, where patients showing low NER capacity in their NTA tissue could be treated 
with either longer radiation treatments or recommended a total mastectomy. The patients 
with normal NER capacity in the NTA could be saved the longer and radical treatments, 
thus making individualized treatment for breast cancer plausible. 
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1.4.2 Unique model system 
 Studies on breast cancer have been traditionally performed on commercially 
available cell lines that have been in use for years and have been established from pleural 
effusion samples obtained from patients having stage IV metastatic breast cancer. 
Moreover, these cell lines have been immortalized using viruses, SV40, hTERT and other 
transforming agents to prevent them from reaching senescence. Hence, commercially 
available cell lines are poor representatives of in-vivo early stage breast cancer and are 
not ideal model systems for studying etiology of breast cancer. This study has been 
performed using early stage sporadic breast cancer cell lines established by the patented 
tissue engineering system developed by Dr. Latimer’s lab. We have a unique advantage 
of having a repository of extended explants and cell lines housing about 150 cell lines 
established from tissues representing various stages of breast cancer as well as 
pathologically normal adjacent breast and non-diseased breast.  
1.4.3 NER in NTA breast in breast cancer 
 We are the first group, to our knowledge, to show two different types of NTA 
tissue in the breast based on NER. NER-related abnormal alterations like polymorphisms, 
gene expression changes and changes in epigenetic regulators have been documented in 
studies involving tumor and adjacent samples in breast cancer (Faraglia et al., 2003; X. 
Fu et al., 2017), colorectal cancer (Z. Zhao, Zhang, & Li, 2017), bladder cancer (Zhi et 
al., 2017) and gastric cancer (He et al., 2012). However, all of the above studies have 
used adjacent tissues to the tumor as normal controls for their study. Nevertheless, a few 
studies document abnormalities in the adjacent sample as well (Faraglia et al., 2003; Gao 
et al., 2018; Kayser et al., 2005). Therefore, we are the first group reporting a pathway-
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wide alteration in the NTA breast that is shared with the tumor the majority of the time, 
and that this might be a contributing factor in local recurrence, and at the same time may 
serve as the basis to continue adjuvant radiation therapy after lumpectomy. Where the 
NER capacity is normal in the NTA, these patients could be given the normal standard 
treatment that is currently given to early stage breast cancer patients. A larger study could 
then confirm the effect of individualized treatment given to early stage breast cancer 
patients after screening them based on their NTA tissue’s NER capacity on 5- and 10- 
year survival rate. 
1.5 Limitations of this study  
1.5.1 Sample Size 
 The major limitation of this study is the limited sample size. The study was 
designed with the aim of using cell lines as model systems, as they are easily manipulable 
and this was a requirement in order to study regulation of the NER pathway. Preliminary 
studies (on which this study is based) were conducted on primary cultures of tissues from 
isogenically matched tumor-NTA pairs. The fact that cell lines could be established from 
these was something that was realized and tried at a later point of time by Dr. Latimer in 
her lab. Establishment of cell lines from primary tissues without the use of immortalizing 
agents is extremely challenging, and maintenance of these cell lines is taxing, time-
consuming and intensive in terms of reagents and resources. Initially, an ideal sample 
size of at least 3 pairs per group of High: Low and Low: Low pairs was proposed for this 
study. However, we had only one representative cell line pair available for each of our 
groups. We therefore proceeded with in-depth molecular analysis of these 2 cell line pairs 
(4 cell lines) for the purpose of this study. The advantage of this approach lies in the 
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creation of person-specific maps of common and uncommon genetic changes between the 
NTA and the tumor, with the NTA reflecting pre-existing changes before transformation. 
In addition, the Lab is currently working on an IRB for obtaining fresh tissues from early 
stage breast cancer surgeries to identify more putative representative pairs for the 
aforementioned groups and establish cell lines from the same. The molecular analyses 
conducted in this study will be applied to the new cell line pairs as well in near future to 
gain power for the current study. 
1.6 Summary 
 This study aims to address one of the most pressing problems in healthcare in the 
current time.  Breast cancer is still the leading cause of mortality among women in the 
USA, and our study aims to contribute towards strategies in the reduction of the same, by 
providing evidence that shows the NTA breast to be a pre-neoplastic stage in breast 
carcinogenesis. We therefore will be able to establish a temporal scheme or a 
“Vogelsteinogram” of the events that take place during breast carcinogenesis and show 
that loss of NER is an important event in this scheme. This will help fulfill our long-term 







2.1 DNA Repair 
2.1.1 DNA Damage  
 Maintaining the integrity of the genome is essential for life. This is implemented 
by ensuring the fidelity of deoxyribonucleic acid or DNA, the blueprint of life (Jeggo, 
Pearl, & Carr, 2016). DNA in our cells is subject to damage from endogenous as well as 
exogenous agents. A cell is estimated to incur about 70,000 damage lesions per day in its 
DNA (Tubbs & Nussenzweig, 2017). Failure to ensure DNA fidelity can result in 
accumulation of damage inflicted by such agents, leading to the damage becoming 
permanent and therefore leading to formation of mutations. 
2.1.1.1 Endogenous DNA damage 
 Endogenous processes that result in DNA damage primarily constitute replication 
errors, spontaneous alterations to the chemical structure of the bases by chemicals and 
reactive oxygen species. Sometimes, during the replication of DNA in the S-phase of the 
cell cycle when a cell prepares for division, wrong bases are inserted thereby creating a 
mismatch in the base paring of nucleotides. The rates of generation of mismatches during 
DNA replication are in usually within the range of 1 x 10-8 to 1 x 10-6, in spite of the 




become mutations and affect the stability of the genome (Loeb & Monnat Jr, 2008). 
Another source of endogenous DNA damage is oxidation via reactive oxygen species, 
that are generated during normal metabolic functions performed by the cell, including 
those by the mitochondria. These reactions lead to the formation of superoxide, peroxide 
and hydroxyl radicals, that are known to alter about 20,000 nucleotides each day in the 
mammalian genome (Donigan & Sweasy, 2009). Depurination alters the purine 
nucleotides thereby giving rise to abasic sites and ultimately resulting in strand breakage 
(An et al., 2014). Endogenous DNA damage is also caused due to spontaneous chemical 
reactions that alter bases to offer a more chemically stable structure for the base. These 
reactions include deamination, depurination and oxidation. Deamination of cytosines 
convert them to thymine, methyl-cytosines to uracil, adenine to xanthine and guanines to 
hypoxanthine (Griffiths et al., 2005). These alterations are serious mutagenic events and 
are the targets of DNA repair mechanisms in the body. 
2.1.1.2 Chemical carcinogens 
Naturally occurring chemicals in the environment as well as those artificially 
made or produced as by-products of human activities can cause DNA adducts. Some 
intercalate into the base pairs of the helix leading to DNA damage. These chemicals are 
known carcinogens as their cancer-causing potential has been demonstrated by 
experiments on in-vitro as well as murine model systems (Rodgers, Udesky, Rudel, & 
Brody, 2018; Rudel, Ackerman, Attfield, & Brody, 2014). An example of these include 
chemicals from smoke like benzo[a]pyrene diol epoxide (Alexandrov, Rojas, & Rolando, 
2006). This is a polycyclic aromatic hydrocarbon that forms adducts with DNA after 




2.1.1.3 Ionizing radiation 
 Ionizing radiation is one of the major sources of external DNA damaging agents, 
inflicted by cosmic radiation from outer space. The risk of exposure to ionizing radiation 
increases with increases in altitude. People residing at high altitudes get exposed to 
higher levels of cosmic radiation than those at sea level (Friedberg, Walker, Siede, & 
Wood, 2005). Also, frequent air travelers, which includes pilots and flight crew are at a 
high risk for exposure and thereby at an increased risk for cancer (Sanlorenzo et al., 
2015). Another major source of ionizing radiation is X-rays and g-rays used in diagnostic 
technologies in clinics and hospitals. Numerous studies have reported the association of 
exposure to radiation via such diagnostic procedures and risk of breast cancer (S. Bhatia 
et al., 2003; Boice Jr, Preston, Davis, & Monson, 1991; Pijpe et al., 2012). Ionizing 
radiation causes either direct DNA damage by catalyzing bond breakage leading to single 
and double strand breaks, or cause DNA damage indirectly by generating reactive oxygen 
species (Lomax, Folkes, & O'neill, 2013).  
2.1.1.4 Ultraviolet radiation 
 Ultraviolet radiation or UV is another main source of exogenous DNA damage 
causing agents, the exposure to which occurs via sunlight. The UV spectrum can be 
divided into three segments, UV-A (315-400 nm), UV-B (290-315 nm) and UV-C (290-
100 nm). Among these, UV-C is the most destructive forms of UV light in terms of DNA 
damage, although it is mostly filtered out by the ozone layer in the earth’s atmosphere 
(S.-L. Yu & Lee, 2017). 
 DNA damage from UV light manifest in 6 forms which are now known products 




Two main types of by-products of UV radiation damage that are biologically significant 
in eukaryotes are cyclobutane pyrimidine dimers (CPDs) and 6,4-photoproducts. CPDs 
are two pyrimidine rings joined by two covalent bonds, whereas 6,4-photoproducts are 
made by one bond between 6’ end of one pyrimidine ring and 4’ end of the other 
pyrimidine ring. Both these UV products cause helix distortion and strand breaks, but 
6,4-photoproducts are more helix distorting than CPDs, although the latter occur more 
frequently. Damage to DNA by UV light has been extensively studied in the context of 
DNA repair, and therefore most germicidal lamps used for experiments studying DNA 
damage and repair use UV-C irradiation (Bykov, Hemminki, Sheehan, & Young, 1999; 
Osakabe et al., 2015; Rauth, 1986). 
 
 
Figure 0.1 Six types of lesions that are now known to be caused by UV damage to DNA. 
Two main lesions are cyclobutene pyrimidine dimers and 6,4-photoproducts. Along with these, 




Spore photoproduct (observed in certain bacteria), 8-oxoguanine (product of reaction with 
reactive oxygen species generated due to UV) and single strand breaks due to UV light. (Yagura 
et al., 2011) (Link to License: https://creativecommons.org/licenses/by/3.0/) 
 
2.1.2 Mammalian DNA repair mechanisms 
 Cells have evolved with specialized conserved mechanisms to prevent damage in 
DNA, thereby ensuring fidelity and integrity of DNA and the stability of the genome. In 
eukaryotes, there are 5 major DNA repair pathways, some of which are specific to the 
type of lesion occurring in DNA following exposure to damage-causing agent. These are 
base excision repair, mismatch repair, double strand break repair comprising of 
homologous recombination and non-homologous end joining, and nucleotide excision 
repair. 
2.1.2.1 Base excision repair 
 The base excision repair or BER pathway repairs non-helix distorting DNA 
damage, mostly resulting from endogenous damage of DNA, prior to DNA replication. 
These damages mostly result from endogenous processes like methylation, deamination, 
alkylation, oxidation and depurination (Krokan & Bjørås, 2013; Wallace, 2014). This 
pathway excises single bases that have been damaged with the help of specific enzymes 
that cleave the bond between deoxyribose sugar and the base. These enzymes are known 
as DNA glycosylases and were discovered first in E. coli by Lindahl  in 1974 (Lindahl, 
1974). Eleven distinct types of lesion-specific glycosylases are known and about 28 
genes are required for BER to function (Krokan & Bjørås, 2013) 
2.1.2.2 Mismatch repair 
 Mismatch repair (MMR) is a conserved DNA repair pathway that repairs 




mismatches caused due to a wrong base insertion by a DNA polymerase that escape the 
proof-reading mechanism of the polymerase (Kunkel & Erie, 2015). Mismatch repair also 
corrects for insertion or deletion loops, also called IDLs, that occur when DNA strands 
dislocate while replication due to slipping over each other. The steps involved in this 
pathway are recognition of the mismatch, excision and degradation of the strand 
containing the mismatch and re-synthesis of the strand (Jiricny, 2013). Mutations in 
genes involved in mismatch repair have been associated with microsatellite instability 
and lynch syndrome (hereditary non-polyposis colorectal cancer) (Richman, 2015).  
2.1.2.3 Homologous recombination 
 Homologous recombination is among the two major pathways (along with non-
homologous end joining) that repairs double strand breaks, gaps in DNA as well as cross 
links in DNA (Xuan Li & Heyer, 2008). This pathway uses the sister chromatid as a 
template to repair double strand breaks and hence is considered a more robust pathway 
which is free of errors compared to non-homologous end joining. Homologous 
recombination operates by location of the damage through the 5’ end and creates a 3’ 
overhang. This fragment locates the complementary sequence on the sister chromatid 
with the formation of a complex called the D-loop. After extension of the 3’ strand using 
the sister chromatid as the template, the complex is dissolved, and the repair process is 
completed by ligation of the newly synthesized strand with the parent (Jasin & Rothstein, 
2013; Krejci, Altmannova, Spirek, & Zhao, 2012). Mutations in the genes involved in 
homologous recombination have been implicated in ovarian and breast cancers, 




Poly-ADP-ribose polymerase or PARP1 inhibitors are now being used to exploit this 
specific vulnerability in DNA repair in these mutation carriers. 
2.1.2.4 Non-homologous end joining 
 Non-homologous end joining is the other double strand break repairing pathway. 
However, it is different from homologous recombination in the sense that it does not use 
a template for repairing the damaged strand. The broken strand is simply ligated repairing 
the break but not the flanking sequence, which makes this pathway prone to mutation 
with errors likely to be perpetuated. Whereas homologous recombination dominates 
during the S-phase of the cell cycle (involving DNA replication), non-homologous end 
joining mainly occurs during G1 and G2 phases of the cell cycle and is the dominant 
pathway for the repair of double strand breaks (Karanam, Kafri, Loewer, & Lahav, 2012). 
Repair by non-homologous end joining mainly occurs by identification of the break and 
subsequent binding of Ku proteins, which then leads to trimming of nucleotides around 
the break. This is followed by gap synthesis and ligation. The structure of the ends in the 
break determine the exact mechanism and proteins to be used for repair (Chang, 
Pannunzio, Adachi, & Lieber, 2017). Mutations in factors involved in non-homologous 
end joining have been implicated in certain lymphomas (Moshous et al., 2003) and also 
other cancer types like cancers of the breast, ovaries and the colon/rectum (F.-M. Hsu, 
Zhang, & Chen, 2012). 
2.1.3 Nucleotide Excision Repair 
 Nucleotide Excision Repair (NER) is one of the major DNA repair mechanisms. 
Also called ‘long-patch repair’, this pathway repairs inter and intra-strand crosslinks in 




4-PPs). The functionality of NER is important primarily because the lesions repaired by 
this mechanism distort the geometry of the DNA helix thereby destabilizing the genome. 
The major steps involved in NER include recognition of the damage, opening of the 
DNA helix by helicases, incision and excision of the fragment of DNA containing the 
damage by endonucleases and finally re-synthesis of the excised strand and its ligation to 
the parent strand. There are about 20 canonical genes involved in the NER pathway, the 
protein products of which are crucial for NER to occur and they are outlined along with 
their function in Table 2.1. 
2.1.4 Types of NER 
 NER can be divided into two main types, Global Genomic Repair and 
Transcription Coupled Repair. The site of damage is what dictates the type of NER 
pathway used to repair it. The main difference between the two NER sub-pathways is the 
damage recognition step. Damage that cause adducts which stall the transcription 
machinery are repaired by the Transcription-Coupled Repair pathway of NER. In 
contrast, adducts formed in the bulk of the genome that comprises of non-transcribed 
DNA is repaired by the Global Genomic Repair pathway of NER (Costa, 2003). Lesions 
detected in transcribed strands are removed faster than that in the rest of the genome 
(Hanawalt, 2002). Apart from the differences in recognition of damage between the two 
sub-pathways of NER, the subsequent steps are the same in both pathways. 
2.1.5 Mechanism of NER 
 Repair by the NER pathway (Figure 2.2) commences with recognition of the 
damage. The trigger for initiating NER comes from two scenarios. Transcription Coupled 




damage and recruits CSB. Recognition in Global Genomic Repair is performed by the 
XPC-RAD23B or XPC-hHR23B complex (Sugasawa et al., 1998). This complex detects 
helix distortions caused by 6-4-PPs readily. CPDs, however, are too subtle to be 
recognized by the XPC-hHR23B complex and hence, the presence of DDB proteins 
(especially p48 or DDB2) aid lesion recognition in Global Genomic Repair (Tang, 
Hwang, Ford, Hanawalt, & Chu, 2000). CSB is the recognition protein in transcription 
coupled repair and is a part of the RNA polymerase II complex (van Gool et al., 1997). 
CSB causes a conformational change that results in the temporary dislocation of RNA 
polymerase II from the fork, thus allowing access of the repair machinery to the site of 
damage. The CSA complex is then recruited by CSB, which consists of two more 
proteins, ring box protein 1(RBX1) and Cullin 4A (CUL4A). If RNA polymerase II fails 
to recruit proteins to perform NER, it is then degraded by ubiquitylation and the damage 
is left to be recognized by NER (Hanawalt & Spivak, 2008). 
After lesion recognition by either of the two aforementioned ways, a change in 
DNA configuration leads to open structure formation in DNA with the help of TFIIH, 
XPA, XPG and XPC (Citterio et al., 2000; Evans, Fellows, Coffer, & Wood, 1997). XPA 
is also recruited to the open complex where it is required for the formation of the pre-
incision complex by interacting with CSA, CSB, RPA and RNA polymerase II. XPD and 
XPB are the two helicases involved in unwinding of the double helical structure, where 
XPD has a 5’ to 3’ helicase function and XPB unwinds the DNA in a 3’ to 5’ direction 
(Fuss & Tainer, 2011; Schaeffer et al., 1994). Both helicases are assisted by a cyclin 




TFIIH machinery (Fuss & Tainer, 2011; Roy et al., 1994). XPA, along with RPA1, 
ensures proper unwinding and bending of DNA to facilitate incision.  
XPG and ERCC1-XPF complex are the two endonucleases that excise the 
fragment containing the damage and are both required to carry out incision of DNA 
around the site of damage. Where XPG incises the strand at about 2-8 nucleotides away 
from the site of damage from the 3’ end, ERCC1-XPF nicks the DNA at about 15-24 
nucleotides from the damaged base at the 5’ end of the strand containing the damage 
(Hunting, Gowans, & Dresler, 1991; Shivji, Podust, Huebscher, & Wood, 1995; Sijbers 
et al., 1996). The 3’ hydroxyl group left by the ERCC1-XPF complex after the strand is 
excised is a perfect template on its own for DNA synthesis using Pol d and Pol e, which 
are known to be the primary polymerases involved in DNA synthesis during NER 
(Hunting et al., 1991; Shivji et al., 1995). Ultimately, DNA ligase I joins the re-






Figure 0.2 Schematic of the NER pathway. This diagram describes the major steps in NER 
which are 1) damage recognition by XPC-hHr23B in global genomic repair (GG-NER) or by 
CBS in transcription coupled repair (TC-NER); 2) Unwinding of the DNA helix by helicases 
XPB and XPD along with XPA and RPA; 3) Incision of strands by XPG and ERCC1-XPF 
followed by excision of the damage-containing fragment; 4) Re-synthesis of the excised strand by 
using the complementary strand as template and its ligation to the parent strand. The 5th step 
shows a repaired double-stranded DNA. From Research and Development (R&D) Systems 2003 




Table 2.1 List of the 20 canonical NER genes in alphabetical order, their functional role in the pathway; their contribution 
towards functional NER capacity and the phenotype of their human as well as mouse mutants (Andressoo et al., 2006; 
Andressoo et al., 2009; Bogliolo et al., 2013; Costa, 2003; Coverley, Kenny, Lane, & Wood, 1992; de Boer & Hoeijmakers, 2000; 
Friedberg et al., 2005; Fuss & Tainer, 2011; Jaspers et al., 2007; Niedernhofer, 2008; Schärer, 2013; M. Tian, Shinkura, Shinkura, & 












CCNH CAK Part of the cdk-activating kinase 
(CAK) complex; Regulates the 
function of CDK7; provides stability 
to the TFIIH complex 





Part of the cdk-activating kinase 
(CAK) complex; aids the activity of 
helicases in the pathway by providing 
stability  
- No known human 
mutant 
Unknown 
DDB1  Recognizes minor helix distorting 
damage in global genomic repair 




DDB2 XPE Recognizes minor helix distorting 
damage in global genomic repair 
along with XPC 
40-50% Xeroderma 
pigmentosum 
Defective CPD removal 








Mostly inviable. If they 
live, they are small in 















ERCC2 XPD 5’®3’ helicase; unwinds DNA to 








skin and eye tumors due 
to increased cancer 
predisposition; defective 
repair of oxidative DNA 
damage 
ERCC3 XPB 3’®5’ helicase; unwinds DNA to 








are embryonic lethal; no 
evident signs of 
Cockayne syndrome 
observed 
ERCC4 XPF 5’ endonuclease that makes an 
incision at the 5’ end of the damage-
containing strand by forming a 





growth defects and 
premature death 
ERCC5 XPG 3’ endonuclease that makes an 







ERCC6 CSB Recognizes damage in the 
transcription-coupled repair pathway 
of NER 
100% Cockayne Syndrome Skin cancer upon UV 
exposure; no evident 
Cockayne syndrome 
phenotype 
ERCC8 CSA Recognizes damage in the 
transcription-coupled repair pathway 
of NER 
100% Cockayne Syndrome Skin cancer upon UV 
















GTF2H2 TFIIHp44 Member of the TFIIH complex. Aids 
in stabilizing the repair complex 
- No known human 
mutant 
Unknown 
GTF2H3 TFIIHp34 Member of the TFIIH complex. Aids 
in stabilizing the repair complex 
- No known human 
mutant 
Unknown 
GTF2H4 TFIIHp52 Member of the TFIIH complex. Aids 
in stabilizing the repair complex 
- No known human 
mutant 
Unknown 
RAD23B hHR23B Involved in damage recognition in 
global genomic repair by binding to 
XPC 
- No known human 
mutant 




Member of the replication protein A 
family that binds to the undamaged 
strand of DNA. Prevents the 
formation of secondary structures 
that could interfere with repair and 
protects DNA strands from nucleases 





Member of the replication protein A 
family that binds to the undamaged 
strand of DNA. Prevents the 
formation of secondary structures 
that could interfere with repair and 
protects DNA strands from nucleases 





Member of the replication protein A 
family that binds to the single 
stranded DNA. Prevents the 
formation of secondary structures 
















that could interfere with repair and 
protects DNA strands from nucleases 
XPA - Verifies damage and proper 





Skin cancer upon UV 




Recognizes damage in global 




skin cancer after UV 
exposure, lung and liver 
tumors after chemical 
carcinogen exposure. 
Increased predisposition 








2.1.6 Measurement of NER capacity  
2.1.6.1 Unscheduled DNA Synthesis  
 The Unscheduled DNA synthesis (UDS) assay is the gold standard assay used for 
the measurement of NER capacity and was developed by Dr. James Cleaver (Cleaver & 
Thomas, 1981). This assay is traditionally used as a diagnostic test for Xeroderma 
pigmentosum and other repair syndromes and measures the incorporation of a 
radiolabeled nucleotide into DNA during the process of DNA repair after an insult with a 
fixed dose of a damage causing agent (UV-C light in this case). Incorporation of the 
radiolabeled nucleotide is detected by autoradiography. Autoradiography results in the 
formation of silver grains in photographic emulsion directly over the nuclei of cells 
wherein DNA underwent repair. The number of silver grains is directly proportional to 
the DNA repair capacity of that sample, when expressed relative to the traditional 
control, which is a fibroblastic cell explants established from newborn foreskin. This 
assay is known as ‘Unscheduled’ DNA synthesis, because repair is measured by 
assessing repair over nuclei that are not in their S-phase (Scheduled DNA synthesis) 
wherein DNA is replicated. In the UDS assay, silver grains are also incorporated in cells 
undergoing cell division which show up in the assay as immensely populated by silver 
grains (Figure 2.3) as opposed to the non-S phase cells. These S-phase nuclei are 
excluded from grain-counting (Latimer & Kelly, 2014). However, the percentage of cells 






Figure 0.3 Bright field image of cells run on the UDS assay at 1000x magnification under oil 
immersion. Panel A shows an unirradiated field while Panel B shows an irradiated field. The tiny 
black dots are silver grains and those on top of non-S-phase nuclei are counted. The densely 
populated grains over 3 nuclei represent S phase cells, indicating mass accumulation of 3H-
thymidine during DNA replication. Re-printed with permission from Latimer and Kelly, 2014. 
 
 UV-C light is used mainly due to its ease of use and dose optimization, no side 
effects and also because it produces two main lesions, namely cyclopyrimidine dimers 
(CPDs) and 6,4-photoproducts (6,4PPs), both of which are repaired by the NER pathway. 
Our lab uses a UV-irradiating machine (or the “cell tanning salon”) to irradiate plated 
cells as described previously (Steier & Cleaver, 1969). This exposure chamber contains 3 




This machine also contains an electronic shutter of a diameter of 6 inches to ensure a 
fixed dose delivery where the time of dose given is based on the intensity of the UV 
bulbs measured by a dosimeter (Figure 2.4).  
Figure 0.4 UV-irradiation chamber or the cell tanning salon. This machine is used to deliver a 
fixed and uniform dose using a time-controlled shutter and UV bulbs on top along with the speed-
controlled rotating turntable at the bottom. (Latimer and Kelly, 2014) 
 
  
The UDS assay possesses some strong advantages. First, it measures total 
genomic repair capacity of the cells. Transcription Coupled Repair remediates damages 
only in a tiny fraction of total genomic repair, hence is not a good measure of the total 






(along with Transcription Coupled Repair), this makes it one of the most robust 
laboratory techniques for measuring NER capacity. Second, this assay also allows for the 
measurement of proliferation in the cells being assayed  (Latimer & Kelly, 2014). Finally, 
the UDS assay measures complete repair in cells, as opposed to using lesion-directed 
antibodies in ELISA based methods that are not representative of all the lesions generated 
and repaired by NER (Matsunaga, Hatakeyama, Ohta, Mori, & Nikaido, 1993; Mori et 
al., 1991). 
 The drawbacks of using the UDS assay to measure NER capacity would be the 
need to use a radiolabeled nucleotide. The use of radioactive chemicals requires training 
personnel in specialized handling, use and disposal of the same, and their use also 
endangers the experimentalist to radiation exposure hazard. Moreover, manual counting 
of grains seems to be the best method for retrieving data from slides run on the UDS 
assay. Although liquid scintillation counters have been used in literature for assays 
measuring the incorporation of 3[H]thymidine (Sawada, Furihata, & Matsushima, 1989), 
these have been used for DNA extracts and not feasible for fixed cells. 
2.1.6.2 Host cell reactivation assay 
 Host cell reactivation assay measures DNA repair in the actively transcribed 
genome in cells. This assay involves transfection of a plasmid, that is previously 
damaged by irradiation, into cells whose repair capacity is to be assessed. The plasmid 
contains a reporter gene, usually luciferase, that generates bioluminescence upon active 
transcription/repair of the plasmid. The emitted light can be measured by a luminometer. 
This assay uses the host cell’s repair machinery to repair the damage in the transfected 




transcribed DNA (Latimer, 2014). There are newer and advanced modifications that have 
been tested as alternatives for the traditional host cell reactivation assay. Eukaryotic 
mammalian plasmids with a gene coding for a modified green fluorescent protein 
maxGFP was irradiated with UV light and transfected into cells to measure their repair 
capacity. The expression of the protein was measured by flow cytometry and the results 
found were highly reproducible, with stable and efficient transfections observed along 
with cellular viability (Mendez et al., 2011).  
 Although the host cell reactivation assay provides an alternative to the UDS assay 
in terms of the lack of use of radioactive chemicals as well as efficiency in time required 
for the assay, there are drawbacks to the use of this assay. First, host cell reactivation 
only measures transcription-coupled repair and therefore is not indicative of total 
functional NER capacity of cells. Moreover, transfecting a recombinant DNA assumes 
repair kinetics and dynamics of both moieties happen the same way, which may not be 
the case (Latimer, 2014). 
2.1.7 Measurement of NER gene expression 
2.1.7.1 Expression microarrays 
 Gene expression profiling with the help of chip-based arrays is one of the most 
comprehensive and cost-effective technologies to study the transcriptome of the desired 
organism or sample (human in our case). Affymetrix assays enable comprehensive 
measurement of steady state RNA levels for about 38,000 human genes and are the most 
commonly used assays in literature to look at the entire transcriptome in parallel (Auer, 
Newsom, & Kornacker, 2009). Among the available human gene expression profiling 




complied from 4 different publicly available databases, namely UniGene, dbEST, 
GenBank and RefSeq. This chip contains about 54,000 probe sets for detection of about 
47,000 transcripts for the 38,500 known genes (Affymetrix, 2003). 
 In this technique, total RNA isolated from eukaryotic samples is first primed with 
oligo-dT primers and converted to cDNA via reverse transcription. After the first and 
second strand cDNA synthesis, the single stranded antisense RNA is biotin-labelled. This 
biotinylated cRNA is fragmented and hybridized to the oligonucleotide probes on the 
Genechipâ. These probes represent the genes and transcripts being evaluated for 
expression by the array. Hybridization is detected by addition of a streptavidin-
phycoerythrin antibody and its detection by a second biotinylated anti-streptavidin 
antibody attached to a chromophore using a Genechipâ Scanner. This scanner measures 
color intensities of probes hybridized to the Genechipâ and expression values are 
produced in the form of .cel files (Figure 2.5). 
 Expression microarrays come with certain advantages. First, they are an 
affordable technique for quantification of the transcriptome. Also, as microarrays have 
been around for a while and have been used extensively for gene expression profiling, the 
various sources of errors and bias are well understood in the field. However, they have 
several drawbacks of their own. First, they come with probe bias, that is the transcripts 
and genes are quantified only if they exist (S. A. Martin, Dehler, & Król, 2016). 
Therefore, this technique cannot be used to detect novel genes or transcripts or to detect 
genes or transcripts for which probes are unavailable. Moreover, microarrays have a 
lower resolution, accuracy and sensitivity for detecting differential expression than some 





Figure 0.5 Schematic of gene expression microarray profiling using the Affymetrix 
Genechipâ HG U133 Plus 2.0 array. (Ryan et al., 2004) 
2.1.7.2 RNA sequencing 
 RNA sequencing is a cutting-edge technique that has evolved in the last decade as 
an extension of the second-generation DNA sequencing methods. Though sequencing 
methods like Sanger sequencing and 454 sequencing (also called as pyrosequencing) 
have been available and were among the earliest sequencing techniques (Heather & 
Chain, 2016), RNA sequencing is one of the newest next generation sequencing 
technologies that employs the sequencing by synthesis methodology. Sequencing by 
synthesis uses the traditional chain termination method of sequencing employed in 
Sanger sequencing in combination with the immobilization of the template on a glass 




detection of incorporation and thus, the sequence of RNA (Sanger, Nicklen, & Coulson, 
1977; Weber, 2015). Illumina is now the leader in RNA sequencing instrumentation and 
preparatory kits where the company has developed a wide variety of sequencing 
instruments from benchtop sequencers having a smaller output to high throughput 
parallel sequencers for multi-sample deeper sequencing. The workflow of a sequencing 
run on using the Illumina technology is shown in Figure 2.6 and described below. 
 Preparation of the steady state RNA sample for sequencing involves a few major 
steps, all included in library preparation. First, RNA is fragmented such that it reaches a 
desired fragment length and is enriched for the desired type of RNA. Fragmentation is 
achieved by either physical (shearing or acoustic methods), enzymatic (nucleases or 
transposases) or chemical (heat or divalent ions) methods (Head et al., 2014). The 
fragment size (or insert size) is just a few tens of bases longer than the desired read 
length. Enrichment of a specific RNA molecule type in the sample is done by specialized 
methods. Exome sequencing targeting the messenger RNA alone uses poly-A selection to 
deplete other forms of RNA. In the ribo-depletion method ribosomal RNA, being the 
most abundant RNA species, is depleted to enrich for messenger RNA, small non-coding 
RNA and transfer RNA molecules (Hrdlickova, Toloue, & Tian, 2017).  
 Following fragmentation and target RNA selection, library preparation method 
usually involves conversion of RNA to cDNA by either the addition of adapters (8bp 
fragments for Illumina-compatible library preparation methods that help differentiate 
samples from one another), random priming or priming with the help of oligo-dTs. This 
is usually followed by amplification to allow for complexity of library preparation. 




out by sequentially amplifying each of the strand after degrading the other (Hrdlickova et 
al., 2017). Finally, the created library can also be size selected to enrich for certain 
populations of amplicons, like small RNAs, in case that is the desired application (Röther 
& Meister, 2011).  
 In Illumina sequencers, the prepared library of fragments of sample RNA is then 
loaded onto glass slides containing lanes called flow cells. Each flow cell is coated with 
oligonucleotides, the sequences of which are complementary to the adapter molecules. 
When the samples are allowed to hybridize to the oligonucleotides on the flow cells, they 
undergo a process called ‘bridge amplification’ by which clusters of forward and reverse 
strands are generated (Dündar, Skrabanek, & Zumbo, 2015). The cluster generation 
ensures that the light signal emitted after insertion of a base during sequencing is within 
the detection range for the camera used. Sequencing at a single base resolution is carried 
out using ‘Sequencing by Synthesis’ technology which uses a modification of Sanger’s 
Chain Termination method to sequence cDNA fragments. Reversible chain termination 
allows repeated cyclic addition of bases and their subsequent fluorescence-based 
detection (Figure 2.6) (Buermans & Den Dunnen, 2014). 
 Analysis of RNA sequencing data is a complex process for which the standards in 
the field are still being established. However, there are some commonly used and 
recommended practices for RNA sequencing data handling and analysis (Figure 2.7). 
Raw sequence data from the sequencing runs is usually in the form of FASTA or FASTQ 
files and performing quality control on the raw unaligned reads is recommended to 
ensure optimum read quality based on Phred scores. Phred scores range from 10-60 and 




the probability of 1 erroneous base call in 10 base calls. The higher the score, the more 
accurate is the base calling at that position, for example a score of 60 indicates an 
accuracy of 99.9999% (Ewing, Hillier, Wendl, & Green, 1998). After ensuring the 
optimum quality of raw reads, alignment of raw reads is performed to the reference 
genome of interest, in this case the human genome. A vast variety of aligners are 
available for the user to choose from. A major sub-classification of aligners is whether 
they are spliced or non-spliced. Spliced aligners (also known as splice aware aligners) 
can recognize intron gaps while non-spliced aligners (splice unaware aligners) are usually 
used for alignment of output from DNA sequencing runs and will not recognize and 
relate to large gaps in alignment as introns (Engström et al., 2013). The most common 
aligners used for RNA sequencing data are STAR (Dobin et al., 2013), Tophat (Kim et 
al., 2013), MapSlice (K. Wang et al., 2010)and GSNAP (T. D. Wu & Nacu, 2010). Hisat 
is another new aligner by the designers of Tophat and its usage is increasing in the 
literature (Kim, Langmead, & Salzberg, 2015).   
 Verification of optimum alignment is made by post-alignment quality control and 
read filtering and adapter trimming is performed as necessary. Illumina’s output of raw 
reads is trimmed for adapter removal. This is followed by expression quantification and 
measurement of differential expression among sample groups under investigation (Figure 
2.7). A plethora of algorithms and software solutions, either freeware or proprietary 
solutions are available for the analysis of RNA sequencing data. An important 
consideration while designing RNA sequencing experiments is the read depth. Typically, 
a read depth of 10-25 million reads per sample is sufficient for differential expression 




sample depth. De-novo assembly of the genome (in the absence of a reference genome 
for a particular sample) requires a read depth up to 100 million reads per sample 
(Consortium, 2011) (Yichuan Liu et al., 2013).  
 RNA sequencing has some great advantages over microarray technologies which 
are outlined in Table 2.2, it but also has its own drawbacks. Nevertheless, RNA 
sequencing has served as a validation technique for microarray due to higher resolution 
(single base) and sensitivity. This is particularly important for the purposes of this study 
for two reasons. Firstly, RNAse protection assay was used previously in our work as a 
validation strategy for microarray analysis (Latimer et al., 2010), but this assay is 
complex and time consuming, and is also limited by its multiplexing ability and lack of 
probe flexibility. Secondly, RNA sequencing not only helped with gene expression 
validation, but also with the investigation of single nucleotide variants in the coding 












Figure 2.7 Flowchart illustrating the commonly used steps for RNA sequencing data 
analysis. Input of raw FASTA or FASTQ reads is followed by quality control and alignment to a 
reference genome. Post-alignment QA/QC is then performed to check for optimum alignment> 
reads are annotated if the reference genome for the organism being studied is available. If not, the 
genome is constructed using specialized algorithms and this requires a high coverage of the 
genome. Quantification of expression is the performed, which is followed by measurement of 





Table 2.2 Major differences between Microarray and RNA sequencing (G. Russo, 
Zegar, & Giordano, 2003; Y. Wang, 2014) 
 
Parameter Microarray RNA sequencing 
Cost Low High 
Resolution Low High (Single Base) 





Alternative Splicing,  
Novel transcript discovery 
 
Sensitivity Low High 
Probe Bias Yes No 
Amount of RNA required 1 ug 100 ng 
Multiplexing of samples in 
a run 
No Yes 




Easy data portability and 
storage 
Yes No 
Data reproducibility Yes Yes 
 
2.1.8 Diseases caused due to defects in the NER pathway 
 The genes involved in NER pathway are different in terms of their contribution to 
functional NER capacity. This was demonstrated by early work on mutant mouse models 
of these genes that were assayed for their NER capacity, as well as human mutants that 
showed severe phenotypes due to mutations in NER genes and therefore, loss of the 
ability to perform NER (Table 2.1). Three diseases are associated with NER deficiency, 




2.1.8.1 Xeroderma pigmentosum 
 Xeroderma pigmentosum is primarily autosomal recessive disorder and its name 
implies dry and pigmented skin (von Hebra & Kaposi, 1866). Individuals with xeroderma 
pigmentosum are characterized by extreme sensitivity to sunlight resulting in severe skin 
pigmentation and an unusually high predisposition to cancer (Bradford et al., 2010; de 
Boer & Hoeijmakers, 2000). Patients with xeroderma pigmentosum have a 2000-fold 
higher risk of getting skin cancers as well as cancers of internal organs, and usually die 
prematurely than a normal human at 8 years of age from cancer (Kraemer, 1997). 
Although the incidence of this disease is very rare in the US (1 in 250,000), xeroderma 
pigmentosum has an unusually high incidence in the Japanese population (Imoto et al., 
2013; Lehmann, McGibbon, & Stefanini, 2011). 
 James Cleaver discovered that xeroderma pigmentosum patients are intrinsically 
deficient in their ability to perform NER (Cleaver, 1968). This discovery was made 
independently by Richard Setlow as well (Setlow, Regan, German, & Carrier, 1969). The 
severity of the loss of NER function depends on the gene that harbors the mutation. Eight 
complementation groups were discovered in xeroderma pigmentation using fusion 
experiments on cells obtained from patients suffering from this disease. These groups 
were XP-A to XP-G and XPV, and the residual repair capacity after a mutation in each of 
these complementation groups can be found in Table 2.1(for XPV, the residual NER 
capacity is still 100%). Restoration of NER capacity after fusing two cells from two 
different patients (and thereby forming a heterokaryon) indicated that the mutations are in 
two different genes in each of the patients and they complemented each other. However, 




gene which was the deemed non-complementary. The link of NER deficiency to cancer is 
shown unequivocally by the susceptibility of xeroderma pigmentosum patients to skin 
and other cancers. 
2.1.8.2 Cockayne syndrome 
 Named after Edward Cockayne who discovered this disease phenotype in 1936, 
Cockayne syndrome is characterized by sensitivity to sunlight, mental retardation, stunted 
growth and development as well as progeroid symptoms (Cockayne, 1936). However, 
Cockayne syndrome patients do not have a susceptibility to cancer like xeroderma 
pigmentosum patients, the reason for which is not known to date (de Boer & 
Hoeijmakers, 2000; Kraemer et al., 2007). CSA and CSB are the two complementation 
groups that have been identified, and germline mutations in these two genes are the cause 
for Cockayne syndrome’s phenotype. These two proteins are localized to the 
mitochondria, and they play an important role in the repair of mitochondrial DNA 
(Aamann et al., 2010; Kamenisch et al., 2010). As the impairment in the function of 
mitochondria has been implicated in neurodegenerative disorders, this might be a 
possible explanation for the phenotype for this disease. As these genes are involved in 
damage recognition in the transcription-coupled repair pathway, UV-induced 
mutagenesis mechanism does not result into a cancer predisposition in these patients as it 
does in xeroderma pigmentosum. A possible explanation is that the global genomic repair 
pathway, being intact, compensates for the lack of transcription coupled-repair(Reid-





 Trichothiodystrophy is an autosomal recessive disorder characterized by 5 major 
phenotypic traits, namely photosensitivity, ichthyosis (meaning dry, scaly and thickened 
skin), decreased fertility, brittle hair due to deficiency in sulfur, short stature and 
impaired growth (Stefanini, Botta, Lanzafame, & Orioli, 2010). This disease was 
discovered from a mutation in the XPD gene by Stefanini and colleagues and manifests 
as a deficiency in the NER pathway (Stefanini et al., 1986). Three complementation 
groups have been identified – XPB, XPD and TTD-A. Patients suffering from 
trichothiodystrophy, although showing a mix of phenotype between xeroderma 
pigmentosum and Cockayne syndrome, do not have an increased susceptibility to cancer 
(Stefanini et al., 2010) 
2.1.9 NER and Breast Cancer 
 There have been a few studies that have studied NER in the context of breast 
cancer. The earliest accounts come from studies by Kovacs et al. who studied NER in the 
lymphocytes of breast cancer patients (Table 2.3). Their studies involved using the UDS 
assay to measure the NER capacity of lymphocytes obtained from patients with breast 
cancer and comparing them to those from healthy controls. This group also studied NER 
capacity in the blood of healthy women who had a familial history of breast cancer 
(women whose mothers, or sisters, or mothers and sisters had breast cancer) and 
compared them to that of controls that did not have a family history of breast cancer. 
They found that the NER capacity as measured by the UDS assay was low for both these 
test groups of women compared to controls (Table 2.3). Another group, Shi et. al. (2004) 




patients and comparing them with those from non-diseased controls. Matta et. al. (2012) 
again showed significantly lower NER capacity in lymphocytes from Puerto Rican 
women with breast cancer compared to those from controls.  
 A major drawback of all the studies mentioned above used lymphocytes from 
blood of patients as surrogates of breast or breast function to correlate NER capacity with 
the incidence and risk of breast cancer. Latimer et. al. (2003) have shown previously that 
peripheral blood lymphocytes have low baseline NER capacity than normal breast, 
ovaries and the skin. Therefore, NER is tissue specific and lymphocytes are not a good 
representative of the NER capacity in the breast (Latimer et al., 2003). Correlation of 
breast cancer risk with the NER capacity of lymphocytes, therefore, would not be 
accurate.  
 Another drawback of most of these studies is that they have used the host cell 
reactivation assay to measure the DNA repair capacity. As discussed previously, this 
assay measures transcription-coupled repair and hence is not an indicator of total 
functional NER capacity of the samples. We have been the first group in literature to 
study NER capacity using the functional UDS assay to measure total NER capacity in 
early stage sporadic breast tumor samples and compare them with that of non-diseased 
breast control samples. We showed that NER capacity in stage I breast tumors is 
intrinsically low in sporadic Stage I tumors compared to the NER capacity of 23 non-
diseased breast reduction explants, thereby establishing the foundation of the link of NER 







Table 2.3 Overview of studies measuring NER capacity in breast cancer 


















64 healthy women 
having a familial 
history of breast 
cancer and 48 
control women 
without a family 
history of breast 
cancer 
UDS 45 out of 64 
women had low 
DNA repair as 
measured by the 
UDS assay. 
Only 8 out of 48 

















women with breast 
cancer compared 









(Q. Shi et al., 
2004) 
The association of 
DNA repair with 
breast cancer risk 







with breast cancer 








was lower by 
60% compared 
to controls 
(Matta et al., 
2012) 
DNA 
repair capacity of 
lymphoblastoid 
cell lines from 
sisters discordant 





158 breast cancer 
patients and 154 
sister controls 






(Kennedy et al., 
2005) 
Factors associated 
with breast cancer 
in Puerto Rican 
women 
Lymphocytes from 
465 breast cancer 
















2.2 Breast Cancer 
2.2.1 Anatomy of the breast  
 The breast is a lactiferous gland that produces milk in the human body. The breast 
consists of lobes, which are in turn made up of multiple lobules. Lobules are the milk-
producing structures in the breast. These lobules located at the back of the breast anterior 
to the sternum are connected to the nipple via a network of branching ducts that converge 
at the nipple. These lobules are known as terminal ductal lobular units or TDLUs and 
about 20-40 TDLUs constitute each lobe in the breast (Hoda, Rosen, Koerner, & Brogi, 
2014). 
 The microenvironment of the breast consists of epithelial and stromal 
components. The luminal epithelial cells lining the lobules and ducts form the epithelial 
component, where this epithelium in the lobules is what produces milk. Epithelial cells 
are situated on a myoepithelial cell lining that contracts to release the milk from the 
apical surface of the luminal epithelial cells in the lumen of the duct, upon stimulation by 
oxytocin. Therefore, each TDLU consists of epithelial cells lining the lumen, an outer 
myoepithelial lining which is finally covered by an outer basement membrane (Hoda et 
al., 2014). The stroma of the breast constitutes collagen, fibroblasts, macrophages, 
plasma cells, peripheral blood lymphocytes and blood vessels. The majority of the breast 
consists of fat made up of adipocytes, and these are necessary for the formation of 
secondary structures during embryogenesis (Figure 2.8). It is usually the epithelial cells 
that line the ducts and lobules which undergo uncontrolled proliferation and show 





Figure 2.8 Anatomy of the breast. Panel A shows gross anatomy of the breast. Panel B shows a 
cross section of a TDLU stained with hematoxylin and eosin. A magnified image of a single 
lobule is shown in the top right corner of Panel B that shows a single lobule lined with epithelial 
cells around a hollow lumen. Panel C shows a scanning electron micrograph of a lobule. Adapted 
from Vidi et. al., 2013 and cancergov.org. 
 
 
2.2.2 Breast cancer incidence, mortality and survival rates  
 Breast cancer still remains a debilitating disease for women in spite of 
advancement in diagnostic technologies and treatment modalities. Breast cancer 
comprises of about 15% new cases of cancer diagnosed in the US, and about 252,000 
cases were expected to be diagnosed in 2017 (Howlader et. al., 2017). Breast cancer is 
not only prevalent in the US but is also the most common cancer worldwide among 
women and second most common among all cancers. Breast cancer has a worldwide 
incidence of about 1.6 million cases and an age adjusted rate of 43.3 per 10,000 person-
years. It was also shown to have the highest cumulative risk of either incidence or 
mortality compared to all cancer types (Ferlay et al., 2015). 
In the US, 40,610 deaths were estimated from breast cancer alone for the year 
2017, and breast cancer is second on the causes of death from cancer, after lung cancer 




cause of mortality among women worldwide, followed by cervical/uterine and lung 
cancer (Ferlay et al., 2015).  
Although the 10-year relative survival rate for women diagnosed with breast 
cancer is 89.7% with this survival percentage having increased by 16.1% since 1975, this 
number dramatically decreases with increase in stage. About 3 million women are 
presently living with breast cancer in the US, thereby making breast cancer one of the 
major sources of cancer burden (Howlader et.al., 2017). 
2.2.3 Risk factors for breast cancer 
 Certain factors increase the risk of getting breast cancer, and they can be 
classified into either modifiable or non-modifiable risk factors. Non-modifiable risk 
factors are the ones that are inherited and cannot be changed, such as age, race, ethnicity 
as well as germline mutations that predispose an individual towards breast cancer. 
Modifiable risk factors are environmental and lifestyle conditions which expose the 
individual to certain factors that can cause carcinogenesis, such as smoking, diet, 
pregnancy, breastfeeding, alcohol and the use of hormone replacement therapy or 
contraceptives (Gierach & Vogel, 2004). 
 Genetic susceptibility is a key risk factor for breast cancer involving two genes, 
BRCA1 and BRCA2. Inherited germline mutations in either of these genes increases the 
risk of developing breast cancer by approximately 70% by the time a woman reaches 80 
years of age (Kuchenbaecker et al., 2017). Age is another major risk factor for breast 
cancer, where women older than 65 years of age are about 6 times more likely to get 
breast cancer than women younger than 65 (S. E. Singletary, 2003) (Howlader et al., 




white women who are pregnant before the age of 20 have a 50% less risk of getting 
breast cancer over their period of life (Britt, Ashworth, & Smalley, 2007). This has been 
attributed mainly to a more differentiated and therefore a more stable state of the 
epithelial cells of the breast, as the mammary gland undergoes differentiation during 
pregnancy to prepare for lactation (J. Russo, Tay, & Russo, 1982). 
 Smoking, both in the active or passive form, has been correlated with a higher 
breast cancer risk by multiple studies compared to non-smokers (Bjerkaas et al., 2014; 
Catsburg, Miller, & Rohan, 2015; B. Li et al., 2015). About 5300 chemicals are found in 
the smoke from a cigarette, most of which are known chemical carcinogens (Perfetti & 
Rodgman, 2014). Chemicals found in tobacco smoke such as benzo[a]pyrene cause 
adducts in DNA which are remediated by DNA repair pathways, especially NER. Hence, 
impaired DNA repair may be a major risk factor in breast cancer (Schärer, 2013). Studies 
have also linked alcohol consumption with breast cancer risk, mostly due to increased 
estrogen levels associated with alcohol consumption (K. W. Singletary & Gapstur, 2001). 
The risk increases with every glass of alcohol consumed, reaching up to 40% for 3 
glasses of alcohol per day (Ellison, Zhang, McLennan, & Rothman, 2001; S. M. Zhang et 
al., 2007). 
2.2.4 Breast Cancer Classification 
 Malhotra et. al., have laid out breast cancer classification based on 3 broad 
classes, namely histological, molecular and functional. Histological classification 
categorizes breast cancer based on the location of origin within the breast (Malhotra, 




2.2.4.1 In-situ breast carcinomas 
  In-situ breast carcinomas are comprised of breast cancers that are localized (also 
known as Stage 0) can be limited either to the lumen of the duct (ductal carcinoma in-situ 
or DCIS) or the lobules (lobular carcinoma in-situ or LCIS). In-situ carcinomas can 
become invasive, with 10-year rate being 5.4/1000 person-years for DCIS and 7.3/1000 
person-years for LCIS (C. I. Li, Malone, Saltzman, & Daling, 2006). 
2.2.4.2 Invasive breast carcinomas 
Invasive breast carcinomas are comprised of breast cancers that have spread from 
their site of origin but may still be contained within the breast. Invasive carcinomas are 
further classified into subtypes based on histology, and are laid out in a well 
characterized diagram by Malhotra et al. (Figure 2.9) 
2.2.5 Molecular subtypes of breast cancer 
 Gene expression profiling techniques have allowed to analyze breast cancer cases 
on a molecular basis and hence have given rise to molecular subtypes of breast cancer. 
Sørlie et al., and Perou et al., performed pioneering work which enabled the subtyping of 
breast cancer cases into 5 major classes based on gene expression profiling, namely 
Luminal A, Luminal B, Her2 overexpressed, Basal and Normal-like (Perou et al., 2000; 
Sørlie et al., 2001). A newer sub-class called Claudin-Low has also been established in 
the basal type (Prat et al., 2010). Molecular subtype classification is either based on 
immunohistochemistry (IHC) markers or on gene-based assays. Gao and Swain (2018) 





2.2.5.1 Luminal A type BC 
This class of breast cancer comprises tumors that overexpress Estrogen receptor 
(ER) but not the Progesterone receptor (PR) or the HER2 receptor. Luminal A breast 
tumors are defined as ER-positive, PR < or = 20%, HER2-negative and Ki67 (a cellular 
proliferation marker) <14% (Goldhirsch et al., 2013). Luminal A is the most common 
type of BC diagnosed (about 55%), has the best prognosis among all breast cancer sub 
types and also has the lowest grade (X. Dai et al., 2015; O'Brien et al., 2010; Sørlie et al., 
2003). Because these tumors are characterized by overexpression of estrogen receptors, 
they respond well to hormone therapy like tamoxifen (Brenton, Carey, Ahmed, & Caldas, 
2005). 
 
Fig. 2.9. Histological classification of breast cancer. Each of DCIS, LCIS and Invasive 





2.2.5.2 Luminal B type BC 
 Nearly 40% of diagnosed BC types are Luminal B and are ER+ along with being 
either HER2-positive or HER2-negative. HER2-positive Luminal B BCs can have any 
PR or Ki-67 levels, whereas HER2-negative Luminal B type can have either Ki-67³20% 
and PR-, or alternatively Ki-67 <20% and have a high recurrence score based on gene 
expression panels (X. Dai et al., 2015; Goldhirsch et al., 2013). Luminal B BCs usually 
have high histological grades and poorer prognosis than Luminal A type, similar to non-
Luminal BCs. The lack of PR expression in some of these tumors, which is a predictor 
for hormone therapy response, makes these tumors less responsive to endocrine 
treatments for BC (Tran & Bedard, 2011). 
2.2.5.3 HER2 enriched BC 
 Breast tumors overexpressing HER2 receptors can be either hormone receptor 
(ER and PR) positive or negative, i.e., HR+ or HR-. These tumors show overexpression 
and/or amplification of the ERBB2 gene and other cell proliferation related genes. 
Patients with HER2-enriched disease are treated with targeted HER2 antagonists like 
trastuzumab or HerceptinÒ, although HER2-enriched tumors that are HR+ have a better 
prognosis than HR- ones, and this observation was made even independent of 
trastuzumab treatment in clinical trials (Piccart-Gebhart et al., 2014; Tolaney et al., 
2015). However, HR status does not affect response of these tumors to trastuzumab 
(Gianni et al., 2012; Perez et al., 2014; Pogue-Geile et al., 2015). 
based on the degree of differentiation of the tumor cells (discussed later on). Adapted and 




2.2.5.4 Triple negative breast cancers or TNBC 
Triple negative BCs are the cases where there is no significant overexpression of 
either the hormonal receptors (ER-negative, PR-negative) or the HER2 receptors (HER2-
negative). These characteristic makes their treatment challenging, and they are generally 
the most aggressive tumors due to the lack of molecular targets (Malorni et al., 2012). 
TNBC are the most lethal form of breast cancer at every stage. Being devoid of 
expression of hormonal receptors or HER2 receptors, these cases are usually treated with 
non-targeted conventional chemotherapeutic agents (Gradishar et al., 2016). Triple 
negative breast cancers are more frequently observed among and correlated with 
premenopausal women, women below the age of 40 (Bauer, Brown, Cress, Parise, & 
Caggiano, 2007), carriers of BRCA1 or BRCA2 mutation (Peshkin, Alabek, & Isaacs, 
2011), women belonging to the African American ancestry (Dietze, Sistrunk, Miranda-
Carboni, O'regan, & Seewaldt, 2015). 
2.2.5.5 Basal type BC 
Basal type of breast cancer are characterized by homogeneity in their tumors and 
high expression of genes peculiar to the normal myoepithelial layer surrounding the ducts 
in the breast, such as smooth muscle markers, b4 integrin, and high molecular weight 
cytokeratins  (Bertucci, Finetti, & Birnbaum, 2012). Basal type and triple negative breast 
cancers show a lot of similarity, however basal BC cases are classified with gene 
expression arrays (Perou et al., 2000), as opposed to triple negative breast cancers, that 





2.2.5.6 Claudin Low BC 
Claudin Low breast cancer is a relatively newer discovery among molecular BC 
sub types and is quite similar in characteristics to the triple negative type, as in it lacks 
the expression of hormone receptors as well as HER2 enrichment. In addition, Claudin 
Low BCs show a low expression of tight junction proteins like claudin 3,4 and 7 as well 
as E-cadherin (Dias et al., 2017). This class of BC has an intermediate prognosis between 
Luminal A type and the ones that have a poor prognosis like Luminal B and triple 
negative BC types. 
2.2.5.7 Normal-like BC  
Normal-like breast cancer is characterized by over expression of progesterone 
receptors (PR-positive) but a lack of expression of estrogen receptor, HER2 receptor and 
Ki-67 (X. Dai et al., 2015). This subtype, defined by gene expression microarray 
analyses, shows the over expression of genes specific to the adipose tissue and other non-
epithelial cell types (Sørlie et al., 2001). 
2.2.6 Functional classification of breast cancer 
Functional classification of breast cancer is based on tumor stage and tumor 
grade. Tumor stage is defined by the TNM staging guide by the American Joint Cancer 
Commission, which comprises of a combination of clinical examinations, surgical 
interventions and imaging techniques (Amin et al., 2018). T in the TNM staging guide 
refers to tumor size, N to lymph node status and M to metastasis. Taken all together, a 
final cancer stage is defined which forms the basis of the course of treatment along with 
immunohistochemical marker analyses and now molecular subtyping. TNM staging 





TNM class Subclass Definition 
T1 T1mi Tumor size £ 1mm 
 T1a Tumor size >1mm but £ 5 mm   
 T1b Tumor size > 5 mm but £ 10 mm   
 T1c Tumor size >10 mm but £ 20 mm   
T2 - Tumor size >20mm but £ 50 mm   
T3 - Tumor size > 50mm  
T4 T4a Extension to the chest wall  
 T4b Ulceration and/or ipsilateral satellite nodules and/or edema 
of the skin 
 T4c Both T4a and T4b 
 T4d Inflammatory carcinoma 
NX - Lymph node status could not be determined 
N0 - No regional lymph nodes metastasis 
N1 - Metastases to movable ipsilateral level I, II axillary lymph 
nodes 
N2 N2a, N2b, N2c Metastases in ipsilateral level I, II axillary lymph nodes 
that are clinically fixed or matted; or in clinically detected 
ipsilateral internal mammary nodes in the absence of 
clinically evident axillary lymph node metastasis  
N3 N3a, N3b, N3c Metastases in ipsilateral infraclavicular (level III axillary) 
lymph node(s) with or without level I, II axillary lymph 
node involvement; or in clinically detected ipsilateral 
internal mammary lymph node(s) with clinically evident 
level I, II axillary lymph node metastases; or metastases in 
ipsilateral supraclavicular lymph node(s) with or without 
axillary or internal mammary lymph node involvement 
 
M M0 No evidence of distant metastasis 
 M1 Distant detectable metastasis by clinical, radiological and 
histological interventions (>0.2mm) 
 
Table 2.4a. Definitions of the TNM classes for clinical classification of stage for breast 
cancer. Further discussion on the N subtypes is out of scope of this dissertation Adapted from 





Stage T (Tumor Size) 
 
N (Lymph Node 
Status) 
M (Metastases) 
IA T1  N0 M0 
IB T0 N1mi M0 
 T1 N1mi M0 
IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
 
Table 2.4b. TNM staging guide for breast cancer. Adapted from the AJCC’s staging poster 
based on Edge & Compton, 2010. 
 
Tumor grade is defined based on the cell differentiation status and the 
morphological characteristic of the tumor cells and is an indication of the prognosis of the 
disease in that patient. A tumor is classified into one of 4 grades, where grade 1 has the 
best prognosis and signifies normal-looking cells similar to that of the tissue of origin that 
are well differentiated. tumor grade 2 has worse prognosis that grade 1, but better than 
tumor grade 3 and 4, and is characterized by abnormal looking cells that are somewhat 
like the cells from the tissue of origin. Tumor grade 3 consists of poorly differentiated 
cells and is considered a high grade with poor disease prognosis. Tumor grade 4 has the 
worst prognosis and is characterized by undifferentiated cells that are completely 








Fig 2.10 Histological images depicting grade of tumor cells of the breast. a) Well-
differentiated normal looking tumor cells with well-defined lumen lined by a monolayer of 
cells in ducts; b) Abnormal cells with intermediate differentiation leading to multiple layers of 
cells causing narrowing of ducts; c) poorly differentiated abnormal tumor cells with hardly 
visible ductal lumens. (Rakha et al., 2010) 
 
2.2.7 Treatment for Breast Cancer  
2.2.7.1 Surgery 
 Error! Bookmark not defined. Surgery for tumor removal is considered as 
preferred route of treatment for Stages I, IIA, IIB and sometimes stage III. Up until the 
1970s, radical mastectomy, which involves removal of both breasts along with axillary 
lymph nodes and chest wall muscles, was considered the standard of care. However, 
mastectomy posed a severe disadvantage from a patient’s psychological and social 
perspective and also posed challenges for breast reconstruction (Arroyo & López, 2011; 
Gerber, 2017; Guthrie & Cucin, 1980)Early accounts of modified radical mastectomy 
were given by Madden, Kandalaft and Bourque in 1972.   
Surgical resection of the tumor is the most preferred way of treating early stage 
BC and is referred to as lumpectomy. Lumpectomy is now the chosen as well as preferred 




factors prevent this course of treatment in certain patients, such as the inability to receive 
radiation treatment (Gradishar et al., 2016). This standard of care has followed six 
clinical trials that showed lumpectomy with adjuvant radiation has the same outcome as 
mastectomy (B. Fisher et al., 2002; Veronesi et al., 2002). There has also been a 
reduction in local recurrence rates after breast conserving surgeries, with the rate being 
less than 10% in 10-year follow-up studies (Anderson et al., 2009; Wapnir et al., 2006).  
Margin width during resection of the tumor has been a subject of debate to date. 
There has been considerable variation found in determination of how much of the 
surrounding histopathologically normal tissue to excise along with the tumor, and the 
decision is usually surgeon-specific (Barrio & Morrow, 2016). The usual process 
involves the surgeon resecting the tumor along with at least a 2 mm pathologically 
normal margin surrounding the tumor and this excised specimen is then sent to be 
analyzed by a pathologist. The pathologist then evaluates the specimen after staining the 
margin to determine if the margin is “positive” or “close”, meaning the tumor either 
extends to the full length of the margin or is very close to the margin. In such a case, re-
excision is carried out, until the margin of the resected specimen is “negative”, meaning 
no tumor is seen infiltrating the margin (Figure 2.11) (Brown et al., 2010). The most 
recent NCCN guidelines on breast tumor resection recommend “no ink on tumor” to be 
sufficient, which means the absence of tumor on the inked margin is sufficient for 
surgical resection of stage I and II breast cancers with adjuvant radiation therapy 






Figure 2.11 Histopathological sections of inked margins after tumor resection from breast 
conserving surgery. The pink stain indicates epithelium, where the white sections mostly 
indicate adipose tissue. Black solid arrows point towards the edge of the malignant tissue. Panel 
A indicates a positive margin, where the tumor is invading the margin. Panel B is considered 
close to the margin as the tumor is within 1 mm of the inked margin. Panel C is considered a 
negative margin, where at least 2 mm or more of the margin is seen outside of the tumor. 
Reprinted with permission (Brown et al., 2010) 
 
2.2.7.2 Radiation therapy 
 Because of the high recurrence rates of breast cancer with lumpectomy alone, 
radiation therapy is given to patients along with breast conserving surgery, known as 
adjuvant radiation therapy. According to the NCCN guidelines, patients undergoing 
lumpectomy for Stage I, IIA and IIB are recommended whole breast irradiation. A dose 
of 45-50 Gy is recommended to be administered at a frequency of 1.8 to 2 Gy per 
fraction, or a dose of 42.5 Gy at 2.66 Gy per fraction (Gradishar et al., 2016). An 
additional boost of radiation therapy is recommended for patients that have a higher 
tumor grade or are above the age of 50 years. A further strong recommendation of 
mammary node irradiation is also given by these guidelines for patients that are positive 




  Accelerated partial breast irradiation can be considered for certain patients if they 
meet the required criteria. Patients with early stage breast cancers that are ER-positive 
and did not have lymph node positivity can be considered for partial breast irradiation, 
according to the consensus guidelines by the American Society for Radiation Oncology 
(ASTRO) (Smith et al., 2009). While studies have shown benefit by using accelerated 
partial breast irradiation (Formenti et al., 2004; Polgár et al., 2007), studies have also 
shown conflicting results and an inferior cosmetic outcome(Jagsi et al., 2010).  
 Clinical trials have shown adjuvant radiation therapy given along with 
lumpectomy reduced local recurrence of breast cancer (Anderson et al., 2009) (Wapnir et 
al., 2006). Important clinical trials have also shown radiation therapy along with 
lumpectomy has similar outcomes as that of mastectomy, which is why adjuvant 
radiation therapy is imperative for early stage breast cancer treatment (B. Fisher et al., 
2002; Veronesi et al., 2002). Finally, patients that have advanced stage breast cancer 
receive neo-adjuvant radiation therapy along with chemotherapy to de-bulk the tumor 
prior to surgery to make it operable (Lerouge et al., 2004).  
 Radiation therapy uses ionizing radiation to destroy cells by either directly 
damaging the genome or by causing the production of free radicals that damage DNA 
(Baskar, Dai, Wenlong, Yeo, & Yeoh, 2014). The inability of breast cancer cells to 
efficiently repair their DNA due to defective DNA repair mechanisms is taken advantage 
of by using radiation therapy which selectively destroys cancer cells faster than normal 





 Treatment of chemotherapeutic agents is recommended for advanced breast 
cancer patients with stage III or IV breast cancer or with patients having triple negative 
breast cancer. Chemotherapeutic agents target cancer cells by a variety of mechanisms as 
outlined in Figure 2.12 
 
 
Figure 2.12 Mechanisms of action of chemotherapeutic agents used in breast cancer. Most 
drugs targeting cancer cells work by targeting the cell division stages, like DNA replication, 
mitotic phase, promoting DNA supercoiling by inhibiting topoisomerases. Other agents act via 
mechanisms independent of the cell cycle. Reprinted from mycancergenome.org 
 
 Chemotherapy is usually given as a combination of drugs acting via two different 
mechanisms, mainly to prevent chemotherapy resistance which is a debilitating problem 
in cancer treatment for late stage cancers (Housman et al., 2014). Two main 




These agents might be substituted for anthracyclines due to cardiac toxicity by these 
agents. Gemcitabine is also often used as a single chemotherapy agent. 
 For breast cancers that are ER positive, i.e., luminal type, hormone therapy is 
administered. The drugs primarily block the activity of estrogen, which is required for 
cellular growth and proliferation in the breast. Two main categories of drugs under 
hormone therapy are selective estrogen receptor modulators (SERMs) (examples are 
tamoxifen, raloxifene and toremifene) or aromatase inhibitors. Aromatase inhibitors are 
the drugs of choice for post-menopausal women as they do not block the production of 
estrogen by the ovaries but block the conversion of androgens to estrogen mediated by 
the enzyme aromatase. This is the main mechanism of estrogen production in post-
menopausal women (Abdulkareem & Zurmi, 2012). Resistance to hormone therapy is 
quite commonly observed and it occurs mainly due to loss of expression of hormone 
receptors or an alteration in the signaling pathway responsible for the proliferation and 
growth of cancer cells (W. Fan, Chang, & Fu, 2015). 
 Treatment of breast cancer has improved significantly with the advent of targeted 
therapies, like HER2 receptor antagonists. Trastuzumab (Herceptinâ) is the drug of 
choice for HER2 overexpressing cancers. This is a monoclonal antibody acts by the 
inhibition of HER2 receptors, thereby disrupting the MAPK and PI3K/Akt signaling 
pathways responsible for cellular growth and proliferation. In addition, Trastuzumab also 
activates the PTEN tumor suppressor gene which leads to cell cycle arrest by the 
recruitment of immune cells to the tumor that eradicate cancer cells via antibody-




monoclonal antibodies targeting VEGF, IL5 and PDL-1 (Shepard, Phillips, Thanos, & 
Feldmann, 2017). 
2.3 Non-tumor adjacent (NTA)  
2.3.1 Step-wise progression of cancer 
 Carcinogenesis is a complex process that has been known to proceed in a step-
wise manner. Early studies on development of tumors were performed on rodent models, 
which elucidated a two-step model of carcinogenesis (Berenblum & Shubik, 1947; Fujiki, 
Sueoka, & Suganuma, 2013; Mottram, 1944). However, more recent accounts show 
evidence regarding the fact that development of cancer has been thought to follow three 
main steps, i.e., initiation, promotion and progression (Barrett, 1993; Pitot, Goldsworthy, 
& Moran, 1981).  
2.3.1.1 Tumor initiation 
Tumor initiation has been attributed to an irreversible alteration in a cell in the 
form of mutation or a mutation-like event, more recently termed as an ‘epimutation’. 
Evidence in literature regarding initiation of mammary tumors points to factors including, 
but not limited to, inactivation of tumor suppressors (Simin et al., 2004) or activation of 
oncogenes (Morrison & Leder, 1994) along with dysregulation in matrix 
metalloproteinases (Sternlicht, Bissell, & Werb, 2000), collagen density (Provenzano et 
al., 2008), genes of the notch pathway (Robbins, Blondel, Gallahan, & Callahan, 1992) 
and dietary fat (Welsch, 1987). However, involvement of nucleotide excision repair in 




2.3.1.2 Tumor promotion 
Tumor promotion allows the cell harboring the genetic alteration to bypass 
cellular checkpoints and thrive, which ultimately manifests as a tumor mass in the case of 
solid tumors (Diamond, O'Brien, & Baird, 1980). A multitude of factors can contribute to 
tumor promotion, including endogenous promoters like prostaglandins as well as 
exogenous chemical promoters (Pitot, 1991). Therefore, tumor promotion has been 
thought of as a target for anti-cancer interventions, as they are reversible up until the 
formation of a benign tumor (Marks, Fürstenberger, & Müller-Decker, 2007).  
2.3.1.3 Tumor progression 
Tumor progression is where a formed cell harbors irreversible changes that leads 
to the creation of a subpopulation of cells that go on to become increasingly invasive. 
Such changes involve mutations or mutation-like events in oncogenes (e.g., Ras and src) 
as well as tumor suppressor genes (e.g. p53 and APC) and studies involving early versus 
late stage cancers have shown step-wise accumulation of such changes (Yokota, 2000). 
The number of somatic non-synonymous mutations, which means mutations that cause a 
downstream change in the functional protein coded by the gene harboring the mutation, 
has not been found correlated to stage, suggesting some mutations are lost during tumor 
progression while others are gained (Xia Li, 2016). An ovarian cancer study found losses 
in chromosomal bands to be common in earlier stages, whereas amplifications were seen 
in greater numbers in late stage, making the later a characteristic of tumor progression 
(Shridhar et al., 2001).  A major hallmark of cancer, which is increased genomic 




the loss or reduction in the NER capacity has been mostly implicated to contribute to 
genomic instability (Hanahan & Weinberg, 2000). 
Cancer, therefore is a manifestation of a step-wise accumulation of driver as well 
as passenger alterations where the former are responsible for tumor initiation and 
promotion, while the latter mainly are a characteristic of tumor progression. 
2.3.2 Somatic evolution in carcinogenesis 
2.3.2.1 Driver events 
 Development of cancer is a complex process involving the interplay of a number 
of interconnected events. It is now an established theory, that a solid tumor is the ultimate 
fate of clonal expansion of specific cells that harbor molecular alterations that the cell 
acquires on its way to neoplasia. The initiation of these mutations or alterations could be 
due to a variety of reasons which include, but are not limited to, external insults from 
chemicals as well as internal processes like oxidative damage, in sporadic cases of 
cancer. Now it is important to note that not all the abnormalities seen in a tumor cell are 
present from the start. These changes are acquired during expansion of the cells harboring 
the initial molecular alteration (which is more commonly referred to as the ‘driver’ event 
or events). This driver event provides selective advantage to the cell that helps it to 
bypass cellular checkpoints and proliferate, generating a clone of such cells, by evading 
certain checkpoints that regulate normal cellular growth, proliferation and function. 
These include cessation of replication upon damage detection and cell-to-cell contact, 
apoptosis etc. (Hanahan & Weinberg, 2000). This driver event makes the cell prone to 
further abnormal alterations (known as ‘passenger’ events)  until a final change that gives 




and histology (Vogelstein et al., 2013). Computational approaches can help determine the 
driver events that are involved in the development of cancers. Rajendran and Deng have 
reviewed 12 such approaches to find driver mutations in breast cancer and found 63 
driver genes. An interesting aspect of their results was that none of these genes included 
genes from the NER pathway (Rajendran & Deng, 2017). This point further emphasizes 
the importance of our study in early stage disease with a known phenotype as the 
correlative element.  
2.3.2.2 Passenger events 
The passenger events offer no selective advantage to the cells, but accumulate in 
the pre-neoplastic cells, increasing their mutation burden. This expansion often goes 
unnoticed by clinicians and researchers trying to focus on the disease itself and the 
treatment for its eradication. The harboring of these changes takes time, as a mutation (or 
a mutation-like molecular alteration) is usually a one in a millionth event. This explains 
why the majority of the cancer cases occur later in life (Hahn & Weinberg, 2002; 
Vogelstein et al., 2013). The exception to this rule is pediatric cancers, which more often 
than not, result from genetic predisposition to the disease. Sporadic cancers, i.e., the ones 
that are not attributed to a genetically inherited germline predisposition are mostly seen in 
older individuals. 
 Evidence regarding the theory of clonal selection or ‘stemness’ of a cancer cell 
came from initial studies. The idea that tumors develop from a cell that is preferentially 
selected originated, and this was also called a tumor ‘stemline’ (Nowell, 1976). Rodent 
models of cancer have also shown that cancer that is induced chemically is clonal in 




Deamant, 1987). Rodents have a much more limited lifespan than humans and may 
reflect a narrower range of possibilities simply due to the lack of decades and time for the 
original clone to further evolve(Y. Ma et al., 2015).  Now, molecular studies of tumor 
heterogeneity in humans show that multiple cell types may be present in a neoplastic 
lesion that were initiated by an important event or events that decreased genomic stability 
early and allowed for the explosion and expansion of several alternative successful paths 
forward. The fact still remains that the earlier initiating and promoting events somehow 
led to a tumor mass which is a result of preferential selection of altered cells and their 
clonal expansion. 
 Tumor heterogeneity can be explained with an alternative model, which is the 
cancer stem cell (CSC) theory of development of cancer. This theory states that a single 
mutated cancer stem cell leads to sequential development of generations of differentiated 
as well as more stem cells, thus adding variety into the pool of clonal cancer cells 
(Marjanovic, Weinberg, & Chaffer, 2013).  The CSC theory also stresses the fact that 
tumor evolution is in fact clonal. 
2.3.3 Models of Carcinogenesis 
2.3.3.1 Knudson’s two hit model for carcinogenesis 
  This model served as the earliest account for a multi-step tumorigenesis theory 
which was proposed by Nordling in 1953 (Nordling, 1953) and supported by evidence 
from Knudson in 1971. Knudson used a cohort of 48 patients with retinoblastoma to test 
his mutation models in cases of bilateral versus unilateral retinoblastoma patients and 
their age of onset of the disease. He found a correlation with bilateral retinoblastoma (in 




mutation in the retinoblastoma gene requires only one sporadic mutation event in the 
gene for phenotypic manifestation of the disease. Knudson also found a correlation 
between unilateral retinoblastoma and a two-mutation model, where both mutations in the 
retinoblastoma gene are sporadic events (Knudson, 1971). Thus, this model gave the 
perfect working theory for the identification of tumor-suppressor genes and their 
mechanism of loss of function in cancer.  
Current multi-step models for carcinogenesis are built upon Knudson’s model 
which, although suffices for explaining the occurrence of retinoblastoma, might be 
simplistic in the case of other cancers. Models following this took into account other 
scenarios in tumor suppressor genes that this model does not explain, like 
haploinsufficiency, multiple gene interactions or loss/gain of function isoforms (Paige, 
2003). 
2.3.3.2 Multistep model for colorectal carcinogenesis 
Mathematical and theoretical models had in the past been proposed to enumerate 
the multi-step process of neoplasia (Armitage, 1985). One of the most ground-breaking 
studies that provides clinical evidence for these models was provided by Bert Vogelstein 
and his colleagues. Vogelstein proposed a model for colon carcinogenesis and was able to 
determine the changes that occurred during each step of progression of colon cancer  
from a familial lineage of colon cancer called HNPCC (Hereditary nonpolyposis 
colorectal cancer) (Fearon & Vogelstein, 1990). In this model, pathological and 
molecular changes happening at each step of carcinogenesis from a normal colon tissue 
to a tumor have been delineated. This has been possible as colorectal cancer passes 




germline mutation carrying family (Vogelstein & Kinzler, 1993). The main steps 
involved in the carcinogenesis of the colon are sequential mutations first in the APC 
tumor suppressor gene causing loss of its function and then the Ras oncogene causing its 
activation, and methylation is involved in between these as well. Finally, DDC and p53 
genes are mutated causing loss of both DDC and p53 activity leading to a tumor (Figure 
2.13).  
 
Figure 2.13 Genetic model of colorectal tumorigenesis. Reprinted with permission 
(Vogelstein & Kinzler, 1993)  
  
2.3.3.3 Model for Esophageal Adenocarcinoma: Barrett’s Esophagus 
 A landmark study in 1999 showed a strong association of gastroesophageal reflux 
and the development of esophageal carcinoma. This constant acid reflux leads to a benign 
condition known as Barrett’s esophagus, a precancerous precursor to esophageal 
adenocarcinoma (Lagergren, Bergström, Lindgren, & Nyrén, 1999). Barrett’s esophagus 
is histologically characterized by the replacement of the normal squamous epithelial 
mucosa to a columnar epithelium which is confirmed by an endoscopy (Fitzgerald et al., 
2013). The current guidelines available for the diagnosis of Barrett’s requires the 
presence of intestinal metaplasia, as it has been known to lead to progression and 
therefore neoplastic lesions. Genetic models of carcinogenesis from Barrett’s esophagus 




considerable sampling bias. This model is described in Figure 2.14 and gives further 
evidence for the multi-step carcinogenesis model and field cancerization theory 
(Gregson, Bornschein, & Fitzgerald, 2016). 
 Although the risk of progression of Barrett’s esophagus becoming cancerous is 
low, occurrence of epithelial dysplasia increases the risk of progression significantly 
(Kastelein et al., 2015). Therefore, the model shown by Gregson et. al. mapped the 
overlapping of possible driver mutations and dysplastic phenotype. Barrett’s is riddled 
with a mutation burden of about 10 variants per million bases, a frequency much higher 
than even some malignancies like breast cancer, myeloma, hepatocellular carcinoma and 
colorectal adenocarcinoma(Ross-Innes et al., 2015). Among the early events in dysplastic 
transformation of Barrett’s are mutations in p16, p53 as well as SMAD1 and CDKN2A 






Figure 2.14 Genetic model of transformation of Barrett’s esophagus to esophageal 
adenocarcinoma. Barrett’s esophagus provides an example for the importance of 
histopathologically normal tissue harboring genetic alterations and being a few steps away 
from becoming neoplastic. An interesting aspect of this model is the creation of “fields” and 
not all patches have all the changes shared between them. Reprinted with permission (Gregson 
et al., 2016) (Link to license: https://creativecommons.org/licenses/by-nc-sa/4.0/). 
 
2.3.3.4 Model for breast carcinogenesis 
 Bièche and Lidereau gave one of the first comprehensive models for the 
alterations seen in the development of mammary tumorigenesis. This model shows well 




normal breast undergoes hyperplastic growth that first manifests as in-situ carcinoma 
(ductal or lobular) and then proceeds to invasive breast cancer followed by metastatic 
breast cancer. The major alterations that lead to the transformation included activating 
mutations in MYC and ERBB2 leading to their overexpression. Mutations or loss of 
heterozygosity in tumor suppressor genes TP53 and NME1 is also involved. Loss of 
heterozygosity at a number of locations is seen in the transformation of invasive 
carcinoma to metastatic (Figure 2.15) (Bieche & Lidereau, 1995). 
 
 
Figure 2.15 Model of genetic alterations in mammary carcinogenesis. Reprinted with 
permission (Bieche & Lidereau, 1995) 
 
A caveat to the breast carcinogenesis model is that although conceptually correct, 
the stages in breast cancer do not always necessarily follow this order and have been 
known to skip steps. For example, hyperplasia in the breast may lead to invasive 
carcinoma does not always go through the in-situ carcinoma stage (Page et al., 2003). 
Also, the heterogeneity of breast cancer makes the elucidation of specific alterations 
related to tumorigeneses extremely difficult, as certain mutations tend arise preferentially 




the ductal and medullary tumors than other histotypes  (Marchetti et al., 1993).  
Moreover, distinct molecular profiles and biologies of the subtypes of breast cancer are 
evidence that breast cancer is a complex disease (Guedj et al., 2012).  
Further evidence is needed for a conclusive mammary tumorigenesis model. Most 
of the molecular changes listed at the end of this schematic are from studies performed on 
late stage breast cancers. They are therefore not likely to be drivers but could reflect a 
combination of many generations of genetic changes, some of which occurred rather 
recently in a long progression of changes. To determine the early changes requires a 
study of early stage breast cancer, with isogenically matching tissues.  
2.3.4 Field cancerization 
 The harboring of abnormal genetic alterations predisposing a cell towards 
neoplasia and offering selective growth and proliferative advantage raises an important 
point. If the clonal expansion of cells at each step after acquiring these abnormal 
alterations is factored in, there are patches or “fields” of these abnormal cells generated in 
a 2 and 3-dimensional plane in a tissue. This field of cells harboring the abnormal 
alterations, some of which will be shared with the tumor, have been found to be clonal. 
The cells forming these fields may be otherwise histopathologically normal and lack the 
invasion and metastatic markers found in cancer (Braakhuis, Tabor, Kummer, Leemans, 
& Brakenhoff, 2003).  
The idea of field carcinogenesis was introduced by Slaughter and colleagues in 
1944 and the term was subsequently coined in 1953. Slaughter studied the non-tumor 
adjacent tissue along with tumors in 783 patients with squamous cell carcinoma of the 




microscopically abnormal in all patients studied and the presence of independent multi-
focal tumors was seen in 88 patients, indicating ‘pre-conditioning’ of the surrounding 
benign tissue to ultimately transform to cancerous lesions (Slaughter, Southwick, & 
Smejkal, 1953). 
 An interesting aspect of the field cancerization theory is that it explains the 
development of new tumors from a genetic standpoint during recurrence of a cancer type. 
This phenomenon was originally shown in 1957 by Qualheim and Gall with respect to 
breast cancer, where they analyzed histological sections of 157 resected breasts from 
patients with breast cancer. Out of these, 54% had multi-focal tumors and 29% had 
different histological patterns from one another, suggesting the convergence of two or 
more tumors (Qualheim & Gall, 1957). Another study showed that local recurrences of 
tumors of the head and neck were genetically more closely related to the surrounding 
mucosa than the original primary tumor (Tabor et al., 2001).  
 Evidence for field cancerization has also been shown in the carcinogenesis of the 
skin (Stern, Bolshakov, Nataraj, & Ananthaswamy, 2002), lung (Franklin et al., 1997), 
cervix (T. Y. Chu, Shen, Lee, & Liu, 1999), vulva (Rosenthal, Ryan, Hopster, & Jacobs, 
2002), prostate (Nonn, Ananthanarayanan, & Gann, 2009), colon (Jothy et al., 1996), 
esophagus (DeWard & Critchley-Thorne, 2017) and bladder (Försti, Louhelainen, 
Söderberg, Wijkström, & Hemminki, 2001; Takahashi et al., 1998). 
All in all, the theory of field cancerization emphasizes the importance of studying 
the histopathologically normal tissue surrounding the tumor and this makes the non-
tumor adjacent tissue a great model system for the evaluation of genetic changes 




associated with the non-tumor adjacent tissue that distinguishes it as being cancer prone 
in spite of its normal histological appearance. Our study utilizes such a system. 
2.3.5 In-vitro model systems for normal mammary cells 
2.3.5.1 Human mammary epithelial cultures (HMECs) 
 Evidence for the ability to be able to culture human mammary cells in vitro came 
from the studies of several groups.  Among these was Martha Stampfer and colleagues in 
the 1980s. This group cultured human mammary tissue obtained from non-diseased 
breast reduction mammoplasty surgeries. This procedure is usually performed for 
aesthetic or medical purposes as women with large breasts suffer from poor posture, 
backaches and breast pain (Kerrigan et al., 2001). Stampfer and colleagues established 
HMECs by gentle laceration of breast reduction tissue and culturing it in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum. 
Collagenase and hyaluronidase enzymes were used to break down the stroma and the 
basement membrane. Finally, they showed that used of an enriched medium 
supplemented with supernatant medium of the early HMECs, which they called 
conditioned medium (CM) led to stimulation of growth of mammary cells in culture up to 
a couple sub-cultures, after which the cells start to show senescence and decrease in their 
proliferation. While the enriched medium supported the outgrowth of epithelial cell 
types, a non-enriched medium was shown to favor the growth of myoepithelial cells that 
have a more fibroblastic phenotype (Stampfer, Hallowes, & Hackett, 1980).  
A modified culture protocol showed that the use of a pituitary extract without the 
use of serum extended the number of subcultures to 20 passages for these human 




later shown by expression microarray analysis to be myoepithelial in origin (Ince et al., 
2007). 
 The culture of HMECs have now evolved to include the use of basement 
membrane extracts or extra-cellular matrices (ECMs), to support the growth of non-
transformed mammary cells in-vitro. This extract was first isolated from a tumor in mice 
and had properties of a liquid at 4°C. but forms a gel-like consistency at 370 C (Kleinman 
& Martin, 2005). A commonly known brand for this is Matrigel (Bissell & Hall, 1987; 
Kleinman & Martin, 2005). These basement membrane extracts contain growth factors, 
collagen, lamelin and other components, that mimic the basement membrane in-vivo 
(Benton, Kleinman, George, & Arnaoutova, 2011). Use of the ECM to culture HMECs 
have shown acini formation along with production of milk proteins with breast epithelial 
cells and this has been extensively studied by Bissell and colleagues (Ghajar & Bissell, 
2008) primarily from mouse mammary glands. The formation of tubular capillaries is 
observed with endothelial cell culture on ECM (Arnaoutova, George, Kleinman, & 
Benton, 2009) . Where normal cells appear to grow as aggregates on ECM, culture of 
cancer cells show an independent and invasive morphology and therefore ECM is used in 
an assay to study the invasiveness of cancer cells (Albini et al., 1987).  
2.3.5.2 MCF-10A as a normal breast line 
 MCF-10 is a cell line derived from a woman who had a fibrocystic disease and 
underwent subcutaneous mastectomy by the Michigan Cancer Foundation. This line had 
the characteristics of a normal cell line, wherein it had a diploid karyotype for earlier 
cultures and some rearrangements and a near-diploid karyotype in further subcultures. 




hormones and growth factors and did not form tumors upon transplantation in mice. 
Interestingly, the continuation of growth of this cell line in vitro was observed to be 
dependent on the concentration of Ca+. When MCF-10 was cultured in regular DMEM 
with 5% equine serum containing Ca+, the cells still reached senescence and were mortal. 
However, upon transferring to a medium containing lower calcium chloride 
concentrations and maintaining the cells in culture for a period of 849 days, MCF-10 
cells acquired resistance to calcium-induced senescence and showed an immortal growth 
pattern in DMEM with regular calcium concentrations (Soule et al., 1990; Soule & 
McGrath, 1986). This immortal sub-line of MCF-10 was termed as MCF-10A which was 
widely used thereafter and is still used as a model for normal human mammary cells in 
literature (Qu et al., 2015). 
2.3.6 In-vitro model systems for breast tumors 
 Commercially available cell lines are commonly used as model systems to study 
the cancers of the breast as well as other organs. These cell lines provide advantages of 
having unlimited growth potential and high turnover rate. They also lack the 
disadvantage of cellular heterogeneity that comes with using tissue samples and therefore 
produce reliable and reproducible results. These commercially available cell lines are 
used extensively in literature and have broadened the horizons of our knowledge 
regarding metastasis and hormonal therapy in cancer (Burdall, Hanby, Lansdown, & 
Speirs, 2003). 
 A major drawback with these cell lines is that they are established from pleural 




others) (Riaz et al., 2013). These therefore are not representative of early stage breast 
cancer and would not be proper model systems to study the etiology of breast cancer.  
 Subsequent cell lines from earlier stage breast cancers are becoming more 
common (J. W. Shay, Wright, & Werbin, 1991; Van Der Haegen & Shay, 1993).  
However, immortalization of these cell lines has been achieved using immortalizing 
agents like viruses (SV40), Papilloma virus components and telomerase (hTERT) which 
have been known to affect multiple DNA damage signaling and repair (Boichuk, Hu, 
Hein, & Gjoerup, 2010; J. Shay, Wright, Brasiskyte, & Van der Haegen, 1993; Van Der 
Haegen & Shay, 1993). 
2.3.7 Tissue engineering system of the Latimer Lab 
 Due to the drawbacks mentioned above, we have established a novel tissue 
engineering system to overcome the drawbacks with the available model systems 
mentioned above. Using this tissue engineering system, the Latimer Lab has established 
over 150 extended explants (< 13 passages) and cell lines (> 13 passages) from the 
following: breast tumors representing all stages and molecular types of breast cancers 
(85% success), matched histopathologically normal tissues adjacent to the tumors (75% 
success), ductal carcinoma in-situ and normal non-diseased breast tissue obtained from 
women undergoing reduction mammoplasty surgeries (100%) for aesthetic or medical 
purposes.  
 Using this system, tissue samples are minced and plated onto a basement 
membrane extract to support the growth of cells in these cultures. A specialized nutrient 
medium is used which was originally established from a growth medium used for 




(Latimer, 2000). These primary cultures are then allowed to grow by maintaining them at 
37°C. and 10% CO2 after which they are passaged into extended explants. These 
extended explants are then deemed as cell lines after passage number 13, as this is when 
they establish a stable, albeit slow, growth pattern (Figure 2.16). There are no 
immortalizing agents used in this culture system in order to keep them pristine and true to 
their origin. Validation of representative cell lines in this collection has been performed 
using karyotype analysis, expression microarray analysis, RNA-seq analysis and 
validation of ER status using RT-PCR. 
 The advantage of this culture system is that it has allowed us to perform extensive 
molecular studies on matched cell line pairs of tumor and non-tumor adjacent samples 
from the same patient, which would otherwise not be possible on tissue samples or 
primary cultures of the same. At the same time, the slower rate of growth of our breast 
cultures is a drawback as it leads to longer experimental turn over times. Also, these 
cultures, just like 2-dimensional culture systems, tend to select for a more fibroblastic 
morphology among mixed cultures. However, we have previously compared differences 
between NER capacities between fibroblastic and epithelial cell types in our breast 
cultures and found no significant difference between the two cell types (Latimer et al., 
2003).  The presence of basement membrane extract in these dishes maintains epithelial 
cells which in the primary and early passaged state form 3D structures that can 
differentiate all the way to ductal systems in non-diseased breast and some non-tumor 






Figure 2.16A Tissue engineering system at the Latimer Lab. Tissue samples obtained from 
patients undergoing breast surgery are minced and placed into dishes or slides coated with 
basement membrane extract at 37°C and 10% CO2. These primary cultures are further passaged 













Figure 2.16B Latimer tissue engineering system.  This timeline shows the progressive 
differentiation manifested by non-diseased breast reduction mammoplasties placed into 
primary culture 
 
2.3.8 NTA in breast cancer 
 Blood is commonly used as a normal control for studies involving cancer, 
especially for the discovery of biomarkers (H. Dai et al., 2017; Mudenda et al., 1994). 
This is mainly to eliminate invasive procedures to aid in diagnosis as blood is easy to 
obtain. However, tissue specific differences make blood a poor representative for 
comparison of cancer cell types. We have previously shown that the NER capacity in 
peripheral blood lymphocytes is lower than that of normal breast tissue samples (Latimer 
et al., 2003). Therefore, the importance of using non-diseased tissue of similar origin as 
the tumor has been recognized in the scientific community, which is hard to obtain in 
majority of the cases. 
 The tissue adjacent to the tumor from the same lineage, which we call the non-
tumor adjacent or NTA, has been used traditionally in literature as a normal control to 
establish cancer biomarkers and tumor-specific abnormalities. Certain important studies 
showed karyotypic changes in the adjacent normal tissue and therefore, laid the 
groundwork for the NTA tissue being genetically altered (E. R. Fisher & Paulson, 1978; 
Teixeira, Pandis, Bardi, Andersen, & Heim, 1996; Teixeira et al., 1995). However, 




prevalent in the literature after factoring in field cancerization, studies to date still 
generally use NTA as a normal control or at least as a measure of “pre-existing” variants. 
Table 2.5 delineates the use of NTA in breast cancer and shows the need for further 
evidence of the possible genetic abnormality of the NTA tissue, seeing that it is still being 




Table 2.5 Studies using NTA in breast cancer and their context of use 
NTA Status Study description and major finding Reference 
NTA used as normal 
control  
Low Caspase-I expression in breast cancer compared to tumor adjacent, 
promoting proliferation and invasion 
(Y. Sun & Guo, 2018) 
 Reduction of isocitrate dehydrogenase-I expression and high Snail 
expression correlates with poor prognosis of breast cancer 
(W.-S. Liu et al., 2018) 
 PD-L1 overexpression in breast cancer, correlated with lymph node status, 
grade and clinical stage  
(F. Li, Ren, & Wang, 
2018; Raji et al., 2013) 
 Effects of 4-hydroxyltamoxifen on human breast cancer cells and 
confirmation of gene expression patterns in breast cancer tissues and tumor 
adjacent tissues 
(Fang, Yao, Luo, & 
Zhang, 2018) 
 Increased 5-formylcytosine and 5-caboxymethylcytosine in tumors 
compared to adjacent normal; distinct DNA methylation profiles in different 
molecular subtypes of breast tumors compared to tumor-adjacent tissues 
(Guo et al., 2017) 
 Higher expression of matrix metalloproteinases MMP-2 and MMP-9 in 
breast cancer as compared to tumor adjacent tissues; potential use as 
biomarkers to predict prognosis 
(Hai Li, Qiu, Li, & 
Wang, 2017) 
 Increased PRKDC expression (DNA-dependent kinase catalytic subunit-
involved in DNA repair) in breast tumors compared to non-tumor adjacent 
breast samples 
(G. Sun et al., 2017) 
 Expression quantitative loci analysis of 71 SNPs in 376 invasive breast 
FFPE samples compared with 264 tumor-adjacent normal tissues; found 21 
loci associated with expression variation in 271 genes compared to tumor-
adjacent normal 
(Quiroz-Zárate et al., 
2017) 
 Differential gene expression using breast tissues and non-tumor adjacent 
samples in Lebanese women using the Affymetrix HG U133 Plus 2.0 array 
(Makoukji et al., 2016) 
 Premature polyadenylation of MAGI3 leading to the activation of an 
oncogene observed in 160 breast tumors but not in matched normal adjacent 
tissues  





NTA Status Study description and major finding Reference 
 Overexpression of TPX2 in breast cancer compared to adjacent breast 
leading to cell migration and invasion 
(Y. Yang et al., 2015) 
 HAX1 and Ki-67 overexpression in breast cancer than adjacent normal 
tissues, leading to promotion of tumor invasion and metastasis 
(Sheng & Ni, 2015) 
 Global hypomethylation of 5-methylcytosines as a biomarker in breast 
cancer, compared with 309 normal adjacent tissues  
(Tsai et al., 2015) 
 R-Ras activation seen in normal adjacent tissues but not in breast cancer 
tissues, suggesting a protective role of R-Ras in breast cancer 
(J. Song, Zheng, Bu, Fei, 
& Shi, 2014) 
 Field emission electron microscopy used to identify benign adjacent tissue 
from cancerous tissues 
(Pandya, Chen, Goodell, 
Foran, & Desai, 2014) 
 STAT3 activation leads to malignancy and metastasis in breast cancer 
tissues compared to normal tumor-adjacent breast tissues  
(X. Liu et al., 2014) 
 Mitochondrial DNA as a biomarker for breast cancer, significantly lower in 
buffy coat and tumor tissue but not in serum as compared to non-tumor 
adjacent breast tissue 
(Zhou & Chen, 2014) 
 Melanoma-associated antigen MAGE-A9 overexpression indicative of poor 
prognosis in breast cancer as compared to normal adjacent tissues  
(Xu et al., 2014) 
 Upregulated expression of TACSTD2 and Cyclin D1 in breast cancer 
compared to non-malignant tumor-adjacent tissues 
(Lin et al., 2013) 
 High expression of ALCAM (activated leukocyte cell adhesion molecule) in 
tumors compared to adjacent breast tissue; associated with metastasis and 
invasion 
(Piao et al., 2012) 
 DNA adducts due to PhIP ( a chemical in charred meat and tobacco smoke) 
are not present in non-tumor adjacent breast samples acquired from 70 
breast cancer patients  
(Gu et al., 2011) 
 Differential gene expression in breast cancer tissues compared to tumor-
adjacent normal breast tissue in Saudi women 




NTA Status Study description and major finding Reference 
 Formation of 4-ABP-DNA adducts due to smoking associated with breast 
cancer; compared with 55 normal adjacent breast tissues 
(Faraglia et al., 2003) 
NTA abnormal Fibroblasts from tumor-adjacent tissue promote cell growth in the presence 
of breast cancer cells, but otherwise suppress progenitor cells in a normal 
breast environment 
(Chatterjee et al., 2018) 
 Hypermethylation of CDKN2A in tumor-adjacent tissues and tumor-distant 
tissues compared to normal non-diseased breast tissues; supports field 
cancerization theory  
(Spitzwieser et al., 2017) 
 Heterogenous patterns of enhancement in quantitative imaging 
characteristics of tumor-adjacent parenchyma showed an enrichment in the 
tumor necrotic factor pathway and a poor survival in breast cancer 
(J. Wu et al., 2017) 
 Tumor-induced STAT1 expression was shown to affect surrounding tissue 
causing dysregulation of tissue homeostasis. Field effect of cancer was 
shown in the tumor microenvironment  
(Zellmer et al., 2017) 
 HIN-1 methylation was found to be a putative biomarker for detecting field 
cancerization in breast cancer 
(Spitzwieser, Holzweber, 
Pfeiler, Hacker, & 
Cichna-Markl, 2015) 
 NF-kB as an inflammatory marker and a potential inhibitory target in 
adjacent stroma of the breast 
(Katanov et al., 2015) 
 IGF-2 expression in invasive breast tumors was higher than in the tumor-
adjacent tissue. However, expression of IGF-2 in the tumor-adjacent tissue 
was in turn higher than that in non-diseased breast tissue  
(Jun Qiu, Yang, Rao, Du, 
& Kalembo, 2012) 
 Differential as well as shared miRNA expression profiles among 3 breast 
tumors, their adjacent normal tissues and non-diseased breast tissues 
(Persson et al., 2011) 
 Hypermethylation of 8 tumor suppressor genes detected in all of the tumor 
tissues from invasive carcinoma of the breast as well as tumor-adjacent 
tissues. However, this was not detected in WBC samples of same patients 




NTA Status Study description and major finding Reference 
 Gln allele due to an XRCC1 polymorphism is detected frequently in tumor-
adjacent breast than in non-diseased breast samples from reduction 
mammoplasty 
(Ali, Meza, Rogan, & 
Chakravarti, 2008) 
 Structural polymorphism on chromosome 11 detected in both tumor DNA 
and tumor-adjacent breast DNA, which is also a hotspot for DNA 
methylation 
(Clark & Smith, 2008) 
 Differential expression of insulin-like growth factor 1 (IGF1) in tumor and 
tumor-adjacent tissues from invasive breast cancer; no difference in IGF 
between tumor and tumor-adjacent breast in benign disease 
(Shin et al., 2007) 
 Study provides evidence of field cancerization. Aneusomy of chromosome 
1 and 17 detected shared in 66% of tumor-adjacent samples, similar to that 
of the tumors 
(Botti et al., 2000) 
 Residual tumor found in 60% tumor adjacent samples on which mastectomy 
was performed, and residual tumor also found in distant sites  
(Singer, 1993) 




Lower lipid metabolism by alcohol intake in ER+ breast tumors and their 
tumor adjacent tissues; gene set enrichment was similar in ER- tumors and 
their tumor adjacent tissues 
(J. Wang et al., 2017) 
 Detected 4 somatic variants in cell-free DNA from frozen breast tumor 
samples; found high number of variants in the tumor-adjacent FFPE 
samples, most of which were C>T transitions 
(Weerts et al., 2017) 
 Promoter methylation of ABCB1, ABCC1 and ABCG1 analyzed in breast 
tumors, tumor adjacent and tumor distant tissues based on previous studies 
showing the phenomenon in tumor adjacent tissues; did not find significant 
methylation in tumor adjacent 
(Spitzwieser et al., 2016) 
 Adjacent adipose tissue from invasive breast cancers were compared to 
those from non-malignant samples; found increased inflammatory markers 
in the adjacent adipose tissue of invasive breast cancers 




NTA Status Study description and major finding Reference 
 Differences in the proteomics of tumor adjacent stroma and tumor-distant 
stroma of invasive ductal carcinomas 
(Reddy et al., 2014) 
 Tumor-adjacent breast did not show gene expression profile that 
differentiate breast tumors from non-diseased breast reduction samples, but 
tumor-adjacent breast samples from ER-/PR-/HER2- tumors clustered with 
those from basal type 
(Finak et al., 2006) 
 Smoking caused pattern of adducts called diagonal zone of radioactivity in 
30% of tumor and tumor-adjacent breast tissues 





2.4 Epigenetic regulation of gene expression 
 The age old adage for mechanism of carcinogenesis states that specific genetic 
alterations in the sequence of nucleotides, known as mutations, in certain genes either 
results in a loss of tumor-suppressing functions of these genes or a gain of oncogenic 
function (Grandér, 1998). Cancer research has now progressed to include alterations in 
the genome that are heritable and do not involve a direct change in the DNA sequence. 
These are epigenetic alteration and they are known as an ‘epimutations’ (Handy, Castro, 
& Loscalzo, 2011). Epigenetic mechanisms of regulation include DNA methylation, 
histone and chromatin modifications and regulation via small and long non-coding RNA 
molecules. These mechanisms can affect transcriptional regulation of genes. 
2.4.1 Non-coding RNA molecules as regulators of gene expression 
 In Chapter 4 of this thesis, we did not find methylation to be the putative pathway 
of regulation of NER in our cell line pairs studied. Therefore, we will be exploring the 
role of small non-coding RNA molecules, especially microRNA, in the regulation of this 
pathway. This has been previously studied in the lab with respect to late stage breast 
cancer (As Sobeai, 2017). 
Non-coding RNA (ncRNA) molecules are important regulatory moieties that alter 
gene expression by specific mechanisms particular to the type of ncRNA. These include 
transfer RNA (tRNA), ribosomal RNA (rRNA), micro RNA (miRNA), small interfering 
RNA (siRNA). small nuclear RNA (snRNA), small nucleolar RNA (snoRNA) and long 
non-coding RNA (lncRNA).  
 Small non-coding RNA molecules, especially miRNAs, are involved in post 




regulate translation. miRNAs are approximately 19-21 nucleotide-long single-stranded 
fragments of RNA that most often bind to the 3’ UTR of mRNA (Bartel, 2004). 
Depending on the specificity and site of binding, mRNA and lead either to mRNA 
degradation or its inhibition towards translation (Doench, Petersen, & Sharp, 2003; 
Hutvágner & Zamore, 2002; Yan Zeng, Wagner, & Cullen, 2002). Small interfering RNA 
on the other hand, have perfect complementarity to their mRNA binding sites, induce 
mRNA degradation upon binding and are about 20-25 nucleotide-long (Agrawal et al., 
2003). Small nuclear RNA is involved in mRNA splicing and snoRNA plays a role as a 
guide in rRNA modifications. Long non-coding RNAs are more than 200 nucleotides in 
length and are involved in regulation of the aforementioned small ncRNA molecules 
(Kung, Colognori, & Lee, 2013). 
2.4.2 Chromatin modifications  
 Histones are proteins that give structure to chromatin, as DNA coils onto the 
histone proteins, thus forming nucleosomes. Transcribed DNA, which is about 2-3% of 
the genome, is in an open configuration called Euchromatin, which readily allows access 
to DNA for transcription factors to bind and initiate gene expression. Heterochromatin, 
on the other hand, is tightly coiled chromatin, usually found with heavy methylation and 
deacetylation of histones. Out of the many modifications, those that may alter 
transcription and thereby gene expression include acetylation, methylation, ubiquitination 





2.4.3 DNA methylation 
DNA methylation is the most studied epigenetic mechanism, with the earliest 
account of the mechanism as a hereditary epigenetic mark and its direct role in gene 
silencing came in 1975 (Holliday & Pugh, 1975; Riggs, 1975).  Methylation is more 
associated with heterochromatin, which is the highly condensed, tightly-coiled chromatin 
configuration. Euchromatin, which is the less condensed and open chromatin 
configuration, is transcriptionally active and therefore devoid of a heavily methylated 
DNA signature (Handy et al., 2011; Keshet, Lieman-Hurwitz, & Cedar, 1986; Richards 
& Elgin, 2002). 
2.4.4 Sites of DNA methylation 
2.4.4.1 CpG islands 
 DNA methylation occurs at the C5 position of cytosine bases at cytosine-guanine 
dinucleotides in DNA, also known as CpG sites. CpG refers to 5’ – cytosine – phosphate 
– guanine – 3’ on one strand of DNA, and this would form a palindromic dinucleotide 
sequence along with the complementary strand. The genomes of vertebrates are usually 
depleted in CpG sites, due to the spontaneous deamination of cytosine to thymine (Bird, 
1980). CpG dinucleotides are known to be present in clusters on the promoter regions of 
genes and are generally unmethylated. These clusters are known as CpG islands. CpG 
islands are defined as a 200 kb DNA fragment with a GC percentage of greater than 50% 
and an observed to expected ratio of C to G greater than 0.6 (Gardiner-Garden & 
Frommer, 1987; Larsen, Gundersen, Lopez, & Prydz, 1992). Researchers have used CpG 




regions of a majority of Eukaryotic genes are overlapping one or more CpG islands 
(Antequera & Bird, 1993; Lee, Salido, & Yen, 1994; Tribioli et al., 1994)..  
Not all CpG islands lie on promoter regions of genes and promoter-associated 
CpG islands constitute a fraction of the total number of known CpG islands in the 
mammalian genome. Larsen et. al. have stated that all housekeeping genes are CpG 
island-rich whereas only a fraction of tissue specific and coding genes have CpG islands 
5’ of  their promoters (Larsen et al., 1992). 
2.4.4.2 Structure of a CpG island 
  While CpG island was discovered as clustered CpG sites, mostly overlapping 
promoter regions of genes, important CpG sites have been discovered a couple thousand 
bases upstream and downstream of a CpG island. This region, known as the CpG island 
“shore”, is 2kb upstream and downstream of the CpG island,  known as the north shore 
and the south shore of a CpG island respectively (Irizarry et al., 2009). Moreover, 
genomic regions 2kb upstream and downstream of the shore regions, known as CpG 
island “shelves” have also been implicated to be important in gene expression regulation 
and are queried in methylation array technologies. Apart from the CpG dinucleotides that 
are a part of CpG islands and their flanking shore and shelf regions, orphan CpG sites 
that are present in gene body regions or other regions of the genome not enriched by GCs 
are known as “Open-sea” regions (Figure 2.17) (Sandoval et al., 2011). 
 
Figure 2.17 Diagrammatic representation of a CpG island, shore and shelf regions. (Huang 





2.4.5 Mechanism of DNA methylation 
 DNA methyltransferases are the class of enzymes that methylate the cytosines of 
DNA, and three major methyltransferase enzymes have been identified, namely DNMT1, 
DNMT3a and DNMT3b. DNMT3a and DNMT3b are involved in de-novo methylation 
(Okano, Bell, Haber, & Li, 1999) whereas DNMT1 is responsible for maintaining 
methylation patters after DNA replication (Leonhardt, Page, Weier, & Bestor, 1992). 
During gametogenesis, the DNA undergoes a wave of demethylation and a complete 
reprogramming of DNA methylation occurs after implantation via the de-novo 
methyltransferases (Razin & Cedar, 1993). All three methyltransferase enzymes are 
therefore involved in embryonic development and viability (E. Li, Bestor, & Jaenisch, 
1992). 
 Demethylation of 5-methylcytosines occurs by spontaneous deamination to uracil 
or oxidation. This then is a target for the base excision repair pathway, as this change 
from cytosine to uracil is a major mutagenic event if not remediated (Kow, 2002). 
Chemical demethylation in cells can be induced in-vitro by 5-aza-2’-deoxycytidine, 
which is a DNA methyltransferase inhibitor and will inhibit the maintenance methylation 
that occurs after replication of DNA(Creusot, Acs, & Christman, 1982).  
2.4.6 Role of DNA methylation in eukaryotes 
 DNA methylation plays a major role in X-chromosome inactivation, imprinting of 
genes and gene silencing. Imprinting of genes refers to inheritance of expression patterns 
from parental genes, meaning that the copy for a gene obtained from each parent may 




requires specialized methylation patterns specific to the individual that are established 
and maintained from embryonic development into adulthood (Surani, 1998). 
Methylation is also responsible for X chromosome inactivation. In females, 
though there are two copies of the X-chromosome, only one is active while the other is 
randomly inactivated to ensure both males and females have the same X-linked dosage of 
genes (Monk & Grant, 1990).  
 DNA methylation has also been known to regulate tissue specific gene 
expression. This phenomenon is particularly observed in rabbit globin genes where 
undermethylation allowed expression of these genes in erythroid cells, but this was 
absent in non-erythroid cells (Shen & Maniatis, 1980). Expression of placental lactogen 1 
is found only in the placenta and not in any other tissues in rodents, and it was shown to 
be regulated by DNA methylation as well (J.-H. Cho et al., 2001). The regulation of 
tissue-specific gene expression by methylation is described in Figure 2.18. This 
phenomenon is particularly observed during embryonic stem cell differentiation. CpG 
sites in embryonic stem cells are largely unmethylated at CpG-rich regions (Fouse et al., 
2008). During differentiation, this pattern changes as cell-type specific methylation 
patterns are established onto the CpG sites (Meissner et al., 2008). CpG poor regions 
(that are otherwise globally hypermethylated) undergo demethylation during cellular 





2.4.7 DNA methylation and cancer 
2.4.7.1 Hypomethylation of DNA in cancer 
The earliest evidence of involvement of DNA methylation in cancer came in 1983 
where Feinberg and Vogelstein showed reduced methylation of specific genes in colon 
cancer and Gama-Sosa et.al., showed global hypomethylation in human neoplasms 
compared to normal human tissues (Feinberg & Vogelstein, 1983; Gama-Sosa et al., 
1983). Overall, a trend of DNA hypomethylation is seen in cancer, and this 
hypomethylation is mostly observed in non-genic (non-protein coding) areas of DNA. 
One explanation that has been proposed is that cancer-related mutations in the 
methyltransferase enzyme DNMT3b leads to the formation of inactive catalytic units of 
the enzyme. This abnormal alteration in the enzyme either makes it non-functional or 
competes for the binding of the functional DNMT3b (Ostler et al., 2007).  
 
Figure 2.18 Mechanisms of cell-type specific regulation of transcription by CpG 
methylation. CpG-rich regions like the CpG islands are, under normal conditions, found to be 
less methylated, where CpG poor promoters are found highly methylated. Transposons and 
repeats in DNA are always heavily methylated to ensure their silencing and hence, stability of 
the genome. Methylation prevents the binding of transcriptional factors (TFs) that activate 
transcription, whereas it favors the binding of methyl-CpG-binding domain (MBD) proteins 
thereby repressing expression. Reprinted with permission. (Carrió & Suelves, 2015) (Link to 




Another possible mechanism of DNA demethylation leading to the 
hypomethylated state in cancer is the activity of MBD2 (methyl-CpG-binding-protein-2), 
which preferentially binds to methylated CpG sites and catalyzes the breaking of the 
bond cleaving the methyl group from the cytosine (Bhattacharya, Ramchandani, Cervoni, 
& Szyf, 1999). 
DNA hypomethylation in cancer activates regions that are otherwise repressed 
transcriptionally in normal tissues. For example, viral genes are usually silenced with the 
help of DNA methylation, and hypomethylation of such integrated viral DNA (Badal et 
al., 2003). Moreover, DNA hypomethylation of repetitive DNA elements known as 
satellite DNA has also been observed in some ovarian tumors (Widschwendter et al., 
2004). Specific proto-oncogenes like MYC, RAS and HOX11 are known to be 
hypomethylated in cancer, leading to their activation and expression (Borrello et al., 
1992; Van Tongelen, Loriot, & De Smet, 2017; Watt, Kumar, & Kees, 2000). Overall, 
hypomethylation of DNA in cancer increases genomic instability due to the activation of 
these repetitive elements, transposons and specific onco-genes as well eventually paving 
the way towards a tumor phenotype(Kulis & Esteller, 2010). 
2.4.7.2 Hypermethylation of DNA in cancer 
 DNA methylation causes gene silencing for certain genes which is observed in all 
types of cancers. Since the discovery of the function of methylation, a number of studies 
have found associations with promoter hyper methylation and gene silencing in cancer. 
Most of these hypermethylated genes in cancer are tumor suppressor genes, which upon 
silencing by methylation lose function and lead to oncogenesis. Examples of these genes 




(Drexler, 1998), proteins involved in cell cycle adhesion thereby preventing abnormal 
proliferation of cells (Seuk Kim, Han, Shim, Park, & Kim, 2005) and transcription factors 
that regulate gene expression (Akiyama et al., 2003). Moreover, CpG island methylation 
of certain small non-coding RNA molecules like microRNAs have been known to silence 
their expression. These microRNAs have tumor suppressor functions and their silencing 
is observed to be implicated to contribute towards a tumor phenotype (Davalos & 
Esteller, 2010). Although the exact mechanism and reason for why only specific genes 
are methylated remain unclear, numerous studies show that methyltransferase enzymes 
preferentially target certain genes for methylation that eventually aid in the survival of 
cancer cells (Gopalakrishnan, Van Emburgh, & Robertson, 2008). 
2.4.8 DNA methylation in breast cancer  
 DNA methylation has been extensively studied in breast cancer. Evidence for 
methylation-mediated silencing of tumor suppressor genes has been shown, such as the 
inactivation of the retinoblastoma protein interacting zing finger gene RIZ1 by its 
promoter methylation in breast cancer cases (Du et al., 2001). Cyclin D2, an important 
cell cycle regulator gene has also been found to be silenced via hypermethylation of its 
promoter region in 50% of studied breast cancer cases by Evron and colleagues (Evron et 
al., 2001). Hypermethylation of CpG sites in the promoter region of the p53 gene has 
been found in breast tumors, which is has been proposed to be an alternative mechanism 
of inactivation of this tumor suppressor gene in the absence of a deleterious p53 mutation 
(Kang et al., 2001).  
One of the most interesting findings in breast cancer related to methylation is the 




regulatory proteins analogous to the epithelial marker HME1. The expression of this gene 
was observed to be reduced in breast cancer cell lines (but not in other types of cancer 
lines) by serial analysis of gene expression as well as by northern blotting. The 
mechanism of reduced expression of 14-3.3-s was found to be hypermethylation of the 
promoter region of this gene and revival of its expression after treatment with 5-aza-2’-
deoxycytidine provided evidence for methylation being its inactivating mechanism 
(Ferguson et al., 2000). An interesting aspect is that downregulation of this gene was also 
observed in the tissue adjacent to the breast, suggesting hypermethylation of  14-3.3-s is 
an early event in mammary tumorigenesis (Umbricht et al., 2001).  
The 20 canonical NER genes are rich in CpG islands in their promoter regions 
and previous work in Dr. Latimer’s laboratory showed the restoration of gene expression 
of 3 NER genes, CDK7, TFIIHp34 and TFIIHp52 after treatment of two early stage 
breast cancer lines (JL BTL-8 and JL BTL-29) with 5-aza-2’-deoxycytidine (Johnson, 
2006). Methylation in breast cancer with regards to NER is understudied in literature, as 
there is a gaping void of the lack of evidence for the role of methylation in regulation of 
the NER pathway in breast cancer. Interestingly the 14-3.3-s gene was used as a positive 
control in these experiments. 
 Involvement of methylation with respect to DNA repair has been shown for 
BRCA1 (double strand break repair), MGMT (repairs DNA damage created by alkylating 
agents and hMLH1 (mismatch repair) (Asiaf et al., 2015; Esteller, 2000; Jacot et al., 
2013). Jaime Matta and colleagues have shown that promoter hypermethylation of a gene 
belonging to the kinesin family, KIF1A, is associated with the incidence of breast cancer 




study showed that 17-beta estradiol (E2) causes the hypermethylation and therefore 
reduced expression of ERCC1 and XPC in the MCF7 cell line, which is restored upon 
treatment with 5-aza-2’-deoxycytidine treatment (Singh, Treas, Tyagi, & Gao, 2012). 
 2.4.9 Measurement of DNA methylation status 
Genome wide methylation profiling per CpG locus can be performed via the 
Methylation EPIC array by IlluminaÒ, which is also known as Illumina’s 850K 
methylation array, employs about 850K probes targeting important CpG sites curated by 
methylation experts. This chip includes more than 90% of the content of Illumina’s 450K 
array (Sandoval et al., 2011) and additional CpG sites that lie outside of CpG islands, 
FANTOM enhancers, DNase hypersensitivity areas as well as gene promoter regions 
(Illumina, 2017). MethylationEPIC arrays involve detection of the methylation status of a 
CpG site by employing single base extension of bisulfite-converted DNA fragments at 
CpG site after the fragment hybridizes to a BeadChip. Bisulfite conversion results in the 
conversion of unmethylated cytosines to uracil, while the methylated cytosines remain 
intact. Depending on the assay design, either the occurrence or absence of base extension 
determines the methylation status of the site (Balog et al., 2002). 
This assay employs two types of assay designs employing two different types of 
probes, namely Infinium I and Infinium II. Where Infinium I assay design has two beads 
each for an unmethylated and methylated locus, the Infinium II type has only one bead 
for both, methylated and unmethylated loci (Figure 4.2). Single base extension was 
carried out using the bisulfite-converted fragment of DNA hybridized to the probe, and 
laser excitation was used to detect the inserted base and therefore to determine the 




which ranges from 0 to 1, where 0 denotes an unmethylated site, 1 denotes a completely 
methylated site and 0.5 denotes a hemi-methylated site. The values are never exactly 0,1 
or 0.5,  and are continuous between 0 and 1, as the methylation status for each locus is an 
average of methylated and unmethylated bread types across about 30 bead replicates 
(Kuan, Wang, Zhou, & Chu, 2010).  
Analysis of data from methylome profiling can be performed with a variety of 
software solutions, both freeware and proprietary. Free software is provided by Illumina 
called Genome Studio that has a Methylation module enabling the analysis of both the 
450K and 850K arrays. The most commonly used programs are R-based packages. 
RnBeads (Müller, Assenov, & Lutsik, 2015) is the most popular one along with ChAMP 
(Y. Tian et al., 2017), both of which have recently developed user-friendly interfaces for 
inexperienced R users. All these software solutions enable differential methylation 
analyses, principle component analyses as well as hierarchical clustering. However, 
RnBeads was chosen as it provides, apart from individual CpG site level methylation, 
region-level differential methylation analysis where differential methylation data is 








Figure 2.19 Infinium type I and II assay designs for probes in Illumina MethylationEPIC 
array. Infinium I design employs two types of beads, one each for methylated and 
unmethylated loci respectively. Detection of methylation is based on primer extension for the 
correct bead type. Infinium II employs only one type of bead for both methylated and 
unmethylated loci and primer extension happens for both loci, however insertion of the correct 
base determines methylation status. The two types of assay designs ensure a broad coverage of 
a large number of CpG sites.  
  
 While methylation profiling using array technologies has advantages, like 
profiling of the entire methylome at low cost compared to some of the newer sequencing-
based methylation assays like bisulfite sequencing. However, it has the drawbacks 
commonly seen with array technologies. Probe bias is a major limitation, as only those 
CpG sites are queried for which probes have been designed based on evidence in 
literature (G. Russo et al., 2003).  Methylation arrays are generally used first, to 
determine where differential methylation is occurring, and then can be followed by more 




Chapter 3  
Two varieties of non-tumor adjacent breast found outside early stage 
sporadic breast cancer 
3.1 Introduction 
Breast Cancer remains a debilitating problem, the leading cause of mortality 
among women and the second most common cancer after skin cancer (R. L. Siegel, 
Miller, & Jemal, 2016). About 262000 cases were estimated to be diagnosed for the year 
2017 and 42600 women were expected to die from breast cancer in the US alone 
(Howlader et al., 2018). Breast cancer is also an expensive problem, with costs towards 
treatment increasing by an increase in the stage of breast cancer (Blumen et al., 2016). 
Although, breast cancer mortality has reduced by 38% from 1989 to 2014 and the stage 
of diagnosis has now been lowered owing to more frequent mammographic screening 
mandated for pre-menopausal women between the age of 45-54, there are about 3 million 
women walking with breast cancer to date in the US (Howlader et al., 2018). 
 Familial cases of breast cancer caused due to the inheritance of germline 
mutation in genes like BRCA1 and BRCA2 are relatively well studied in literature but 
constitute only 15% of cases of the total breast cancer incidences (Ashford, 2014). The 
etiology of sporadic breast cancer is largely unknown. As Stage I breast cancer is the 




there is a pressing need for determining the etiology and the molecular natural history for 
early stage breast cancer, ultimately aiming towards breast cancer eradication. 
 Genomic instability is a hallmark of all cancers, and is mainly caused due to the 
impairment of conserved mechanisms of repair of DNA in the human body that allows 
for accumulation of DNA damage and ultimately resulting in accumulation of mutations 
or epimutations leading to cancer (Hanahan & Weinberg, 2000). Out of the 5 major DNA 
repair mechanisms, Nucleotide Excision Repair (NER) is a particularly important one, as 
it remediates bulky adducts and inter as well as intra-strand crosslinks in DNA that distort 
the double helical DNA structure. These damages are caused due to exogenous agents 
like UV light, adducts from carcinogens in tobacco smoke like benzo[a]pyrene, as well 
as via endogenous cellular processes like oxidative stress and replication errors. 
(Friedberg et al., 2005). The link between NER and cancer has been shown by the disease 
Xeroderma Pigmentosum, which renders the individual extremely sensitive to sunlight 
(as NER repairs UV damage). Xeroderma-pigmentosum-casing mutations, which lead to 
a deficiency in the ability to perform NER, raises their risk for getting skin cancers by 
2000-fold, along with a high risk for internal cancers as well (Bradford et al., 2010; 
Kraemer, 1997)h. Therefore, NER plays an important role in cancer. 
 We have shown previously that NER capacity is intrinsically deficient in Stage I 
sporadic breast tumors compared to that of non-diseased breast reduction epithelium 
(BRE) using the traditional gold-standard Unscheduled DNA Synthesis (UDS) assay 
(Latimer et al., 2010). Gene expression also followed the trend of functional NER 
capacity, where DNA microarray results (that were validated by RNAse protection assay) 






Figure 3.1 NER capacity of Stage I primary breast tumors (n = 19) relative to that of non-
diseased BRE (n = 23). Solid lines through the two groups indicate their respective averages 








Figure 3.2 Gene and protein expression of NER genes followed the trend of functional 
NER capacity in the sporadic Stage I primary breast tumors. A) Gene expression 
microarray showed a low expression signature in all NER genes in Stage I tumors (solid bars, n 
= 3) relative to BRE (open bars, n = 3), with 9 genes significantly downregulated at p<0.05, 
which were TFIIHp44 (P = 0.024), RPAp32 (P = 0.031), XPD (P = 0.013), CSA (P = 0.046), 
CDK7 (P = 0.026), XPE (P = 0.035), DDB1 (P = 0.0002), hHRAD23B (P = 0.032), and 
RPAp70 (P = 0.036) B) RPA showed 19 out of 20 genes significantly downregulated in Stage I 
breast tumors relative to BRE except for ERCC1. C) Western blotting revealed expression of 
XPA, DDB2, and CSB proteins to be significantly downregulated in Stage I tumors relative to 




 Cancer is known to be a multistep process, with step wise changes occurring and 




Bert Vogelstein derived and established a breakthrough model of colorectal 
carcinogenesis that delineated the steps that a normal colorectal tissue would undergo at 
the genetic and epigenetic level towards neoplasia (Vogelstein & Kinzler, 1993). Such a 
multistep model exists for breast cancer as well that delineates the genetic alterations that 
take place during mammary carcinogenesis (Bièche & Lidereau, 1995) (Figure 2.15). It 
has been known that certain changes happening earlier in the trajectory of tumor 
formation, like acquiring genomic instability, accelerate additional deleterious changes 
and lead to a full-blown tumor (Rivenbark & Coleman, 2012; Vogelstein & Kinzler, 
1993; Willenbucher et al., 1999).  
The theory of field cancerization states that the pathologically normal tissue 
adjacent to the tumor harbors some of the genetic and epigenetic anomalies that are 
ultimately found accumulated in the tumor (Heaphy, Griffith, & Bisoffi, 2009; Rivenbark 
& Coleman, 2012; Trujillo et al., 2011). The pathologically normal non-tumor adjacent or 
NTA tissue therefore is a great model system to study shared changes that the normal 
tissue acquires on its way to becoming neoplastic. NTA has been used extensively in the 
literature and while some research groups detected karyotypic and other abnormalities in 
the NTA (Aran et al., 2017; Spitzwieser et al., 2017; Teixeira et al., 1995), others are 
either using the NTA as a normal control (Guo et al., 2017; Ni & Kuperwasser, 2016) or 
have deemed the finding of abnormalities in the NTA a result of contamination with the 
tumor. No study to date exists that has studied NTA with regards to sporadic breast 
cancer and NER, and our study fills this major void in the literature. 
We hypothesized that genetic alterations, including a loss of NER capacity, will 




early stage tumor, and proposed to study this hypothesis on the functional as well as 
transcriptional level of the NER pathway. We were able to identify two varieties of NTA 
samples with regards to their NER capacity. One group was named as Low: Low group 
of NTA/tumor pairs as they showed lower NER capacity in the NTA as well as tumor 
than the average of non-diseased breast samples. The other group identified was the 
High: Low group of NTA/tumor pairs having higher NER capacity in the NTA but lower 






3.2.1 Procurement of samples and establishment of cell lines 
 We established primary NTA cultures from isogenically matched NTA tissue 
samples procured along with the tumor samples as described previously (Latimer et al., 
2003). Upon resection of the tumor and the 2cm margin of histologically normal tissue 
around the tumor to ensure complete removal of the tumor, the tumor was sampled from 
a non-necrotic region and the NTA tissue was sampled about 1.5cm away from the 
margin of the tumor (Figure 3.3). All surgeries were performed at Magee Women’s 
Hospital (Institutional review board approval 0609002).  
 
Figure 3.3 Procurement of the NTA sample and its matched tumor sample. The black 
outline indicates resected tumor along with a 2cm margin. White portion indicates the 
histologically normal margin around the light blue tumor. Red circle indicates portion of the 
tumor cut out and handed to the lab, and the navy-blue circle indicates portion of the 
histologically normal NTA sample cut out and handed to us, approximately 1.5cm away from 
the tumor margin. The NTA sample was verified by a pathologist.   
 
Primary cultures for some of these matched pairs were expanded into cell lines as 
described in Chapter 2 (Figure 2.16). These cell line pairs were used for molecular 
analyses in this study. 
3.2.2 Unscheduled DNA Synthesis (UDS) Assay  
 The Unscheduled DNA synthesis (UDS) assay is the gold standard assay used for 






is traditionally used as a diagnostic test for XP and measures the incorporation of a 
radiolabeled nucleotide into DNA while DNA is allowed to be repaired after an insult 
with a fixed dose of a damage causing agent (UV-C light in this case). Incorporation of 
the radiolabeled nucleotide is detected by autoradiography after fixation of cells. 
Autoradiography generates silver grains above the nuclei of cells whose DNA underwent 
repair, and the amount of silver grains is directly proportional to the repair capacity of 
that sample, when expressed relative to the traditional control, which is a fibroblastic cell 
lines established from newborn foreskin.  
ID of the High: Low and Low: Low pairs was conducted on the NER capacity 
data on available early stage breast cancer cell line pairs of the tumor and its matched 
NTA based on UDS assays run in the past. The goal was to identify at least one 
representative of each of the High: Low and Low: Low cell line pair groups. One Low: 
Low cell line pair was already available, but there was no cell line available from the 
High: Low pair to be able to go ahead with further molecular analyses. Therefore, the 
UDS assay was used mainly to be able to identify at least one representative of the High-
Low pair group in order to proceed with downstream aims of the study. 
3.2.3 Identification of High: Low pairs 
 Available cell line pairs were run on the UDS assay with the aim of identifying a 
High: Low representative pair. Each cell line among the pairs was plated in duplicate (2 
slides) on 2-well chamber slides in MWRI medium with a dilution of 1:20 from a 
confluent 12.5cm2 flask to ensure optimum confluence for the experiment. The well 
closer to the cover glass was used as an irradiated control and covered during irradiation. 




10% fetal bovine serum (FBS) and 1% of 100x penicillin/streptomycin antibiotic 
solution. Plated cells were irradiated with UV-C light at a dose of 14J/m2 using the UV-
irradiation machine (Latimer & Kelly, 2014). Cells were then allowed to incubate for 2 
hours in a DMEM medium containing 3H-methyl thymidine at a concentration of 10 µCi/ 
mL (PerkinElmer Life Sciences®) (#Part NET027W001MC) in a Forma Series II Water 
Jacketed CO2 incubator that is dedicated to radioactive treated cultures at 37oC in 5% 
CO2. This was followed by a 2-hr chase with 10 mM non-radioactive thymidine (Sigma-
Aldrich®) (Cat# T1895) to avoid non-specific binding of the radionucleotide. Following 
the chase, cells were washed with 1X sodium citrate (Sigma-Aldrich®) (Cat# 1613859) in 
PBS and fixed using 33% acetic acid (Fisher Scientific®) (Cat# A38-500) in ethanol 
(Sigma-Aldrich®) (Cat# E7023) and 70% ethanol in distal water for 15 minutes each. The 
chambers were snapped off and gaskets peeled off of the slides, after which the slides 
were immersed in 4% perchloric acid solution (Fisher Scientific®) (Cat# A228) overnight 
at 4oC.  
The next day, slides were rinsed in distilled water and taken to the dark room, 
where they were dipped in photographic emulsion (Caresteam®) (Cat# 8895666), placed 
in slide boxes followed by wrapping them with 3 layers of foil to ensure light-tightness, 
and allowed to expose for a total of 11 days at 4oC. Two of the control slides were kept in 
a separate slide box as a tester, to be developed first in order to ensure optimum exposure. 
On day 12, the tester slides were developed in D-19 developer (Kodak®) (Cat# 1464593), 
fixed using a Kodak fixer (Kodak®) (Cat# 1971746), dried and then Giemsa stained 




nuclei to ensure optimum exposure. Upon confirmation, the rest of the slides were fixed, 
developed and stained, after which they were allowed to dry overnight and were ready for 
grain counting. 
3.2.4 Data analysis for the UDS assay 
 Silver grains over 100 non-S phase nucleus on both chambers (irradiated and 
unirradiated control) were counted by 3 independent counters. Local background was 
also counted for each field and subtracted from the counts on the non-S phase nuclei. 
Unirradiated counts for 100 non-S-phase nuclei were subtracted from irradiated counts 
for 100 non-S-phase nuclei to remove a second layer of background. Descriptive statistics 
were performed using the Data Analysis Tool Pack in Microsoft Excel and mean counts 
per nucleus on each slide and counter were averaged. Final NER capacity was expressed 
as percent relative to foreskin fibroblast (normal skin) controls. 
 S-phase indices were calculated for each cell line, which gives a measure of the 
proliferation of the cell line. This was calculated by counting the total number of cells in 
the S-phase on the unirradiated side of each slide for each cell line. This number of S-
phases was expressed as a percentage of the total number of cells counted for that side for 
the particular slide. Percentages were averaged for each counter and slide for a particular 
cell line. 
3.2.5 Isolation of total RNA  
 Total RNA was isolated using the miRNeasy mini kit for total RNA isolation 
(QiagenÒ) (Cat#217004) according to manufacturer’s protocol. Briefly, Qiazol lysis 
reagent was added onto cells plated on 4 flasks (125cm2), such that each flask received a 




309635) and the lysate out of 2 flasks was moved into one 1.5 mL tube, homogenized 
using a syringe with a 22-gauge needle by aspirating it up and down through the needle, 
and allowed to stand for 5 mins at room temperature. 140 µL of chloroform was added to 
the lysate, the tube was manually shaken vigorously for 15 seconds and allowed to stand 
on the benchtop for 3 minutes. The mixture was then centrifuged at 12,000 rpm and 4°C 
for 15 minutes to separate the aqueous layer containing RNA. This top aqueous layer was 
then separated out by pipetting it off carefully, making sure not to disturb the other layers 
to avoid contamination. 1.5 volumes of 200 proof ethanol were added to this separated 
layer at room temperature, mixed well and the solution was added to a column in 
volumes of 700 µL successively followed by centrifugation at a speed >10,000 rpm for 
15 seconds, until all of the solution is passed through the column and centrifuged.  
DNA digestion was performed with RNAse-free DNase kit (QiagenÒ) 
(Cat#79254) by incubating the column with 80 µL solution of DNase in buffer RDD for 
15 minutes at room temperature. DNase digestion was followed by washes with buffers 
RWD and RPE (twice) to prevent carry over of ethanol into the final sample. A final dry 
centrifugation for 1 minute at maximum speed (14,000 rpm) ensured complete drying of 
column and finally the sample was eluted in 50µL of RNAse-free distilled water. Each 
sample was run on Agilent’s TapeStation 4200 system (Cat# G2991AA) to assess quality 
and concentration according to manufacturer’s instructions and protocol. 1 µL of sample 
was mixed with 5µL of sample buffer (Agilent, Inc.) (Cat #5067-5577), and this solution, 
along with RNA ScreenTapes (Agilent, Inc.) (Cat #5067-5576), was loaded onto the 
TapeStation 4200 machine in 8-tube strips, with the first tube containing a sizing RNA 




3.2.6 Expression microarray using the Affymetrix HG U133 Plus 2.0 chip 
 Total RNA sample for each cell line of the Low: Low and High: Low cell lines 
along with controls, FF-F and JL BRL-6 were isolated in triplicate and a total of 1µg of 
total RNA at a concentration of 100 ng/µL for each sample was sent for gene expression 
microarray to the Genomics core at the Hussman Institute of Human Genomics, 
University of Miami. These samples were run on the Affymetrix HG U133 Plus 2.0 chip 
according to manufacturer’s instructions. The core sent back raw data comprising probe 
intensities for those hybridized to the respective RNA sample from the microarray run as 
.cel files (one .cel file per sample) which were further analyzed to obtain gene expression 
results. 
3.2.7 Analysis of expression microarray data  
 Gene expression values were obtained from the raw .cel files using Genespring 
software (Agilent, Inc.). The Probe Logarithmic Intensity Error Algorithm (PLIER) was 
used to normalize probe intensities across all samples and normalized data was 
downloaded as text files. All probe intensities corresponding to a single gene were 
averaged and values were expressed relative to the average of tumor line for that gene ad 
for each pair of cell line. Hypothesis-driven pairwise Student's t-tests were performed. 2-
tailed t-tests were performed for Low: Low pair as no difference in the expression was 
hypothesized, and 1-tailed for High: Low pair as the NTA line was hypothesized to have 
higher expression of NER genes than that of the tumor line. Data was plotted as column 




3.2.8 RNA Sequencing 
 RNA sequencing was used as a cross platform validation tool for the results 
obtained from gene expression microarrays, and also because this technology will enable 
not only quantification of gene expression, but also obtaining sequence information for 
genes and transcripts of interest, and the latter will serve a future mechanistic aim of this 
study, i.e., to study mutations in the exonic regions – if any- that might be indicative of a 
change in downstream functional expression of this gene and its products (Chapter 4 and 
5). Data obtained from RNA sequencing can be used in future to look at other important 
applications of RNA-seq, like finding products of gene fusions (fusion transcripts)-a 
common phenomenon observed in cancer, as well as looking at pathways and genes other 
than NER to uncover mechanisms underlying breast cancer etiology. 
 Total RNA was isolated from representative NTAL/BTL pairs (BTL/NTAL37 
and BTL/NTAL47) as well as from controls (foreskin fibroblast lines and normal non-
diseased breast cell line JL BRL-6) in triplicate as described above. 1ug of total RNA per 
sample (bearing a concentration of 100ng/µL per sample) was sent for sequencing to the 
Genomics Core at the Hussman Institute for Human Genomics at the University of 
Miami, where the samples were subjected to the following steps to yield raw sequence 
data, comprising RNA sequence information (one in the form of FASTA or FASTQ files. 
After confirming integrity and sample concentration using Agilent’s Bioanalyzer at the 
core, ribosomal RNA was removed to enrich RNA of interest (mRNA, tRNA and other 
small and long non-coding RNA molecules), followed by library preparation on the sent 
samples using Illumina’s TruSeq Stranded Total RNA Sample Preparation kit for human 




depleted from total RNA with the use of RNA Clean XP beads and fragmentation 
followed by priming with hexamers to prepare for reverse transcription. Fragmented 
RNA is then primed with random primers to convert the first strand to cDNA the second 
strand. This was followed by adenylation of the blunt end fragments of RNA to prepare 
them for attachment of adapter oligonucleotides. These adapters allow for multiplexing of 
samples to distinguish samples from one another. Special adapters are also added that are 
complementary to the oligonucleotide probes on the flow cell for hybridization. Adapter-
ligated fragments are then PCR amplified, followed by validation of library, 
normalization and pooling of libraries for multiple samples. The pooled library was then 
allowed to hybridize onto flow cells and sequenced in parallel on Illumina’s Hiseq 3000 
that employs Illumina’s proprietary Sequencing by Synthesis technology to sequence 
every fragment generating a ‘read’, the length of which is usually pre-defined and is 
equal to the number of cycles of base addition and detection. Each cycle involves 
addition of a complementary base tagged with a detection-enabling label that produces a 
base-specific color upon incorporation, followed by cleavage of the label to reduce noise, 
washing off the excess labelled bases and repeat of this process until desired read length 
is reached.  
 Each of our samples were sequenced with a coverage of approximately 40 million 
reads. The sequencing was paired-ended, i.e., each fragment was sequenced from both 5’ 
and 3’ ends to achieve a read length of 150 base pairs. The raw data was delivered to us 
as FASTA files, with two FASTA files per sample (one for each forward and reverse end 
sequenced during paired-end sequencing) and data analysis was performed on these raw 




3.2.9 Analysis of data from RNA sequencing 
 We analyzed data from RNA sequencing on samples for this study using Partek 
FlowÒ software (Partek Inc., MO). FASTA files for all samples were uploaded onto 
Partek’s server using FileZilla software’s file transfer protocol (FTP).  This protocol is 
convenient for transfer of large files, and each FASTA file was approximately 20GB in 
size (making the total file size for all samples to up to 720 GB). Pre-alignment quality 
check was performed to confirm accuracy and of sequence data, which is reported in the 
form of Phred scores along with sequence data in the FASTA files. This was followed by 
alignment of raw reads to human genome reference build 38 (hg38) using GSNAP (T. D. 
Wu, Reeder, Lawrence, Becker, & Brauer, 2016). Post-alignment quality control check 
was performed to confirm optimum alignment. Quantification was performed to the 
annotation model Ensembl Transcripts (Release 88) using Partek’s expectation 
maximization (E/M) algorithm that uses RPKM scaling method (Mortazavi, Williams, 
McCue, Schaeffer, & Wold, 2008; Xing et al., 2006). Strict paired-end compatibility was 
ensured and Partek was made to auto detect strand specificity. Moreover, a read had to be 
100% within a feature (exon/gene in this case) to be mapped to that particular region. The 
output of this quantification task was two nodes of gene counts and transcript counts. The 
gene counts were filtered to remove extremely low or zero values, normalized using log 
transformation, and downloaded as Partek Genomics Suite project format as well as text 
files with features on columns. Finally, normalized gene counts were imported into 
Partek Genomics SuiteÒ where read counts for the 20 canonical NER genes were sorted 
out, downloaded as a text file and opened in Microsoft Excel, where pairwise t-tests were 




One-tailed Student's t-test was used to compare the expression of the 20 NER genes 
between the High: Low pair as NER gene expression was expected to be higher in the 
NTA line compared to the tumor line, while two-tailed t-test was employed for the Low: 
Low pair as no difference in NER gene expression was hypothesized. Comparison of 
quantification of NER genes was also done for the tumor lines compared to the non-
diseased normal breast line JL BRL-6 to ensure both tumors express the low gene 
expression signature for the 20 canonical NER genes based on their functional NER 
capacities. 
 Supervised hierarchical clustering was used to construct a tree-like image called 
as a dendrogram in Partek FlowÒ. Clustering creates a hanging mobile-like figure where 
the arms of the mobile represent samples, and the horizontal distance between those arms 
indicate how closely related sample or sample groups are to each other. The Y-axis of the 
figure represents genes, and gene expression intensity per gene for a sample or sample 
group are represented by a color scheme which denotes over and under expressed genes. 
Clustering was performed on the sample groups containing replicates for each of the cell 
lines analyzed, namely FF-F, JL BRL6, JL BTL37, JL NTAL-37, JL BTL47 and JL 
NTAL-47. These dendrograms represent a visualization of how closely related sample 
groups and replicates are to each other based on the expression profiles of the 20 
canonical NER genes. Hierarchical clustering was performed on the normalized read 




3.2.10 Isolation of total protein 
 Total protein was isolated in triplicate from all cell lines used in this study, i.e. the 
cell lines of the High: Low and Low: Low pairs, JL BRL-6 and FF-F. Cultured 
monolayer of cells were lifted off of the T12.5 flasks using trypsin and centrifuged at 
800rpm for 5 min. Pellets from 4 T12.5 flasks were combined and were resuspended in 
ice-cold PBS and re-centrifuged. This combined pellet was then mixed in a 1.5 mL tube 
with the lysis cocktail containing 100 µL of radioimmunoprecipitation assay (RIPA) 
buffer (Life technologies®) (Cat# 89900) mixed with Halt® protease inhibitor cocktail 
(Life technologies®) (Cat# 78438). This was mixed very well by pipetting up and down 
several times to ensure the pellet was well mixed and cells lysed. This lysate was 
maintained under constant shaking for 30 minutes at 4°C. This mixture was then 
sonicated for 1 min at 4°C in an Ultrasonic cleaner (JSP®) (Model # US-20) and 
centrifuged for 20 minutes at 12,000 rpm at 4°C. The clear supernatant was pipetted off 
carefully to avoid contamination into another tube, and this consisted of total protein, 
which was snap frozen and stored at -80°C. 
PierceÒ  bicinchoninic acid (BCA) assay kit (Life technologies®) (Cat# 89900) 
was used to quantify total protein, which is a colorimetric assay. First, serial dilutions of 
the protein standard (bovine serum albumin provided with the assay kit) were made 
ranging from a concentration ranging from 25-2000 µg/mL. Protein sample was diluted 
10-fold in DNase, RNAse and protease-free water. Detection solution mixture was mixed 
beforehand by mixing reagents A and B in a 1:8 ratio. Three replicates of 25 µL of the 




the detection mixture beforehand in 1.5 mL tubes and added into the wells of a 96-well 
plate by adding one replicate per well. The plate was incubated at 37°C for 30 mins and 
absorbance was measured at 562 nm wavelength on a Synergy H1 plate reader 
(BioTekÒ). 
 A standard curve was plotted using 562nm absorbance values of the BCA 
standards. Unknown protein sample concentrations were obtained using this standard 
curve after correcting for background by subtracting the average of the blank readings 
from the absorbance reading of each sample and standard.  
3.2.11 Western blotting 
 Western blotting was performed to determine expression of NER proteins based 
on gene expression data. This was done to see whether differences in gene expression are 
consistent with the protein expression. RPA3, XPC, RAD23B were selected because they 
showed the highest differences between tumor and NTA lines of the High: Low pair and 
showed no difference in the Low: Low pair. All protein samples were run on sodium 
dodecyl sulfate poly acrylamide (SDS-PAGE) stacked gels. While the stacking gel was 
always 4% acrylamide, the resolving gel percentage was adjusted based on the molecular 
weight of the protein of interest. The percentage of SDS-PAGE for resolving gels used 
were 12.5% for RPA3 (14 kDa), 10% for RAD23B (58 kDa) and 8% for XPC (125 
kDA). A dilution series of foreskin fibroblast protein isolate (5µ, 10µ and 20 µg) was 
used as a control on each gel to determine the sensitivity and linearity and to establish a 




Running and transfer buffers were prepared in advance and allowed to cool at 
4°C. Running buffer consisted of 25 mM Tris, 192 mM glycine, 3.5 mM SDS at pH 8.3 
and transfer buffer was 25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3. Gels were 
cast by mixing required amounts of 30% stock acrylamide-bis (prepared in advance), 
10% SDS, pH-adjusted Tris HCl buffer, TEMED, 10% APS and making up the required 
volume by distilled water. The Tris HCl buffer used was specific to the gel, where 
resolving gel buffer (Bio-RadÒ ) (Cat #1610798) was used for resolving gel and stacking 
gel buffer (Bio-RadÒ ) (Cat #1610799) for stacking gels. This solution was poured into 
the casting chamber in between glass plates and allowed to polymerize for 45 mins.  
Sample preparation involved mixing the required volume for 20 µg of protein 
sample with RIPA lysis buffer to make up a total volume of 7 µL, to which 2.33 µL of 
dye solution was added (10 % b-mercapto ethanol in 4X Laemmli loading dye) (Bio-
RadÒ) (Cat# 1610747). Protein sample mixtures were denatured at 72°C for 10 mins, 
were loaded onto the stacking gels along with dual color molecular weight standards 
(Bio-RadÒ) (Cat# 1610374). 5 µL of the protein standard was mixed with 4.33 µL of 
RIPA lysis buffer to be run as a molecular weight standard or ladder in order to ensure 
the band of interest was the right size for the respective protein detected. Electrophoresis 
of these gels was allowed to run for optimal times (1 hr for XPC, 1 hr 20 mins for 
RAD23B and 1hr 45 for RPA3) at a constant voltage of 150V in the prepared and cooled 
running buffer.  
The protein bands from SDS-PAGE gels were then transferred onto nitrocellulose 
membranes that had a pore size of 0.2 microns (BioTraceÒ) (Cat# 66489) at 4°C. 




(run overnight for XPC and RAD23B at 20V; run for 1 h for RPA3 at 50V) by placing 
the fiber pad – filter paper – gel – membrane – filter paper – fiber pad sandwich into the 
casket in transfer buffer previously prepared and cooled. Each membrane upon which 
protein bands were transferred was washed once with 1X tris buffered saline or TBS 
buffer (Bio-RadÒ) (Cat #1706435) with vigorous shaking and blocked with 5% nonfat 
dry milk (Bio-RadÒ) (Cat# 1706404XTU) in TBST wash buffer. TBST was comprised of 
1X TBS with 10% Tween 20 (Bio-RadÒ) (Cat #1610781), to reduce background signal 
due to non-specific binding of antibodies. Blocking with 5% milk solution in TBST was 
performed for 1 hour for RPA3 and XPC, whereas membranes were blocked for 2 hours 
for RAD23B. Following blocking, membranes were washed with 1X TBST twice with 
vigorous shaking (120 rpm) for 10 mins each and allowed to incubate overnight with 
primary antibodies for the protein of interest (Table 3.1) with slow shaking at 4°C. 
GAPDH was used as an internal loading control and membranes were cut appropriately 
to be able to detect GAPDH simultaneously along with the proteins of interest. 
Table 3.1 Primary antibodies used in Western Blotting  
Protein Detected 
Size  
Source Type Dilution 

























 Membranes were washed in TBST with vigorous shaking for an optimized 




antibodies, for 10 minutes per wash. This was followed by incubation with the secondary 
antibody labelled with the detection molecule, which was goat anti-rabbit horseradish 
peroxidase conjugated secondary antibody (Sigma-AldrichÒ) (Cat# A0545) for RPA3, 
XPC and GAPDH, and rabbit anti-goat horseradish peroxidase conjugated secondary 
antibody for RAD23B (Sigma-AldrichÒ) (Cat# A5420). Secondary antibody dilutions 
and their respective solutions are as described in Table 3.3. These conditions were arrived 
upon after optimization with controls. Incubation with secondary antibody solutions was 
done for one hour, followed by vigorous washes for 10 minutes each with TBST for 
optimized number of times (Table 3.2). Finally, membranes were washed once with TBS 
and were then ready for detection. 
Detection of bands for proteins of interest was performed by chemiluminescence. 
SuperSignal West Femto Kit (Life TechnologiesÒ) (Cat# 34095), a high sensitivity 
detection kit for low expressing proteins, was used to detect XPC, RPA3 and RAD23B 
whereas SuperSignal West Pico kit (Life TechnologiesÒ) (Cat# 34095), a low sensitivity 
kit that can be used to detect highly expressed proteins, was used to detect GAPDH. After 
mixing peroxidase and luminol/enhancer solutions from the respective kits in a 1:1 ratio, 
membranes were allowed to incubate with this solution for 4 mins in a light-proof box. 









Table 3.2 Optimized concentrations of blocking solution, secondary antibody and 

























RPA3 5% non-fat 
milk in 









XPC 5% non-fat 
milk in 










milk in TBST) 
5 
RAD23B 5% non-fat 
milk in 










milk in TBST) 
5 
GAPDH 5% non-fat 
milk in 










3.2.12 Data analysis for western blotting 
 Images obtained from Azure C400 were imported into Image Studio Lite 5.2.5v 
(Li-CorÒ) to measure band intensities. Background was calculated by measuring 
intensities above and below the band of interest and this was subtracted from the band 
intensity. Intensity values for GAPDH for each lane was used to normalize amounts 
loaded for that particular lane, to correct for loading errors. Finally, student’s t-tests were 
used to find differences in expression levels for proteins among the tumor and NTA lines 
of the respective pairs (one-tailed for the High: Low pair and two-tailed for the Low: 




Expression of the respective protein in each cell line was also represented relative to that 






 This study was begun with data generated by one of Dr. Latimer’s laboratory. 
UDS assay was performed on primary cultures of tumor and NTA samples obtained from 
Stage I sporadic breast cancer patients undergoing lumpectomy along with those of breast 
reduction explant (BRE) samples obtained from women undergoing breast reduction 
mammoplasty for non-disease related purposes at Magee Women’s Hospital of the 
University of Pittsburgh Medical Center. Where the NER capacities of all Stage I tumors 
were observed to be significantly lower than that of the average of breast reduction 
epithelium (BRE) (Latimer et al., 2010), the NER capacities of the NTA samples were 
spread out across a range spanning that of the tumor samples as well as the BREs (Figure 
3.6A). The average of the NER capacities of the NTA samples was significantly higher 
than that of the Stage I tumors (p = 0.01).  
 Upon closer examination, it was observed that the NTA samples could be divided 
into 2 groups. Out of the 12 isogenically-matched tumor-NTA samples, 3 NTA samples 
had NER capacities higher than the average of BRE, whereas their matched tumors had 
lower NER capacity than the BRE average (Figure 3.6B). This group was called the 
High: Low pairs group, denoting high repair capacity in the NTA and low in the matched 
tumors. The remaining majority (9/12) of NTA samples had NER capacities lower than 
that of the BREs, similar to those of their matched tumor samples. This group was 
referred to as the Low: Low pairs denoting lower NER capacities than BRE average for 





Figure 3.6A NER capacity of primary cultures obtained from UDS assay. Normal breast 
epithelium (N = 22, star represents a high outlier), early (stage 1) breast tumors (N = 17), 
and histologically normal breast epithelium (N = 13) adjacent to stage 1 tumors.  The 
orange circle represents a sample form the contralateral (unaffected) breast of a breast 
cancer patient).  The turquoise circles represent patients who chose not to have their lymph 





Figure 3.6B. NER capacities of NTA measured by the UDS assay reveals two groups 
of tumor-NTA pairs. A) 3/12 NTA samples have NER capacity higher than the average 
of BRE with their matched tumor samples still having low NER capacity. The difference 
between the two sample groups of the High: Low pairs was significant at p = .036. B) 
9/12 NTA samples showed NER capacities lower than the average of BRE, and similar 
to those of their matched tumor samples. No significant difference was observed 






3.3.1 Identification of High: Low and Low: Low groups 
 Not all of the early stage breast cancer primary cultures and their matched NTA 
cultures surveyed previously were available as cell lines, as at that point in time Dr. 
Latimer’s lab was unaware of their capability to develop cell lines from primary explants. 
In order to proceed with the proposed study, it was a necessity to have cell lines for the 
NTA tumor pairs representative of each of the two groups, High: Low and Low: Low 
pairs, as cell lines are manipulable and essential to carry out in-depth mechanism-related 
investigations. Initially, it was proposed to use 3 cell line pairs for each of the two 
groups, however 3 cell lines per group were not available and we found that we could 
proceed with detailed molecular analyses with 1cell line pair for each of the two groups 
identified previously.  
 A cell line pair representing the Low: Low group from the previously assayed 
pairs using the UDS assay was previously identified. The tumor line of this pair was JL 
BTL-37 and was established from a patient having Stage I breast cancer who had 
undergone lumpectomy for tumor removal. The matched NTA line of this tumor was JL 
NTAL-37, and this cell line pair was one among the 9/12 pairs in Figure 4.2B. 
Unfortunately, none of the pairs from Figure 4.2A representing the High: Low pairs had 
been established as cell lines, i.e., the samples were not passaged. Therefore, in order to 
find a representative cell line for the High: Low group, the UDS assay was run on 
existing early stage breast cancer tumor cell lines and their matched NTA lines that were 
not previously assayed for their NER capacity. One cell line pair was subsequently 





line had a high NER capacity. This pair consisted of JL BTL-47, which was the tumor 
line, and it’s matched NTA line JL NTAL-47. Therefore, 4 cell lines, namely JL BTL-37 
- JL NTAL-37 and JL BTL-47 - JL NTAL-47 were used in the current study, the 





Table 3.3 Characteristics and NER capacity of the cell lines used in this study. * denotes values from experiments done previously by the lab.  
$ From experiments performed for finding the High: Low pair of cell line, average of two individual counters 







Low: Low JL BTL-37 Tumor 44, Caucasian I ER+ 
PR++ 
13.75* 24%* 
 JL NTAL-37 NTA  - - 19.78* 24%* 
High: Low JL BTL-47 Tumor 78, Caucasian II ER+  
PR+ 
28.75$ 5%$ 
 JL NTAL-47 NTA  - - 57.93$ 14%$ 
Control JL BRL-6 Breast 
reduction 










3.3.2 Gene expression microarray results conform to the functional NER capacity in the 
two cell line pairs 
 Gene expression microarray analyses were performed to see whether expression 
of the 20 canonical NER genes conforms to that of functional NER capacity. For 
example, where functional NER capacity was low, gene expression was hypothesized to 
be low as well. First, we saw that both tumor lines (of the High: Low and the Low: Low  
groups) that showed a low NER capacity than the normal breast reduction line JL BRL-6 
also showed a lower gene expression signature as well. 11/20 genes were significantly 
downregulated in both tumor lines JL BTL-37 and JL NTAL-47 relative to the non-
diseased breast line JL BRL-6 (p <0.05) (Figure 3.7). An additional two genes were 
downregulated in the line JL BTL-47 (denoted by # in Figure 4.3, p <0.05). 
 
 
Figure 3.7 Gene expression of early stage tumor lines JL BTL-37 and JL BTL-47 relative to 
non-diseased breast line JL BRL-6. 3 biological replicates were assessed for each cell line. * 
denotes gene expression significantly lower than JL BRL-6 for both tumor cell lines. # denotes 
significant lowering of expression in just JL BTL-47 relative to JL BRL-6 (one-tailed student’s t-






















































































The tumor-NTA pairs where then compared for expression of the 20 canonical 
NER genes conforms to their respective gene expressions. In the Low: Low pair, no 
significant difference was observed for 15/20 genes, while there were 5 genes that still 
showed a significant difference between JL BTL-37 and JL NTAL-37 (Figure 3.8A). In 
contrast, in the High: Low pair, 13/20 genes were significantly higher in the NTA line JL 
NTAL-47 than the tumor line JL BTL-47, indicating an overall down regulation of the 
pathway in the High: Low pair (Figure 3.8B).  
The differences in NER gene expression between the two types of NTAL lines 
was also compared with that of the non-diseased line JL BRL-6 to see if there are 
noticeable differences between the two types of NTA tissue. It was observed that the 
gene expression of majority of NER genes in the NTA line of the High: Low pair, JL 
NTAL-47, was not significantly different from that of JL BRL-6, with only 6/20 genes 
significantly different in expression between JL NTAL-47 and JL BRL-6 (p<0.05, two-
tailed Student’s t-test) (Figure 3.9A). On the contrary, 9/20 genes showed significantly 
reduced gene expression in the NTA line of the Low: Low pair, i.e., JL-NTAL 37, 









Figure 3.8A Gene expression of the Low: Low cell line pair via expression microarray 
showed no significant difference in the expression of majority of NER genes among the 
tumor line and the NTA line. 3 biological replicates were assessed for each cell line. 15 out 
of 20 genes did not show significant differences in expression between the tumor line JL BTL-
37 (open bars) and the NTA line JL NTAL-37 (solid bars). The significant genes were ERCC2 
(p= .007), ERCC6 (p= .03), CDK7 (p= .01), GTF2H4 (p= .003), DDB2 (p= .004) and XPC (p 




Figure 3.8B Gene expression of the High: Low cell line pair via expression microarray 
showed significant difference in the expression of 13/20 of NER genes among the tumor 
line and the NTA line. 3 biological replicates were assessed for each cell line. The 
significant genes were RAD23B (p= .02), ERCC6 (p= .007), RPA1 (p= .0006), ERCC3 (p= 
.01), ERCC4 (p= .01), CDK7 (p= .008), ERCC2 (p= .002), GTF2H3 (p= .04), GTF2H4 (p= 
.01), XPC (p= .005), ERCC8 (p= .002), RPA3 (p= .04) and GTF2H2 (p= .01).  * indicates 
significant differences in expression between the tumor line JL BTL-47 (open bars) and the 



















































































































































































Figure 3.9A Gene expression is not significantly different for majority NER genes in the 
NTA line of the High: Low pair, JL NTAL-47, relative to non-diseased breast line JL BRL-
6. 3 biological replicates were assessed for each cell line. * denotes significantly different gene 
expression in the NTA line (solid bars) compared to the non-diseased breast line (open bars). 
Genes that were significantly different included GTF2H4 (p<.001), ERCC2 (p<.001 ), RPA2 
(p=.001 ), GTF2H3 (p=.007 ), XPC (p= .044), RPA1 (p= .001), RPA3 (p= .03) and ERCC6 (p= 
.008) (two-tailed Students t-test, p<0.05). 
 
 
Figure 3.9B Gene expression is significantly low for 9/20 NER genes of the NTA line of the 
Low: Low pair, JL NTAL-37, relative to non-diseased breast line JL BRL-6. 3 biological 
replicates were assessed for each cell line. * denotes significantly different gene expression in the 
NTA line (solid bars) compared to the non-diseased breast line (open bars). Genes that were 
significantly different included RPA2 (p< .001), ERCC2 (p< .001), GTF2H4 (p< .001), RPA1 
(p< .001), GTF2H3 (p< .001), ERCC3 (p=.02), ERCC8 (p= .04), CDK7 (p= .02) and ERCC1 (p= 























































































































































































3.3.3 RNA sequencing validates results from gene expression microarray in the High: 
Low pair as well as Low: Low pair 
 RNA sequencing was performed to independently validate the gene expression 
microarray assessment of NER gene expression. RNA sequencing is exempt from the 
probe bias that is intrinsic to array technologies. The microarray analyses compared with 
normalized read counts for the NER genes were generally consistent and conformed to 
NER function.  
 Normalized read counts for NER genes in the two tumor lines, JL BTL-37 and JL 
BTL-47 were expressed relative to JL BRL-6, and it was observed that both tumor lines 
showed a low NER signature, but less significantly different genes due to variability in 
JL BRL-6. 3 genes were significantly lower in the Low: Low pair tumor JL BTL-37, 
whereas 8 genes were significantly lower in the High: Low pair tumor JL BTL-47, both 
relative to JL BRL-6 (Figure 3.10).  
Upon comparing the pairs within themselves, expression of NER genes by RNA 
sequencing conforms to that seen in microarray results above. In the Low: Low pair, no 
significant difference was seen in the NER gene expression signature of the tumor line JL 
BTL-37 and the NTA line JL NTAL-37, and no genes stood out significantly different 
among the two lines (Figure 3.11A). This compares with 5/20 genes that stood out 
significantly different in the microarray analyses of this pair (Figure 3.8A). On the 
contrary, in the High: Low pair, 16/20 genes were significantly downregulated in the 
tumor line JL BTL-47 (and therefore higher in expression in the NTA line JL NTAL-47) 




expression profiles of the two types of pairs seen in microarray analyses, and also 
conforms to functional NER capacity in these lines. 
 
 
 The gene expression signature of both NTA lines were also compared with that of 
JL BRL-6 line, which were consistent with the trends seen in the microarray. JL NTAL-
47, which is similar to JL BRL-6 in functional NER capacity and gene expression by 
microarray analyses, showed a similar trend with RNA sequencing, with majority of the 
genes showing no significant difference in NER gene expression signature between JL 
NTAL-47 and JL BRL-6 except for two genes, ERCC5 and ERCC6 (Figure 3.12A). 
However, 6/20 genes were significantly lower in the NTA line of the Low: Low pair (JL 
BTL-37) compared to JL BRL-6 (Figure 3.12B). This is not surprising as the DNA repair 
function was low for this NTA line. 
 
Figure 3.10 Expression of NER genes via RNA sequencing in early stage tumor lines JL 
BTL-37 and JL NTAL-37 relative to the non-diseased breast line JL BRL-6. 3 biological 
replicates were assessed for each cell line. * denotes genes significantly downregulated in JL 
BTL-37, which are XPC (p = .01), GTF2H2 (p = .036) and RAD23B (p = .046). # denotes 
genes significantly downregulated in JL BTL-47, which are XPC (p = .001), GTF2H3 (p = 
0.008), ERCC2 (p = .029), ERCC4 (p = .008), ERCC8 (p = .013), GTF2H4 (p = .035), 































































































Figure 3.11A Gene expression by RNA sequencing showed no significant difference 
among the tumor and NTA line in the Low: Low pair. 3 biological replicates were assessed 





















































































Figure 3.11B Gene expression by RNA sequencing showed 16/20 genes significantly 
different among the tumor and NTA line in the High: Low pair. 3 biological replicates 
were assessed for each cell line. * denotes genes that are significantly higher in expression in 
the NTA line JL NTAL-47 relative to the tumor line JL BTL-47. These genes were DDB1 (p = 
.002), ERCC1 (p = .005), CCNH (p =.01 ), CDK7 (p = .005), ERCC3 (p = .004), ERCC6 (p = 
.002), RAD23B (p = .002), ERCC2 (p = .0002), GTF2H2 (p = .02), GTF2H4 (p = .002), 
ERCC4 (p = .009), RPA1 (p = .002), ERCC8 (p = .004), XPC (p = .00002), RPA3 (p = .01) 




























































































Figure 3.12B Gene expression in the NTA line of the Low: Low pair relative to JL BRL-6 
measured by RNA sequencing showed significant difference in 6/20 of the NER genes. 3 
biological replicates were assessed for each cell line. * denotes the significantly lower 
expressions in genes, which were ERCC2 (p = .03), ERCC8 (p = .02), XPA (p = .049), 
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Figure 3.12A Gene expression in the NTA line of the High: Low pair relative to JL BRL-6 
measured by RNA sequencing showed no significant difference in majority of the NER 
genes. 3 biological replicates were assessed for each cell line. * denotes significantly different 


























































































3.3.4 Hierarchical clustering of samples based on expression of the 20 NER genes by 
RNA sequencing  
 Hierarchical clustering of the cell line groups is shown in Figure 3.13. Clustering 
via the horizontal distances between the groups denote their closeness to each other with 
respect to their NER gene expression profile for the 20 genes. Foreskin fibroblast lines 
(n=3) cluster by themselves on the extreme right showing a distinct gene expression 
profile from the rest of the samples which are all breast-derived lines. JL NTAL-47 
(NTA-II) and JL BRL-6 (normal breast) are all situated in the center and cluster close to 
each other and closer to the foreskin fibroblast lines, denoting a normal-like gene 
expression signature in these lines. 
 JL BTL-37 (Tumor-I), JL BTL-47 (Tumor-II) and JL NTAL-37 (NTA-I) all 
cluster towards the far left and closer to each other than the other normal-like cell lines.  
This shows that they have a similar NER gene expression profile to each other, which is 
distinct from the other lines. An anomaly seen in the dendrogram in Figure 3.13 is one 
replicate of JL BTL-37 (Tumor-I) clustering in the middle along with the JL BRL-6 
(normal breast) and JL NTAL-47 (Tumor-II) lines. This is most likely due to technical 







Figure 3.13 Dendrogram depicting hierarchical clustering for the sample replicates belonging to each cell line using Euclidean algorithm 
and average linkage. Each arm clustering the samples represents one replicate for a particular sample group (n=3 for each group). The 
descriptions of sample groups shown on the top panel along with their color codes are as follows. Human foreskin fibroblasts (dark blue) represent 
2 replicates of FF-F cell lines and one of FF-C cell line, each established from two samples of newborn foreskins. Normal Breast: JL BRL-6 (red); 
Tumor-I: JL BTL-37 (purple); NTA-I: JL NTAL-37 (orange); Tumor-II: JL BTL-47 (blue) and NTA-II: JL NTAL-47 (green). For intensities of 






3.3.4 RNA sequencing on tissue pairs representing Low: Low and High: Low groups 
 We sequenced total RNA isolated from flash frozen tissue pairs (from our tissue 
bank in the Latimer Lab), using same parameters as the samples used in the study, in an 
attempt to increase our limited sample size. Analysis of gene expression for the 20 
canonical NER genes in one Low: Low tissue pair (Sample ID: TP96-36; for which no 
cell line was available) did show a similar pattern as the Low: Low cell line pair in this 
study, where no significant difference was seen in the NER pathway as a whole between 
the tumor tissue and NTA tissue, and 11/20 genes were not significantly different 
between the tumor tissue and NTA tissue via a two-tailed Student’s t-test (Figure 3.14A).  
However, we also analyzed a High: Low pair, where the tumor had an established 
cell line (JL-BTL4) but no tissue for the same, and the matched NTA for the said tumor 
line did not have a cell line established, but we had the flash-frozen tissue for the NTA 
sample (Sample ID: TP95-159). This pair did not follow their trend of functional repair 
capacity, nor did this pair follow the gene expression trend seen in the High: Low cell 
line pair, as only 4 genes were found to be significantly higher in the NTA tissue sample 









Figure 3.14A NER gene expression in a Low: Low tissue pair as measured by RNA 
sequencing. 3 biological replicates were assessed for each sample. The NER capacities of 
these two tissue samples were 19.48% of FF for the tumor and 9.6% of FF for the NTA. 79/20 
genes were significantly different in the NTA compared to the tumor, which were DDB2 (p = 
.001), ERCC5 (p = .03), ERCC1 (p = .02), CCNH (p = .03), RPA2(p = .04), ERCC8 (p = .04), 
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Figure 3.14B NER gene expression in a High: Low pair where tumor was a cell line and 
NTA was a tissue sample, as measured by RNA sequencing. 3 biological replicates were 
assessed for each cell line. The NER capacities of these two tissue explants were 42.59% of FF 
for the NTA and 7.46% of FF for the tumor, which defined them as a High: Low pair. Only 4/20 
genes were significantly higher in the NTA compared to the tumor, which were GTF2H2 (p = 


























































































3.3.5 Western blotting for RPA3 protein expression conforms to its gene expression in the 
Low: Low pair but not the High: Low pair 
 Western blots were performed on protein from 3 biological replicates of JL BTL-
37, JL NTAL-37, JL BTL-47, JL NTAL-47, along with the control, JL BRL-6. A serial 
dilution series of protein sample isolated from normal foreskin fibroblasts was also run to 
confirm that the western was capturing the dynamic range of expression of the respective 
protein. It was observed that RPA3 expression was not significantly different in the Low: 
Low pair lines, namely JL BTL-37 and JL NTAL-37 (Figure 3.15A). RPA3 protein 
expression for each of the cell lines of the Low: Low pair was also not significantly 
different from that of JL BRL-6, and these observations were consistent with the gene 
expression of RPA3 using RNA sequencing. 
 However, in the High: Low pair, contrary to the expected difference from results 
of gene expression studies, no significant difference was observed for RPA3 protein 
expression between JL BTL-47 and JL NTAL-47 (One-tailed Student’s t-test). Moreover, 
RPA3 protein expression was significantly higher in JL BTL-47 than JL BRL-6 (One-
tailed t-test), and this was not seen in RPA3 gene expression as per RNA sequencing 
results (Figure 3.10). Finally, for RPA3 protein expression, JL NTAL-47 was 
significantly higher as compared to JL BRL-6, and this result is also seen in RPA3 gene 
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Figure 3.15A Fold change in RPA3 protein expression in the Low: Low pair JL BTL-37 
and JL NTAL-37 relative to JL BRL-6. 3 biological replicates were assessed for each cell 
line. No significant difference was observed in protein expression of RPA3 in between JL 
BTL-37 and JL NTAL-37. Both these cell lines of the Low: Low pair were also not 
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Figure 3.15B Fold change in RPA3 protein expression in the High: Low pair JL BTL-47 
and JL-BTAL47 relative to JL BRL-6. 3 biological replicates were assessed for each cell 
line. No significant difference was observed in protein expression of RPA3 in between JL 
BTL-47 and JL NTAL-47 (One-tailed Student’s t-test). Both these cell lines of the High: Low 
pair were significantly higher in protein expression of RPA3 than JL BRL-6 (One-tailed and 















JL BRL-6 JL NTAL-47 JL BTL-47






3.3.5 XPC protein expression is consistent with its gene expression in the Low: Low pair 
but not in the High: Low pair 
 XPC gene expression was higher in both NTA lines than the tumor lines, however 
this difference was seen to be significant only in the High: Low pair. Therefore, we 
wished to see if this held true for the protein expression of XPC as well. In the Low: Low 
pair, XPC protein expression was not significantly different between JL BTL-37 and JL 
NTAL-37, as calculated by a two-tailed Student’s t-test. XPC protein expression was also 
not significantly different for both JL BTL-37 (One-tailed Student’s t-test based on gene 
expression) and JL NTAL-37 (Two-tailed Student’s t-test based on gene expression) as 
compared to JL BRL-6 (Figure 3.16A). 
 Interestingly, in the High: Low pair, an inverse relationship was observed 
between XPC gene and protein expression among the tumor and NTA cell lines. XPC 
protein expression was significantly higher by about 3-folds in JL BTL-47 compared to 
JL NTAL-47 (One-tailed Student’s t-test). Expression of XPC protein in JL BTL-47 was 
also significantly higher than that of JL BRL-6 (One-tailed t-test). Nevertheless, we did 
not see any significant difference in the expression of XPC protein in JL NTAL-47 
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Figure 3.16A XPC protein expression shows no significant difference between the cell 
lines in the Low: Low pair as well as relative to JL BRL-6.  3 biological replicates were 
assessed for each cell line. Student’s t-test at a = .05 revealed lower expression in JL BTL-37 
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Figure 3.16B XPC protein expression in the High: Low pair was seen to be significantly 
higher in JL BTL-47 compared to both JL-NTAL46 and JL BRL-6. 
3 biological replicates were assessed for each cell line. * indicates significantly higher 
expression compared to JL NTAL-47 (p = .04, One-tailed Student’s t-test). # indicates 
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3.3.6 RAD23B protein expression is consistent with its gene expression in both High: 
Low and Low: Low pairs, however the difference is not significant in the High: Low pair. 
 According to results of gene expression via RNA sequencing, RAD23B showed 
no difference between the lines of the Low: Low pair and was significantly higher in JL 
BTL-47 of the High: Low pair compared to JL NTAL-47. Also, where RAD23B gene 
expression was significantly lower in both tumor lines relative to JL BRL-6, the NTA 
line of the Low: Low pair was also significantly lower as compared to JL BRL-6, but not 
the NTA line of the High: Low pair. We wished to see if RAD23B’s protein expression 
conformed to this pattern as well. 
  In the Low: Low pair, RAD23B protein expression was significantly lower in the 
tumor line JL BTL-37 relative to JL BRL-6, but not significantly different from JL 
NTAL-37, as expected from gene expression results. However, JL NTAL-37 was not 
significantly different from JL BRL-6 in RAD23B’s protein expression (Figure 3.17A), 
whereas gene expression of RAD23B was significantly lower in JL NTAL37 than JL 
BRL-6 (Figure 3.12B). This could be attributed to the variation in the replicates. 
 In the High: Low pair, RAD23B protein expression was lower in JL BTL-47 than 
that of JL NTAL-47, but this difference was not significant. Future westerns will be 
performed on this protein in these lines to verify these findings. RAD23B protein 
expression was significantly lower in JL BTL-47 relative to JL BRL-6 (Figure 3.17B) 
which is consistent with its gene expression (Figure 3.10). It was not significantly 
different from JL BRL-6 in JL NTAL-47 (Figure 3.17B), as expected from gene 
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Figure 3.17A RAD23B protein expression, although lower in Jl-BTL37 compared to JL 
NTAL-37, is not significantly different between the Low: Low pair. 3 biological replicates 
were assessed for each cell line. * indicates significantly lower expression in JL BTL-37 
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Figure 3.17B RAD23B protein expression, although lower in Jl-BTL47 compared to JL 
BRL-6, is not significantly different between the High: Low pair. The absence of 
significance is probably due to high variation within replicates for JL NTAL-47 and this will 
be repeated by future students in the lab. 3 biological replicates were assessed for each cell 
line. * indicates significantly lower expression in JL BTL-47 compared to JL BRL-6 (p = 
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3.3.7 Summary of gene and protein expression results for RPA3, XPC and RAD23B 
 Table 3.4 below highlights the key findings based on RNA sequencing gene expression and protein expression by western 
blotting for the three NER proteins, namely RPA3, XPC and RAD23B.  
Table 3.4 Summary of gene and protein expression results for RPA3, XPC and RAD23B. Red: RAD23B western goes in the right 
trend as that of gene expression and but the difference is not significant; will be repeated for verification of these findings. 
 Low: Low High: Low 
 JL NTAL-37 
relative to JL 
BTL-37 
JL NTAL-37 
relative to JL 
BRL6 
JL BTL-37 
relative to JL 
BRL6 
JL NTAL-47 
relative to JL 
BTL-47 
JL NTAL-47 
relative to JL 
BRL6 
JL BTL-47 

























































































3.3.8 TP53 gene expression might explain the XPC gene and protein expression 
 We checked the expression of TP53 gene and compared it to that of XPC gene 
expression to be able to explain the results of XPC protein expression, as XPC is 
regulated by p53. Expression of TP53 was found to be significantly lower in both tumor 
lines, JL BTL-37 and JL BTL-47, as compared to that of their respective matched NTA 
lines. The gene expression of TP53 was significantly lower in both tumor lines compared 
to that in JL BRL-6 as well in both pairs (Figure 3.18). This was similar to the trend of 
XPC gene expression and these results have been elaborated on in the discussion. 
 
Figure 3.18 Expression pattern of TP53 in the cell lines of this study by RNA sequencing 
and the concurrent expression pattern of XPC. 3 biological replicates were assessed for 
each cell line. TP53 was significantly downregulated in both tumors, JL BTL-37 (p = .03) as 
well as JL BTL-47 (p = .01) relative to JL BRL-6. XPC expression was also concurrently 
lower in both tumors, JL BTL-37 (p = .02) and JL BTL-47 (p = .002) relative to JL BRL-6. No 




































 Breast cancer is currently affecting the lives of about 3.1 million women in the 
United States, and this number includes women who have received treatment as well as 
those currently undergoing treatment (American Cancer Society, 2017).  The etiology of 
sporadic breast cancer is still largely unknown, and we are the first group to our 
knowledge that show breast cancer etiology in early stage breast cancer lines with respect 
to NER. 
Studies that involve comparisons of matched tumor and NTA samples are usually 
performed on blood samples representing the matched normal from the same patient as 
the tumor sample, which is unsuitable for a study like ours. This is because NER is tissue 
specific as we have shown previously (Latimer et al., 2003). In cases where they use the 
adjacent normal from the tissue of origin as the tumor, samples are analyzed directly after 
obtaining them from patients as either fresh tissues, FFPE (Formalin-Fixed Paraffin-
Embedded) samples or flash frozen tissue samples (Quiroz-Zárate et al., 2017). Studies 
involving such samples, although having the advantage of a large sample size and higher 
power of the study, present several challenges. Firstly, uncultured tissue samples are a 
heterogenous mix of various cell types including stroma, blood vessels, immune cells and 
lymphatic vessels. Tumor heterogeneity in cancer is a widely studied topic, as this 
heterogeneity poses challenges in research for advanced discoveries towards cancer 
treatment (Cyll et al., 2017; Martelotto, Ng, Piscuoglio, Weigelt, & Reis-Filho, 2014). 
We also experienced the challenge posed by tissue heterogeneity. Our findings on 
expression data on tissue pairs representative of the High: Low and Low: Low pairs in 




model systems for in-depth molecular analyses (Figure 3.14A and 3.14B). In these tissue 
pairs, the expression of the 20 canonical NER genes was not consistent to that of 
functional NER capacity. Therefore, although one of the major limitations of this study 
was its limited sample size in terms of representative pairs, our unique cell line pairs used 
in this study (representative of the two groups of High: Low and Low: Low) show classic 
gene expression signatures that conform to their NER capacity, and this could be 
considered as a strength of our study. 
  Secondly, tissue samples or FFPE samples are not experimentally manipulable. 
Therefore, most studies on regulatory mechanisms in cancer are performed on 
commercially available cell lines that are established from advanced-stage cancers, which 
makes them poor representatives for studying early stage cancer etiology. In this study, 
we had the unique advantage of exploring breast cancer etiology of sporadic cases of 
breast cancer using our own cell lines established in the Latimer Lab, where both tumor 
and NTA are obtained from the same patient and the tissue of origin of the neoplasm, 
which in this case is the breast.  
We determined protein expression of NER genes in the Low: Low as well as 
High: Low cell line pairs to see if differences in their gene expression are consistent with 
the encoded protein. This would also aid in our search for a master regulator of the NER 
pathway in early stage breast cancer. RPA3 protein expression in the High: Low pair did 
not follow its gene expression pattern, and we saw no significant difference in its protein 
expression where its gene expression was starkly different within the pair. With regard to 
XPC, the trend in protein expression was significant but in the opposite direction to that 




indicator of downstream protein expression, this correlation does not always hold true, as 
multiple studies have reported non-correlation of protein expression with its gene 
expression (G. Chen et al., 2002; Q. Tian et al., 2004; Vogel et al., 2010). Translational 
control has been reported to be a major indicator of downstream protein abundance in 
cells (Schwanhäusser et al., 2011), and investigation of NER regulation at the 
translational level is, though out of scope for this dissertation research, a future direction 
for this work. 
XPC protein expression being inversely related to its gene expression could be 
related to its regulation by p53. p53 is a major tumor suppressor protein found to be 
frequently mutated in tumors, and a wild-type p53 phenotype induces XPC expression in 
response to UV and ionizing radiation (Adimoolam & Ford, 2002; Amundson, Patterson, 
Do, & Fornace, 2002). Exon 1 of XPC has been shown by ChIP experiments to contain a 
p53 response element (Hastak, Adimoolam, Trinklein, Myers, & Ford, 2012). The gene 
expression TP53 followed the same trend as that of XPC (Figure 3.18). However, high 
protein expression of XPC suggests its regulation at either the post-transcriptional level 
or the translational level. Overexpression of XPC has been shown to mediate degradation 
of p53 via MDM2 ubiquitin ligase , therefore delineating a novel role for XPC as part of 
a negative feedback loop to regulate p53 expression apart from its function as an damage 
recognition protein in NER (Krzeszinski et al., 2014). Further studies are necessary in 
order to validate the occurrence of this in the tumor cell line of the High: Low pair, as it 
is still unclear as to under what circumstances does XPC regulate p53. 
RAD23B protein expression showed a consistent trend with that of its gene 




variation in the replicates for the respective lines. A replication of the western blots for 
RAD23B might yield significant differences upon eliminating the source of variation in 
the band intensities of XPC, even after normalization with respective GAPDH band 
intensities.  
Finally, our findings are clinically relevant. Upon further validation of these 
results in a larger cohort of patient samples, early stage breast cancer patients could 
possibly be screened for their NER capacity or NER gene expression in the non-
pathologic adjacent breast tissue, and their risk of recurrence could be predicted based on 
the same, with a possible increase in the duration of post-operative adjuvant radiation 
treatment for patients that have a low NER capacity in their NTA breast. Moreover, 
identification of a candidate gene based on further studies on regulation of this pathway 
will pave the way for the use of this as a biomarker to predict recurrence in early stage 
breast cancer patients undergoing lumpectomy with radiation therapy. 
3.5 Conclusion/Summary 
 We identified 2 varieties of non-tumor adjacent breast based on their functional 
NER capacities as well as the expression of NER genes. While the NER capacity of their 
matched sporadic early stage breast tumors was low in both varieties, the NER capacity 
of the NTA most likely depends on whether loss of NER was an early or a late event in 
tumorigenesis. Loss of NER being an early event is most likely the case where the NER 
capacity is shared between the tumor and the NTA. However, loss of NER occurred later 
in the trajectory of carcinogenesis where the NTA had a higher NER capacity than the 
tumor. This chapter, coupled with the next chapter on mechanism of NER regulation, will 




sample en route to carcinogenesis. However, replication and validation of this work is 
needed in additional representative cell line pairs of early stage breast cancer tumors and 
their matched NTA lines, which the lab plans to establish by acquiring tissue samples 
after an IRB is in place with a local hospital. This will ultimately allow us to build our 
own “Vogelsteinogram” delineating the complex genetic and/or epigenetic alterations in 
breast tumorigenesis, therefore laying a foundation for the mechanism of sporadic 
carcinogenesis in the breast. Our findings lay the groundwork for being able to use NER 
capacity in the non-tumor adjacent breast tissue as a prognostic marker for recurrence of 
breast cancer and its possible role in advancement of treatment regimens. 
 With our study, we hope to be able to establish a ‘Vogelsteinogram’ for 
sporadic breast cancer from an NER perspective. This study is also clinically relevant as 
we show the non-normalcy of the NTA breast, which raises questions on the margin 
width during lumpectomy and the latter is already a topic of debate among clinicians 
(Houssami et al., 2010). A recent presentation in the 2017 San Antonio Breast Cancer 
Symposium by Dr. Chirag Shah regarding a meta-analysis of 33 studies on breast cancer 
refuted the SSO-ASTRO guidelines of ‘no ink on tumor’ basis of deciding margin width 
This analysis showed a lower risk of ipsilateral breast recurrence with margins wider than 
2mm (Shah, Verma, Sayles, Recht, & Vicini, 2018). Our study also reinforces the 
groundbreaking clinical trial by Fisher and his colleagues which showed that lumpectomy 
with radiation has similar outcomes to that of a total mastectomy, and post-operative 
adjuvant radiation significantly lowers mortality in treated patients, and the latter has 





Chapter 4  
Elucidation of the mechanism of regulation of nucleotide excision repair 
genes in early stage sporadic breast cancer using isogenically matched 
non-tumor adjacent breast cell lines  
4.1 Introduction 
 The multistep nature of cancer involves mutations as well as certain epigenetic 
alterations that lead to the ultimate tumor phenotype (Armitage, 1985; Hanahan & 
Weinberg, 2000; Vogelstein & Kinzler, 1993). The formation of cancer in an organ 
usually takes decades. The carcinogenesis process is sped up by the presence of inherited 
germline mutations, which can be seen in BRCA1 and BRCA2 mutation carriers who 
manifest breast cancer at an earlier age than sporadic breast cancer cases (Dagan, 
Gershoni-Baruch, Kurolap, & Fried, 2017; Thompson et al., 2012). We hypothesized that 
the downregulation of NER in early stage sporadic breast cancer cases, as well as in their 
matched NTA samples in most of the cases, is epigenetic based on the downregulation 
seen in multiple genes and in multiple patients (Latimer et al., 2010; Latimer et al., 2003). 
Moreover, as the rate of occurrence of a somatic mutation is one per 30 million 
nucleotides per genome (Xue et al., 2009), it is highly unlikely that a mutation in each of 
these genes could cause the observed downregulation. Therefore, in this study, we wished 




4.1.1 Epigenetic regulation of gene expression 
Epigenetic regulation refers to the phenomenon which induces a change in the 
expression of genes without a change in the genetic code or sequence of the DNA 
(Jaenisch & Bird, 2003). Out of the three major mechanisms of epigenetic transcriptional 
regulation, which are DNA methylation, histone modifications and regulation by small or 
long non-coding RNA molecules (Handy et al., 2011). Methylation of DNA at the 
cytosine-guanine dinucleotide bases (CpG) is the most widely studied. Methylation of 
DNA is a heritable trait, usually passed on to daughter cells, and from gametes to 
subsequent generations by a mechanism known as imprinting (Reik, 2007). Promoter 
regions of genes are found to be rich in CpG sites (a GC percent of more than 50%), and 
this is what constitutes a CpG island (Illingworth & Bird, 2009). Methylation of CpG 
islands or sites at the promoter region of genes generally suppresses gene expression by 
mechanisms like interference of binding of enhancer proteins, active removal of 
transcription factors like RNA polymerases from the transcription initiation sites, binding 
of specific proteins called methyl-CpG binding domain (MBD) proteins, and rendering of 
the configuration of chromatin unsuitable for transcription (Fuks et al., 2003; Kass, 
Landsberger, & Wolffe, 1997; Plass & Soloway, 2002). 
4.1.1.1 Methylation and Cancer 
Specific oncogenes have been known to be hypomethylated in cancer (Van 
Tongelen et al., 2017), while tumor suppressor genes are hypermethylated at their 
promoter region, thereby silencing the expression of these genes and promoting 
carcinogenesis (Baylin & Ohm, 2006; Robertson, 2005). Overall, DNA has been found to 




transcriptional activation of repetitive elements and viral genes inserted into the human 
genome, thereby increasing genomic instability (Kisseljova & Kisseljov, 2005).  
4.1.1.2 Methylation and DNA repair 
There have been accounts of methylation of NER genes in cancers. 
Hypermethylation of promoter region in XPC has been shown to regulate its gene 
expression in lung cancer (Y. Wu et al., 2007) and downregulation of XPG due to 
promoter methylation has been shown to be implicated in chemotherapy resistance in 
mouse as well as human cell line models (Sabatino et al., 2010). However, methylation 
status of NER genes with regard to breast cancer has not been studied to date. 
4.1.2 Single nucleotide variants in NER genes 
Defects in the NER pathway caused due to germline mutations in NER genes in 
individuals manifests as a disease called Xeroderma Pigmentosum or XP, which 
increases their sensitivity to UV light and increases their risk of getting cancer by about 
2000-fold (Bradford et al., 2010). Seven complementation groups were discovered for the 
major NER genes, and a mutation in each one of these genes affects the NER capacity in 
different degrees, where mutation in one gene has a different contribution towards repair 
capacity than that in the other (de Boer & Hoeijmakers, 2000; Friedberg et al., 2005). 
Although we hypothesized that the downregulation of NER capacity in our early stage 
sporadic breast cancer lines was due to an epigenetic regulatory mechanism, we wished 
to rule out the possibility of a mutation in one of our 20 NER genes.  
Detection of single nucleotide variants or SNVs is a popular approach used in 
literature for data obtained from DNA and RNA sequencing to look for putative 




variants are known single nucleotide polymorphisms or SNPs, which are viable variants 
for a specific base position in the DNA and are deemed such if their occurrence is more 
than 1% in a given population. The variants are a mutation if they occur in less than 1% 
of the population. These definitions telling a SNP apart from a mutation are now 
overlapping (Karki, Pandya, Elston, & Ferlini, 2015). Although SNPs are more of a 
population characteristic, their presence has also been associated with disease risk, and 
several SNPs have been identified conferring an increased (or at times decreased) risk of 
breast cancer as well (Coughlin & Piper, 1999), along with other cancers.  
Polymorphisms in NER genes have been associated with a variety of cancers 
including, but not limited to, gastric cancer (J. Liu et al., 2016), laryngeal cancer (B. Lu 
et al., 2014), melanoma (C. Li et al., 2006), bladder cancer (Qiao et al., 2011), prostate 
cancer (M. Wang et al., 2017), esophageal adenocarcinoma (Tse et al., 2008), and breast 
cancer. With regards to breast cancer, the polymorphisms conferring increased breast 
cancer risk were the ones found in XPC (Pérez-Mayoral et al., 2013), XPG/ERCC5 (C. 
Han et al., 2017), XPD/ERCC2 (Bernard-Gallon et al., 2008; Wonshik Han et al., 2012; 
A. K. Mitra et al., 2009; Smolarz et al., 2014), XPA (W. Han et al., 2012) and RAD23B 
(Pérez-Mayoral et al., 2013) whereas a variant in XPB/ERCC4 (Milne et al., 2006) and 
XPD/ERCC2 (J. Li et al., 2008) was shown to decrease breast cancer risk and have a 
protective effect. 
Our ultimate objective is to understand the molecular progression of breast cancer 
from an NER perspective. Chapter 3 of this dissertation showed that we were able to 
identify two varieties of non-tumor adjacent (NTA) breast obtained as matched pairs 




non-diseased breast and so was that of its isogenically matched tumor sample (Low: Low 
pair of NTA-tumor). NER capacity in the other variety was similar to that of normal non-
diseased breast and higher than its isogenically matched tumor sample (High: Low pair of 
NTA-tumor). We performed gene expression microarray analyses, RNA sequencing as 
well as western blotting on cell line pairs representing the Low: Low and the High: Low 
groups, as elucidated in Chapter 3. The aim for this study was to assess if methylation of 
CpG sites on one or more NER genes is the mechanism of downregulation of NER gene 
expression observed in 3 of our cell line pairs, mostly in their promoter regions where 
these genes have been known to be rich in CpG islands (Johnson, 2006). This study also 
explored the presence of single nucleotide variants that could be indicative of a putative 
mutation in the coding region of the 20 canonical NER genes via variant calling on RNA 
sequencing data. 
4.2 Methods  
4.2.1 Establishment of cell lines from tumor/NTA pairs of tissues  
 Tissue samples were obtained from surgeries performed at Magee Women’s 
Hospital (Institutional review board approval 0609002). Primary cultures were 
established as described previously (Chapter 2) and passaged into cell lines (>13 
passages) (Latimer et al., 2010; Latimer et al., 2003). JL BRL-6 was obtained from a 
breast reduction surgery performed on a non-diseased patient. Two cell line pairs (4 cell 
lines) were used in this study, each of which represent the two groups of NTA-Tumor 
pairs – Low: Low and High: Low, which were obtained from patients with early stage 




histopathologically normal. Their characteristics, along with their respective NER 
capacities as measured by the UDS assay, are as described in Table 3.1 of Chapter 3.  
4.2.2 MethylationEPIC array 
4.2.2.1 DNA isolation 
 DNA was isolated from all four cell lines of the two pairs as well as the control 
lines JL-BRL6 and FF-F in triplicate using the DNeasy mini kit (QiagenÒ) (Cat# 69504) 
according to manufacturer’s protocol. Briefly, cultured monolayer of cells per cell line 
was trypsinized pelleted at 800 rpm for 5 mins after neutralizing with culture medium 
(MWRI). Two flasks of 12.5cm2 area per replicate for each cell line were combined for 
each spin column. The pellet was resuspended in 200µL of PBS in a 1.5 mL Eppendorf 
tube. 20µL of proteinase K and 4µL RNAse A were added to the resuspended pellet, 
mixed by vortexing and allowed to stand for 5 min at room temperature for protein and 
RNA digestion respectively. Then, 200µL of buffer AL (without ethanol) was added to 
this mixture and, after covering the tube with the lid closed tightly, the mixture was 
vigorously shaken manually by inverting the tube for 15sec to ensure uniform mixing. 
The sample mixtures were then incubated at 56°C for 10 mins, after which 200µL of 
100% ethanol was added to it and the sample was mixed thoroughly by vortexing. This 
mixture was then added to a fresh DNeasy Mini spin column provided with the kit with a 
2mL collection tube (provided by the kit) and centrifuged at 8000 rpm for 1 min after 
which the flow through liquid was discarded. The spin column was washed with 500µL 
of buffer AW1 (adding this to the column, centrifuging at 8000 rpm for 1min and 
discarding the flow through along with the collection tube). The column was then washed 




the collection tube. Finally, DNA was eluted into a 1.5mL clean Eppendorfâ tube using 
200µL of buffer AE by centrifugation at 8000rpm for 1 min, and this process was 
repeated with the eluate to obtain maximum yield of DNA. 
4.2.2.2 Methylation EPIC array procedure 
 Isolated DNA was aliquoted into 2D barcoded matrix tubes provided by the core 
facility such that at least 250ng of DNA was sent per sample at a max volume of 45µL. 
These aliquots were then shipped on dry ice to the Center for Genome Technology at the 
Hussman Institute for Human Genomics, University of Miami to be run on Methylation 
EPIC arrays (Illuminaâ) according to manufacturer’s protocol. Briefly, DNA was 
subjected to bisulfite conversion which consisted of the unmethylated cytosine bases 
being converted to uracil and the methylated cytosines remaining unchanged. Bisulfite-
conversion treated DNA was then isothermally amplified overnight, fragmented and 
precipitated to obtain fragmented DNA. These fragments, after resuspension in a 
hybridization buffer, were then made to hybridize to the EPIC BeadChip by overnight 
incubation in the Illumina hybridization oven. The beadchips are designed with attached 
locus-specific oligonucleotides of about 50-base pairs which hybridize to the fragmented 
DNA in this hybridization step. Two types of beads, one each for methylated and 
unmethylated cytosines, enable detection of methylation status by single base extension 
of the oligo using the annealed DNA fragment as template. The single base extension was 
detected with the help of fluorescent labels on beadchips. Beadchips were then scanned 




4.2.2.3 Data analysis 
 Data from the Methylation EPIC array runs, along with the annotation file for the 
array, were received from the core facility in the form of IDAT files, two for each of the 
samples analyzed (one file each for red and green channel). IDAT files were analyzed to 
obtain differential methylation data using RnBeads package in Bioconductor/R (Assenov 
et al., 2014). After running QA/QC on the samples, the data was filtered to remove 
probes that contain single nucleotide polymorphisms (SNPs) and the probes that have 
missing values. Data was normalized using the beta-mixture quantile normalization 
(BMIQ) method (Teschendorff et al., 2012). Differential methylation analysis was 
performed using the rnb.run.differential command. Region-level methylation results were 
analyzed further for finding differentially methylated regions on three levels, namely 
promoter level, gene level and CpG island level. Promoter regions were defined for each 
gene in the analysis by RnBeads as the region 1.5 kbp upstream and 500 bp downstream 
of the transcription start site (TSS). Regions for analyzing gene level and CpG island 
levels were defined based on the manifest file for the assay from the manufacturer. While 
the promoter level and gene level output were already annotated with gene symbols, CpG 
island level output was not. Therefore, Partek Genomics Suite software (Partek Inc.) was 
used to annotate the CpG island level data with gene symbols using human genome 
reference build 37, also known as hg19, and then was filtered for the data exclusively on 
the 20 canonical NER genes. The reference genome build used was hg19 instead of the 





RnBeads performed all pairwise comparisons for the groups included in the 
analysis. The p value under the column comb.p.val was used to assess significance in the 
differential methylation seen at the region level. This represented an aggregated p-value 
for all the CpG sites in a given region based on a generalization of Fisher’s method 
(Makambi, 2003; Müller et al., 2015). Multiple testing correction was not performed 
(usually done via false discovery rate or FDR-based p-values), as we tested a set number 
of predefined hypotheses for just our 20 NER genes. We did not test every possible 
combination that could be done on the data we had, and this is the main reason FDR is 
implemented (Perneger, 1998; Rothman, 1990). 
 Pearson’s correlation coefficients were also calculated in order to correlate log 
expression values of the 20 NER genes to their methylation levels. Sample groups 
constituted of 3 replicates each of JL-BRL6, JL-BTL37, JL-NTAL37, JL-BTL47 and JL-
NTAL47. The expected result was an inverse correlation between methylation and gene 
expression and therefore the correlation coefficient was expected to be negative. 
However, we also noted the instances where the correlation coefficient was positive and 
higher than 0.7 denoting strong positive correlation. Where a correlation coefficient 
below -0.7 (or above 0.7) was observed, simple linear regression was used to see if the 
correlation was significant for that particular gene. 
 The Methylation module in Illumina’s Genome Studio software was used to 
generate box whisker plots and heat maps for visualization of the global methylation 




4.2.3 Variant calling from RNA sequencing data 
 At this point in our work, we transitioned to RNA sequencing to assess gene 
expression levels and validate previously performed expression microarray analyses. 
RNA sequencing also reveals the presence of single nucleotide variants, which might be 
indicative of the possibility of the presence of a mutation in the exonic regions of the 20 
NER genes, to get to the root of the mechanism of differential NER gene expression as 
well as function in our early stage sporadic breast cancer cell line pairs.   
4.2.3.1 RNA isolation and RNA sequencing procedure 
Total RNA was isolated using the miRNeasy mini kit for total RNA isolation 
(QiagenÒ) (Cat#217004) according to manufacturer’s protocol (refer to Chapter 3 for 
details). Quality and concentration check was performed using Agilent’s TapeStation 
4200 system (Cat# G2991AA) according to the manufacturer’s instructions. 1 µg of 
isolated total RNA sample per replicate for each cell line was sent to the Genomics core 
facility at the Hussman Institute for Human Genomics for RNA sequencing, where 
library preparation and sequencing of the samples was carried out, a brief description of 
which can be found in Chapter 3 as well. Data was delivered by the core facility as 
FASTA files which were analyzed further for variant identification. 
4.2.3.2 Data analysis 
Raw FASTA files were uploaded to Partek’s server using FTP with the help of 
Filezillaâ and pre-alignment QA/QC was performed in Partek Flow (Partek Inc.). After 
validating integrity of raw unaligned reads, alignment was performed to the human 
reference genome build 38 (hg38) using 3 aligners, namely GSNAP, HISAT2 and BWA-




Every aligner has a different alignment algorithm and hence, getting a consensus on 
variants called on reads aligned using 3 aligners served as a variant validation strategy. 
Post-alignment QA/QC was performed after alignment using each of the 3 aligners to 
ensure optimum alignment. Aligned reads from each aligner were filtered to remove 
duplicate reads in order to avoid redundant variant calling.  
Variant calling, which means noting differences in base positions compared to the 
reference genome, was performed on sequenced fragments called reads that were aligned 
to the reference genome using all the aforementioned aligners. SAMtools was used for 
this, which uses its mpileup algorithm to call for single nucleotide variants against the 
reference genome, which in this case was the human genome reference build 38 (Heng 
Li, 2011; Heng Li et al., 2009). Variants were filtered to include those only within our 
regions of interest which, in the case of this research study, were the 20 NER genes. This 
was done by importing a gene transfer format (GTF) file for the 20 NER genes, obtained 
using the UCSC Table Browser (Karolchik et al., 2004), into Partek Flow. While 
filtering, only those variants were included to which at least 3 reads mapped, which is a 
validation strategy to weed out artifacts and wrong base detections during sequencing. 
Also, mapping quality was used as a measure of high-quality variants, where this is a 
measure of how well the reads   higher than 30 to filter out artifacts. The filtered variants 
were then annotated with Ensembl transcripts (release 88) as well as with known variants 
from the dbSNP database (build 150) (Sherry et al., 2001). The filtered variants from 
each aligner were then combined to include just the intersects, i.e., common variants 
between all three aligners. The combined variants were downloaded as tab delimited text 




each sample analyzed. These text files were further analyzed using Partek Genomics 
Suite software. 
 Venn diagrams were constructed to find common variants, first between replicates 
of the same line, for consensus and validation, and then between pairs. The aim was to 
find shared variants between the tumor and NTA lines of the Low: Low pair, and the 
variants only in the tumor line but not in the NTA line for the High: Low pair. This 
would narrow down on the variants common to a low NER signature. While constructing 
Venn diagrams in Partek Genomics Suite, a Unique ID column was generated by merging 
columns ‘Chr’ and ‘Position’ for every variant row. The format of the Unique ID column 
was ‘chr.position’, and this was used as the key column to find shared variants. 
4.3 Results 
4.3.1 MethylationEPIC array  
4.3.1.1 Global Methylation for all sample groups 
 Upon using Illumina’s Genome Studio software to visualize global DNA 
methylation distribution as Box-Whisker plots, we saw that the median methylation 
levels (denoted by the red line for each sample group) decreased progressively from JL-
BRL6 group to the JL-BTL37 group. The median methylation for the JL-NTAL47 and 
JL-BTL47 were next, followed by JL-NTAL37 and JL-BTL37. The median methylation 
levels of both tumors are lower than that of their NTA lines, and both are also lower than 





Figure 4.1 Box whisker plot showing methylation value distribution for the 5 sample 
groups assayed. Sample groups constituted of 3 biological replicates for each cell line. The red 
line indicates the median methylation level of each group, which is seen to progressively 
increase from the group having low NER capacity line to that having high NER capacity. The 
numbers in blue for each sample group indicate total number of probes included in the group 
and scale on the y-axis indicates the minimum to maximum values that a b-value can take, i.e., 
0 to 1 where 0 indicates an unmethylated site, 1 indicates a completely methylated site, and 0.5 
would mean a hemi-methylated locus.  
 
 We also created heat maps and performed hierarchical clustering of sample 
groups in Illumina’s Genome Studio software using Euclidian distance metrics of probe 




closely the sample groups related to each other. It was observed that JL-BTL37 clustered 
by itself as a group that showed a distinct methylation profile compared to the other lines, 
depicted by the right-most arm in Figure 4.2. The arm on the left showed JL-NTAL37 
clustered by itself and showing a higher similarity to JL-BTL37 as expected (both 
obtained from the same patient as well as both having low repair). The arms in the middle 
show JL-BRL6 (high repair) cluster by itself and were closely related to JL-NTAL47 
(high repair) and JL-BTL47 (low repair). The cell lines of the High: Low pair (JL NTAL-
47 and JL BTL-47) again clustered together showing a similar methylation profile, and 
this was as expected as well, considering the pair has been derived from the same patient.   
 
Figure 4.2 Hierarchical clustering of sample groups depicting their methylation profiles 
using Euclidian distance. Sample groups constituted of 3 biological replicates for each cell 
line.  Red indicates maximum b-value and green indicates minimum b-value (see scale to the 
right of image). This figure in itself does not depict all of the probes assessed but is however a 
representation of the data to show the clusters generated. This figure is intended to give a 
visual depiction of the closeness of the sample groups to one another in terms of their 





4.3.1.2 Promoter-level methylation for the High: Low pair revealed 2 differentially 
methylated genes, DDB1 and ERCC5, but in the opposite direction to that expected. 
 Promoter regions were predefined by RnBeads for each gene to measure a 
combined methylation level for all CpG sites in the region 1.5 kbp upstream and 500 bp 
downstream of the transcription start site (TSS). The methylation differences were 
expected to be most pronounced in the High: Low pair, owing to the starkly different 
gene expression signatures in the NTA line compared to its matched tumor line Among 
the promoter regions assessed for all the 20 NER genes for the cell lines in the High: Low 
pair, JL-BTL47 and JL-NTAL47, the promoter region for DDB1 and ERCC5 stood out 
significantly differentially methylated between the two groups, with their combined p-
values of 0.002 and 0.045 respectively (Table 4.1). For both these genes, mean 





Table 4.1 Differential methylation for promoter regions of NER genes in the High: Low pair 
Gene  
Promoter Region Genomic Co-ordinates mean.mean.diff*  
(NTAL47-BTL47) comb.p.val# num.sites@ Chromosome Start End 
CCNH chr5 86708337 86710336 -0.0451 0.1047 10 
CDK7 chr5 68529168 68531167 0.0007 0.6071 14 
DDB1 chr11 61109569 61111568 0.1762 0.0016 6 
DDB2 chr11 47234993 47236992 0.0191 0.1032 7 
ERCC1 chr19 45981587 45983586 0.0022 0.4592 5 
ERCC2 chr19 45873677 45875676 0.0019 0.5473 7 
ERCC3 chr2 128051253 128053252 0.0032 0.2727 8 
ERCC4 chr16 14012514 14014513 0.0104 0.2910 11 
ERCC5 chr13 103495694 103497693 0.0388 0.0446 5 
ERCC6 chr10 50747085 50749084 0.0109 0.1671 16 
ERCC8 chr5 60240401 60242400 0.0013 0.2463 12 
GTF2H2C chr5 68854535 68856534 0.0374 0.1073 9 
GTF2H3 chr12 124116875 124118874 -0.0005 0.2933 16 
GTF2H4 chr6 30874461 30876460 0.0542 0.1202 9 
RAD23B chr9 110043918 110045917 -0.0105 0.1627 10 
RPA1 chr17 1731496 1733495 0.0403 0.0535 4 
RPA2 chr1 28240758 28242757 0.0097 0.0559 13 
RPA3 chr7 7757739 7759738 -0.0017 0.7984 2 
XPA chr9 100459140 100461139 0.0509 0.0689 5 
XPC chr3 14219784 14221783 -0.0213 0.2437 14 
*mean of the mean values of differences in b-values for all the CpG sites assessed in the given region 
#combination of p-values for all CpG sites assessed in the given region 





4.3.1.3 Promoter-level methylation in the Low: Low pair revealed 3 significantly 
differentially methylated genes between JL-BTL37 and JL-NTAL37, namely DDB1, 
DDB2 and RPA2, in spite of no significant difference seen in their gene expression in this 
pair 
 Based on gene expression results from RNA sequencing, there was no differential 
methylation expected on the CpG sites within the promoter regions of our NER genes, 
assuming methylation was the regulator mechanism for the gene expression patterns we 
were seeing. However, significant differential methylation was still observed for 
promoter regions of 3 NER genes, DDB1 (p = .003), DDB2 (p = .023) and RPA2 (p = 
.005). The mean of means of b-values at CpG sites in the promoter region for DDB1 was 
higher in JL-NTAL37 than JL-BTL37 for DDB1 (indicated by a positive mean.mean.diff 
value), whereas it was lower in JL-NTAL37 for DDB2 and RPA2 than JL-BTL37 
(indicated by a negative mean.mean.diff value) (Table 4.2). 
4.3.1.4 Gene-level methylation for the High: Low pair showed 3 genes significantly 
differentially methylated, namely DDB1, GTF2H4 and XPA 
 We also looked at gene-level methylation, the regions for which were defined by 
RnBeads based on the reference human genome build 37. RnBeads gave a calculated 
mean difference in b-values and a combined p-value of all the CpG sites assessed in the 
given gene region for each of the 20 NER genes (the number of sites is shown in the 
num.sites column in Table 4.3). It was seen that 3 genes were significantly differentially 
methylated between JL-NTAL47 and JL-BTL47, which were DDB1 (p = .033), GTF2H4 




sites for JL-NTAL47 was higher than that of JL-BTL47 for all the three genes above 





Table 4.2 Differential methylation for promoter regions of NER genes in the Low: Low pair 
*mean of the mean values of differences in b-values for all the CpG sites assessed in the given region 
#combination of p-values for all CpG sites assessed in the given region 
@number of CpG sites assessed for the given region 
 
Gene 
Promoter region genomic co-ordinates mean.mean.diff*  
(NTAL37-BTL37) comb.p.val# num.sites@ Chromosome Start End 
CCNH chr5 86708337 86710336 0.0437111 0.128505 10 
CDK7 chr5 68529168 68531167 -0.00043 0.231331 14 
DDB1 chr11 61109569 61111568 0.0882936 0.00335999 6 
DDB2 chr11 47234993 47236992 -0.0422267 0.0227868 7 
ERCC1 chr19 45981587 45983586 -0.0010492 0.614225 5 
ERCC2 chr19 45873677 45875676 -0.0446693 0.110425 7 
ERCC3 chr2 128051253 128053252 -0.004469 0.418972 8 
ERCC4 chr16 14012514 14014513 -0.0771633 0.0769926 11 
ERCC5 chr13 103495694 103497693 -0.0442703 0.175442 5 
ERCC6 chr10 50747085 50749084 0.0435115 0.0936364 16 
ERCC8 chr5 60240401 60242400 -0.0058256 0.405815 12 
GTF2H2C chr5 68854535 68856534 0.0567372 0.0960323 9 
GTF2H3 chr12 124116875 124118874 -0.013184 0.230684 16 
GTF2H4 chr6 30874461 30876460 0.057679 0.0722285 9 
RAD23B chr9 110043918 110045917 -0.004855 0.19057 10 
RPA1 chr17 1731496 1733495 -0.0354298 0.0917978 4 
RPA2 chr1 28240758 28242757 -0.0766177 0.00466714 13 
RPA3 chr7 7757739 7759738 0.0380316 0.228663 2 
XPA chr9 100459140 100461139 -0.103974 0.0893749 5 




Table 4.3 Gene-level differential methylation of NER genes in the High: Low pair 
Gene 
Gene region genomic co-ordinates mean.mean.diff* 
(NTAL47-BTL47) comb.p.val# num.sites@ Chromosome Start End 
CCNH chr5 86687311 86708836 -0.0042224 0.337844 12 
CDK7 chr5 68530668 68573250 0.00422781 0.126131 10 
DDB1 chr11 61066923 61110068 0.00106784 0.0328631 49 
DDB2 chr11 47236493 47260767 0.0557286 0.12335 12 
ERCC1 chr19 45910591 45982086 0.00650957 0.0565207 74 
ERCC2 chr19 45853095 45874176 -0.0083965 0.259075 24 
ERCC3 chr2 128014866 128051752 -0.0081726 0.079543 9 
ERCC4 chr16 14014014 14046202 -0.0028404 0.118672 22 
ERCC5 chr13 103497194 103528345 0.00800953 0.171167 26 
ERCC6 chr10 50663414 50747584 0.0019062 0.0532732 41 
ERCC8 chr5 60169658 60240900 0.0243352 0.0647655 15 
GTF2H2C chr5 68856035 68890550 -0.0065665 0.287731 8 
GTF2H3 chr12 124118375 124147153 -0.004625 0.0577503 12 
GTF2H4 chr6 30875961 30881883 0.0209659 0.0388729 51 
RAD23B chr9 110045418 110094475 0.00581346 0.146832 17 
RPA1 chr17 1732996 1803376 0.0171036 0.0875882 44 
RPA2 chr1 28218035 28241257 0.0607131 0.171105 7 
RPA3 chr7 7676149 7758238 -0.0030753 0.2402 26 
XPA chr9 100437191 100459639 0.11686 0.0480386 4 
XPC chr3 14186647 14220283 -0.0153689 0.11767 26 
*mean of the mean values of differences in b-values for all the CpG sites assessed in the given region 
#combination of p-values for all CpG sites assessed in the given region 





4.3.1.5 Gene-level methylation for the Low: Low pair showed 10 genes to be significantly 
differentially methylated among JL-NTAL37 and JL-BTL37 
 Gene-level methylation for the Low: Low pair showed some interesting results. A 
total of 10 genes were found to be significantly differentially methylated between JL-
NTAL37 and JL-BTL37. Among the significant genes, DDB1 (p = .01), DDB2 (p = .03), 
RAD23B (p = .047) and RPA1 (p = .02) had higher mean of mean methylation on 
assessed CpG sites in JL-NTAL37 than JL-BTL37 (indicated by a positive 
mean.mean.diff value in Table 4.4). However, for ERCC1 (p = .045), ERCC3 (p = .01), 
ERCC4 (p = .02), ERCC6 (p = .035), GTF2H3 (p = .03), GTF2H4 (p = .001), mean of 
mean methylation on assessed CpG sites in JL-NTAL37 was lower than that of JL-















Table 4.4 Gene-level differential methylation for of NER genes in the Low: Low pair 
*mean of the mean values of differences in b-values for all the CpG sites assessed in the given region 
#combination of p-values for all CpG sites assessed in the given region 
@number of CpG sites assessed for the given region 
Gene 
Gene region genomic co-ordinates mean.mean.diff* 
NTAL37-BTL37 comb.p.val# num.sites@ Chromosome Start End 
CCNH chr5 86687311 86708836 -0.0293 0.0852 12 
CDK7 chr5 68530668 68573250 0.0200 0.2729 10 
DDB1 chr11 61066923 61110068 0.0041 0.0123 49 
DDB2 chr11 47236493 47260767 0.0244 0.0307 12 
ERCC1 chr19 45910591 45982086 -0.0165 0.0446 74 
ERCC2 chr19 45853095 45874176 -0.0189 0.2044 24 
ERCC3 chr2 128014866 128051752 -0.0026 0.0106 9 
ERCC4 chr16 14014014 14046202 -0.0288 0.0206 22 
ERCC5 chr13 103497194 103528345 0.0106 0.2154 26 
ERCC6 chr10 50663414 50747584 -0.0261 0.0346 41 
ERCC8 chr5 60169658 60240900 0.0214 0.2600 15 
GTF2H2C chr5 68856035 68890550 0.0090 0.2034 8 
GTF2H3 chr12 124118375 124147153 -0.0583 0.0258 12 
GTF2H4 chr6 30875961 30881883 -0.0351 0.0016 51 
RAD23B chr9 110045418 110094475 0.0158 0.0474 17 
RPA1 chr17 1732996 1803376 0.0043 0.0224 44 
RPA2 chr1 28218035 28241257 0.0425 0.1071 7 
RPA3 chr7 7676149 7758238 -0.0230 0.1341 26 
XPA chr9 100437191 100459639 0.0019 0.7326 4 




4.3.1.6 CpG Island-level methylation level showed none of the genes significantly 
differentially methylated between the High: Low pair  
 Upon looking at CpG-island level methylation, none of the 20 NER genes stood 
out significantly differentially methylated in the High: Low pair, JL NTAL-47 and JL 
BTL-47 (Table 4.5). 
4.3.1.7 CpG Island-level methylation level showed 3 genes significantly differentially 
methylated in the Low: Low pair 
 CpG Island-level methylation was assessed for NER genes in both pairs using 
RnBeads. However, in the Low: Low pair, 3 genes showed significant differential 
methylation between JL-NTAL37 and JL-BTL37. DDB2 was significant at p = .04, 
where the mean of mean methylation values of CpG sites assessed in the given region 
was higher in JL-NTAL37 than in JL-BTL37. The other two genes, GTF2H4 and RPA2, 
were significant each at p = .0007 and p = .03 respectively and the mean of mean 
methylation values for CpG sites assessed in the region was lower for both genes in JL-












Table 4.5 Differential methylation at the CpG Island-level in the High: Low pair 
$ region id; *mean of the mean values of differences in b-values for all the CpG sites assessed in the given region; 
#combination of p-values for all CpG sites assessed in the given region; @number of CpG sites assessed for the given region 
Gene  
CpG Island genomic co-ordinates 
id$ 
mean.mean.diff* 
NTAL47-BTL47 comb.p.val num.sites Chromosome Start End 
CCNH chr5 86708297 86708878 6834 -0.0008 0.3511 5 
CDK7 chr5 68530598 68531001 6729 0.0005 0.5706 8 
DDB1 chr11 61100074 61100972 14389 0.0002 0.5536 9 
DDB2 chr11 47236405 47236933 14303 -0.0020 0.3735 3 
ERCC1 chr19 45931688 45932295 24107 -0.0078 0.1825 3 
ERCC1 chr19 45926662 45927191 24106 0.0004 0.4399 8 
ERCC2 chr19 45866931 45867362 24098 -0.0091 0.2932 4 
ERCC2 chr19 45873340 45874033 24099 0.0031 0.4013 7 
ERCC3 chr2 128051348 128051857 3354 0.0066 0.2494 5 
ERCC4 chr16 14013752 14014295 19081 0.0054 0.3769 6 
ERCC5 chr13 103498101 103498763 16786 0.0038 0.6164 6 
ERCC6 chr10 50746635 50747329 13027 0.0019 0.2792 8 
ERCC8 chr5 60240780 60241490 6700 0.0001 0.4497 8 
GTF2H2C chr5 68855810 68856161 6734 0.0024 0.3574 7 
GTF2H3 chr12 124118098 124118479 16159 0.0025 0.3639 11 
GTF2H4 chr6 30881534 30882296 7908 0.0193 0.0751 24 
GTF2H4 chr6 30875643 30875957 7907 0.0091 0.3200 3 
RAD23B chr9 110045113 110046303 12030 0.0044 0.2330 9 
RPA1 chr17 1799542 1799756 20154 -0.0104 0.0739 3 
RPA2 chr1 28240585 28241535 744 -0.0262 0.1108 11 
RPA3 chr7 7679841 7680679 9200 0.0014 0.4112 9 
XPA chr9 100459097 100459775 11975 -0.0012 0.7527 1 




Table 4.6 Differential methylation at the CpG Island-level in the High: Low pair 
$ region id; *mean of the mean values of differences in b-values for all the CpG sites assessed in the given region; 
#combination of p-values for all CpG sites assessed in the given region; @number of CpG sites assessed for the given region 
 
Gene  
CpG Island genomic co-ordinates 
id$ 
mean.mean.diff* 
NTAL37-BTL37 comb.p.val# num.sites@ Chromosome Start End 
CCNH chr5 86708297 86708878 6834 -0.0001 0.2629 5 
CDK7 chr5 68530598 68531001 6729 0.0023 0.3060 8 
DDB1 chr11 61100074 61100972 14389 0.0004 0.3330 9 
DDB2 chr11 47236405 47236933 14303 0.0855 0.0395 3 
ERCC1 chr19 45931688 45932295 24107 -0.0090 0.1610 3 
ERCC1 chr19 45926662 45927191 24106 -0.0014 0.5920 8 
ERCC2 chr19 45866931 45867362 24098 -0.0169 0.1876 4 
ERCC2 chr19 45873340 45874033 24099 -0.0006 0.3069 7 
ERCC3 chr2 128051348 128051857 3354 -0.0053 0.3372 5 
ERCC4 chr16 14013752 14014295 19081 0.0013 0.3308 6 
ERCC5 chr13 103498101 103498763 16786 0.0017 0.3801 6 
ERCC6 chr10 50746635 50747329 13027 -0.0014 0.5462 8 
ERCC8 chr5 60240780 60241490 6700 -0.0057 0.4389 8 
GTF2H2C chr5 68855810 68856161 6734 -0.0001 0.3713 7 
GTF2H3 chr12 124118098 124118479 16159 -0.0021 0.3059 11 
GTF2H4 chr6 30881534 30882296 7908 -0.1488 0.0007 24 
GTF2H4 chr6 30875643 30875957 7907 -0.0094 0.1418 3 
RAD23B chr9 110045113 110046303 12030 -0.0049 0.1731 9 
RPA1 chr17 1799542 1799756 20154 -0.0184 0.0722 3 
RPA2 chr1 28240585 28241535 744 -0.0018 0.0289 11 
RPA3 chr7 7679841 7680679 9200 -0.0043 0.4911 9 
XPA chr9 100459097 100459775 11975 0.0033 0.3537 1 




4.3.1.8 Correlation between log gene expression and methylation values at the promoter 
level showed a strong correlation for CDK7, GTF2H2 and XPC, but this correlation was 
not significant. 
   In order to ascertain if methylation was the reason we were seeing gene 
expression patterns of our 20 NER in the two pairs assessed and the normal breast line as 
well, correlation coefficients (R2) were calculated using Microsoft Excel’s ‘CORREL’ 
function for log gene expression values obtained via RNA sequencing and the averages 
of b-values for methylation via the Methylation EPIC array for all the lines assessed. R2 
values range from -1 to 1, where 0 means no correlation between the two parameters 
being studied, 1 means perfect positive correlation and -1 means perfect inverse 
correlation among the parameters being studied (gene expression and methylation in our 
case). The ideal expected outcome, if methylation was indeed the mechanism of 
regulation of expression of the 20 NER genes in our cell lines, would be an inverse 
correlation. This would mean higher methylation indicates a lower gene expression and 
vice versa. A value above 0.7 for direct correlation, or below 0.7 for inverse correlation is 
used as a threshold in literature. 
Correlation of gene expression with methylation at the promoter level showed 2 
genes with an R2 value above 0.7 (for direct correlation), namely CDK7 (R2 = 0.72) and 
GTF2H2 (R2 = 0.85). Only one gene showed an R2 below -0.7 (meaning inverse 
correlation), which was XPC with an R2 = -0.83 (Table 4.7). For the 3 genes above that 
showed high correlation among its gene expression and methylation at the promoter 




two variables. It was found that none of the correlations for either CDK7 (p = .17), 
GTF2H2 (p = .07) or XPC (p = .08) were significant. 
4.3.1.9 Correlation between log gene expression and methylation values at the gene level 
showed a strong correlation for ERCC8, but this correlation was not significant. 
 When correlation coefficients were calculated to see if methylation at the gene 
level for the 20 NER genes correlated with log gene expression, we found one gene, 
ERCC8, that had a R2 of 0.76 (Table 4.8). However, upon checking for significance of 
this correlation coefficient using linear regression, it was not found to be significantly 







Table 4.7 Correlation between Log gene expression values and b-values for 
methylation for promoter regions of the 20 NER genes for all groups. Groups 
consisted of replicates of all cell lines assessed. Positive values indicate a positive 
correlation between gene expression and methylation. Negative values indicate an inverse 
correlation between gene expression and methylation. Rows highlighted in read indicate a 
correlation above 0.7 or below -0.7. None of the correlation coefficients in red were 
significant a=0.05 based on logistic regression run for those genes, namely CDK7, 

















































Table 4.8 Correlation between log gene expression values and b-values for gene-level 
methylation for the 20 NER genes for all groups. Groups consisted of replicates of all 
cell lines assessed. Positive values indicate a positive correlation between gene 
expression and methylation. Negative values indicate an inverse correlation between gene 
expression and methylation. Rows highlighted in read indicate a correlation above 0.7 or 
below -0.7. The correlation coefficient in red for ERCC8 was not significant based on 















































4.3.1.10 Correlation between log gene expression and methylation values at the CpG 
island level showed a strong correlation for XPC, but this correlation was not significant. 
 Lastly, we also ran correlations between log gene expression values and 
methylation values at the CpG-island level for the 20 NER genes. We found that XPC 
had a correlation coefficient below -0.7, indicating a good inverse correlation, as would 
be expected between gene expression and methylation (Table 4.9). However, in spite of 
an R2 of -0.74, this correlation for XPC was not found to be significant via linear 


















Table 4.9 Correlation between log gene expression values and b-values for CpG 
island-level methylation for the 20 NER genes for all groups. Groups consisted of 
replicates of all cell lines assessed. Groups consisted of replicates of all cell lines 
assessed. Positive values indicate a positive correlation between gene expression and 
methylation. Negative values indicate an inverse correlation between gene expression and 
methylation. Rows highlighted in read indicate a correlation above 0.7 or below -0.7. The 































4.3.2 Variant calling using SAMtools on RNA sequencing data 
4.3.2.1 Number of variants detected in all lines 
 We first looked at consensus on single nucleotide variants from the 3 aligners, 
GSNAP, HISAT and BWA-MEM, we chose, and then also looked at consensus for the 
variants among replicates of each line that was run using RNA sequencing. These data 
are summarized in Table 4.10. A number of NER genes showed single nucleotide 
variants in all the 6 lines assessed, including the normal breast line and the foreskin 
fibroblast lines. The total number of single nucleotide variants detected in the NER genes 
for each line did not seem to follow any particular pattern. Therefore, we explored the 
variants in our High: Low and Low: Low pairs further to focus on shared variants, and to 
the variants coinciding with a low NER signature. 
Table 4.10 Total number of single nucleotide variants per sample group in NER 
genes  




JL-BTL37 30 RPA2, ERCC6, GTF2H3, ERCC5, ERCC4, 
RPA1, ERCC2, ERCC1, XPC, RAD23B 
JL-NTAL37 32 ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, 
ERCC6, GTF2H3, XPC, RAD23B 
JL-BTL47 19 RPA2, ERCC6, GTF2H3, ERCC5, RPA1, 
ERCC2, ERCC1, RAD23B 
JL-NTAL47 34 ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, 
ERCC6, ERCC8, DDB1, DDB2, CDK7, 
RAD23B, XPC, RPA1 
JL-BRL6 24 ERCC1, ERCC4, ERCC5, ERCC6, ERCC8, 
XPC, GTF2H3 
FF 25 RPA2, ERCC6, GTF2H3, ERCC5, ERCC4, 





4.3.2.2 Variant calling and Venn diagram construction for single nucleotide variants in 
cell lines of the Low: Low pair revealed 24 shared variants  
 To address our major hypothesis of finding shared alterations between the cell 
line pairs where the NER capacity was shared, we explored shared single nucleotide 
variants between the tumor and the NTA line of our Low: Low pair, JL-BTL37 and JL-
NTAL37. The Low: Low pair showed 24 shared single nucleotide variants (Figure 4.3). 
Upon taking a look at the variants that were shared, except for 3 variants that represented 
intron indels, all the others were also found as known single nucleotide polymorphisms in 
the dbSNP database. The genes that these variants were found, along with their 
association to clinical conditions/response to treatment with certain therapeutic agents are 








Figure 4.3 Venn diagram for variants shared between JL-BTL37 and JL-NTAL37, the 
Low: Low pair. The area of interest in this Venn diagram is the olive-green section in the 
center of the diagram that represents shared variants between JL-NTAL37 and JL-BTL37 (24). 
The light green section shows number of variants that are unique to JL-NTAL37 (8), whereas 

















variants with AA 
change 
Other  
ERCC6 3 3 1 
(rs4253072)  
Homozygous  -  







- rs1047768 – platinum-based chemo response 
(Landrum et al., 2017; NCBI, 2016a) 
ERCC4 1 1 0 - 
 
rs4781563-alters miR-2355-3p binding (Mi et 
al., 2014) 
RPA1 5 5 1 
(rs5030755) 
Heterozygous  rs5030740-altered 
pre-menopausal 
breast cancer risk (J. 
Han et al., 2009) 
 




rs13181- XP, NSC 




rs1052555-platinum-based chemo response; 
rs238406-XP increased toxicity with 
platinum-based chemo in NSC lung cancer; 
increased bladder cancer risk; predisposition 
to head/neck & breast cancer 
(Landrum et al., 2017; Malats, 2008; Amit 
Kumar Mitra et al., 2009; NCBI, 2016b, 





ERCC1 2 1 0 - 
 
rs3212986-platinum-based chemo response 
(Landrum et al., 2017; NCBI, 2016g) 
XPC 2 2 0 -  rs2228001-platinum-based chemo response, 
cardiomyopathy, XP 
(Landrum et al., 2017; NCBI, 2016e) 
RAD23B 1 1 0 - -  
Table 4.11 Characteristics of the shared single nucleotide variants between the Low: Low pair of cell lines and their association with 




 Most of these variants, identified in the dbSNP database as known single 
nucleotide polymorphisms, were associated with an altered response to platinum-based 
chemotherapeutic agents like cisplatin (variants in ERCC1, ERCC2, ERCC5 and XPC) 
(Landrum et al., 2017). One known variant in RPA1, rs5030740, has been shown to have 
altered risk of breast cancer in pre-menopausal women (J. Han et al., 2009). Also, the 
variant in ERCC4 (rs4781563) has been implicated to alter the binding of a microRNA, 
miR-2355-3p (Mi et al., 2014).  
 Among the 24 variants found, 3 variants were unknown, and were a result of an 
insertion/deletion or indel in the sequence of the particular gene. One of those indels was 
in a gene BIVM-ERCC5 readthrough, that codes for a fusion protein which has sequence 
similarity to proteins coded by both genes individually (NCBI(Gene), 2018). The second 
indel was in the 3p-UTR region of ERCC2, which also lies in the exon for another gene 
KLC3. The third indel was in the 3p-UTR of ERCC1 but was also in the exon of a gene 
CD3EAP. 
 We also looked at the variants that were not shared within the Low: Low pair of 
cell lines. 6 variants were seen exclusively in the tumor line JL BTL-37, out of which 5 
were known from the dbSNP database. However, only one of these six variants (in 
GTF2H3) was predicted to produce an amino acid change and had a heterozygous 
genotype (Table 4.12). The one unknown variant was seen GTF2H3 which was a single 
nucleotide change from A to G with a heterozygous genotype, but with no amino acid 
change predicted. However, this unknown variant checked for its location in the 
consensus coding sequence (CCDS) database via the UCSC Genome browser and was 




 There were 8 variants exclusively in JL NTAL-37 that were not shared with JL 
BTL-37, and all of them were known through the dbSNP database. Out of those, one 
variant in ERCC2 showed an amino acid change and has been shown to have 
implications in XP, response to platinum-based chemotherapy and susceptibility to 









Table 4.12 Characteristics of the single nucleotide variants the tumor line of the Low: Low pair, JL BTL-37, that are not 
shared with the NTA line, JL NTAL-37, and their association with disease or clinical outcome studied in literature. 
 








Zygosity of the variants 








1 1 - - - rs3743538: XP 
ERCC5 1 1 - - - rs2296147:  XP; altered response 
to platinum-based chemotherapy 
in gastric cancer and lung 
cancer; colorectal cancer; XP 
(Landrum et al., 2017) 




Syndrome(Landrum et al., 2017) 
GTF2H3 2 1 1 (rs1051793) Heterozygous - - 
RPA2 
 









Table 4.13 Characteristics of the single nucleotide variants the NTA line of the Low: Low pair, JL NTAL-37, that are not shared with the 
tumor line, JL BTL-37, and their association with disease or clinical outcome studied in literature. 
 












Clinical association of 
variants with AA change 
Other 
ERCC1 1 1 - - - - 
ERCC2 1 1 1 (rs1799793) Homozygous XP; certain alleles alter 
response to platinum based 
chemotherapy in TNBC 
and NSCLC; increased 
susceptibility to glioma in 
Asian population; high risk 
of breast cancer for certain 
alleles; increased risk of 
prostate cancer (Agalliu et 
al., 2010; B. H. Fu et al., 
2017; Hardi et al., 2018; C. 
Li et al., 2006; J. Lu et al., 
2015; Qian, Zhang, Qian, 
He, & Li, 2017) 
- 
ERCC3 1 1 - - - - 
ERCC4 2 2 - - - rs2276464:XP; rs1799801: 
XP, increased toxicity to 
platinum based 
chemotherapy; reduced 
cancer risk in a Caucasian 




Shi et al., 2012; Y. Zheng 
et al., 2017) (Landrum et 
al., 2017) 
GTF2H3 1 1 - - - - 
XPC 2 2 - - - rs1126549: XP; 
Cardiomyopathy 








4.3.2.3 Variant calling and Venn diagram construction for single nucleotide variants in 
cell lines of the High: Low pair revealed 11 shared variants  
 Variant calling on the High: Low pair and subsequent Venn diagrams revealed the 
presence of 11 shared variants overlapping the 20 NER genes (Figure 4.4), the 
characteristics of which are described in Table 4.14. Among these, 10 were known 
variants from the dbSNP database. Among the 10 known variants, 4 variants were 
predicted to have a downstream amino acid change, and these were found in ERCC1, 
ERCC5 (2) and ERCC6. The two variants in ERCC5 and one in ERCC6 were both 
homozygous and the one in ERCC1 had a heterozygous genotype. 
Our High: Low pair showed the case where NER capacity was not shared 
between the tumor line and the NTA line. Therefore, we were interested in looking at 
variants that are exclusive to JL-BTL47, and not present in JL-NTAL47. A total of 8 
variants were discovered in some of the NER genes, as show in Figure 4.4 and listed in 
Table 4.11. Among the 8 variants that were found, only 1 was an unknown variant 
resulting from an indel in the 3’-UTR region of RPA1 but was not predicted to cause a 
downstream amino acid change. Out of the remaining 7 known variants, none were 
predicted to cause a downstream amino acid change. The variants in XPG/ERCC5 
showed evidence in literature for an altered response to platinum-based chemotherapy 
and were also implicated in numerous studies for lung cancer, colorectal cancer and 
gastric/esophageal cancer. One variant in XPD/ERCC2 was also implicated in an altered 




in lung cancer and colorectal cancer and has been associated with an increased bladder 
cancer risk (Table 4.11). 
We also looked at the variants exclusively in JL NTAL-47 that are not shared in 
JL BTL-47. A total of 23 variants were seen only in JL NTAL-47, that were not shared 
with JL BTL-47. Out of these, 5 variants showed an amino acid (AA) change, and these 
were the variants in ERCC2, ERCC5 (2), CDK7 and RAD23B. 4 out of 5 of these 
variants had a heterozygous genotype and one in ERCC5 had a homozygous genotype, 
which was associated with an increased risk for a number of cancer types. (Table 4.12) 
 It is notable that among the variants listed in Table 4.11 and 4.15, two variants 
stood out common to a low NER signature. They were rs1047768 in XPG/ERCC5 and 










Figure 4.4 Venn diagram showing variant distribution in the High: Low pair of cell lines, 
JL-NTAL47 and JL-BTL47. The area of interest in this diagram is the red section, which 
denotes variants unique to JL-BTL47 and not shared with JL-NTAL47, possibly characterizing 
a low NER phenotype (8). The light green section denotes variants unique to JL-NTAL47 (23) 






Table 4.14 Characteristics of the shared single nucleotide variants between the High: Low pair of cell lines, JL NTAL-47 and 
JL BTL-47 and their association with disease or clinical outcome studied in literature.  
 












Clinical association of 




1 - - - - 
ERCC5 3 
 




rs9514067: XP (NCBI, 
2016f; Shiomi et al., 2004); 
rs1047768 – platinum-based 
chemo response (Landrum et 












2 1 1 (rs3212986) Heterozygous rs32129686: higher 
nephrotoxicity with 
platinum-based 
chemotherapy for certain 
amino acid substitutions at 
this locus (Khrunin, 












Table 4.15 Characteristics of the single nucleotide variants the tumor line of the High: Low pair, JL BTL-47, but not in the 












of variants with AA 
change Other 
ERCC6 1 1 - -  
ERCC5 2 2 - - rs1047768 – platinum-based chemo response 
rs2296147 – altered response to platinum-based chemotherapy 
in gastric cancer and lung cancer; colorectal cancer; XP 
(Landrum et al., 2017; NCBI, 2016a, 2016j) 
RPA1 2 1 - - rs12727- altered pre-menopausal breast cancer risk 
(J. Han et al., 2009) 
RPA2 1 1 - - rs7356- rectal cancer 
(Naccarati et al., 2012) 
ERCC2 1 1 - - rs238406 – XP; increased toxicity with platinum-based chemo 
in NSC lung cancer and colorectal cancer; increased bladder 
cancer risk (Kweekel et al., 2009; Malats, 2008; NCBI, 2016i; 
W. Wu et al., 2009) 
RAD23B 1 1 - -  - 
 
Table 4. 16 Characteristics of the single nucleotide variants the NTA line of the High: Low pair, JL NTAL-47, but not in the 
















of variants with AA 
change 
Other 
ERCC2 2 2 1 (rs13181) Heterozygous rs13181- XP, NSC 





rs1052555: poor overall 
survival and progression free-
survival with a specific allele 
in non-small cell lung cancer 
(Tan et al., 2017) 
ERCC3 
 
2 2 - - - - 
ERCC4 
 
1 1 - - - rs1799801: XP; increased 
toxicity to platinum based 
chemotherapy; reduced cancer 
risk in a Caucasian population 
study (T.-Y. Shi et al., 2012; 
Y. Zheng et al., 2017) 








(Bodian et al., 
2014); rs17655: 
increased risk of 
gastric, lung, 
colorectal and 
cervical cancer (Joo 
et al., 2016; Y. 
Liang, Deng, Xiong, 
Wang, & Xiong, 
2014; Yong Zeng, 
Wei, Wang, & Liu, 



























(Landrum et al., 2017) 
ERCC8 
 
1 1 - - - rs3117: Cockayne Syndrome 
DDB1 
 
1 1 - - - - 
DDB2 
 
2 2 - - - rs4647760: XP 
RPA1 
 
4 4 - - - rs5030740: altered pre-
menopausal breast cancer risk 
(J. Han et al., 2009) 
CDK7 
 
1 1 1 
(rs34584424) 
Heterozygous - - 
RAD23B 
 
2 2 1 (rs1805329) Heterozygous rs1895329: 
significantly 
associated with 
breast cancer risk in 






1 1 - - - - 
GTF2H3 
 







 There is a general consensus in literature that genomes of tumor cells are found to 
be globally hypomethylated, which is mostly due to the demethylation of repeated 
elements and retro transposons that form almost half of the human genome (Deng et al., 
2006; M Ehrlich, 2006; Melanie Ehrlich, 2009; Feinberg & Vogelstein, 1983; Gaudet et 
al., 2003). We also distinctly saw this observation in our methylation distributions in the 
box whisker plot in Figure 4.3, thus making our observations consistent with those seen 
in cancer. Overall, most NER genes showed no correlation between gene expression and 
methylation. The ones that showed strong correlations were not correlated significantly 
(Table 4.7, 4.8 and 4.9). For differential methylation between the cell lines of each pair, 
we saw differential methylation for 3 genes on the promoter level (Table 4.2) and10 
genes on the gene-level (Table 4.4) between JL BTL-37 and JL NTAL-37 of the Low: 
Low pair, whereas there was no difference in their gene expression by RNA sequencing. 
Also, differential methylation for the High: Low pair at the promoter level showed 2 
differentially expressed genes, DDB1 and ERCC5. However, gene expression for ERCC5 
showed no difference between JL BTL-47 and JL NTAL-47 of the High: Low pair.  
 DDB1 stood out as differentially methylated in both promoter level and gene level 
methylation for Low: Low as well as High: Low pair. Taking into consideration the 
paradigm of promoter methylation leading to gene silencing, we were seeing the opposite 
effect, where methylation was relatively higher in the NTA line of the High: Low pair, 
JL-NTAL47, than the tumor line JL-BTL47. This finding does not conform to its 
expression levels, where DDB1 expression is lower in JL-BTL47 than in JL-NTAL 47 




methylation of a repressor binding site on the promoter region of DDB1. Repressors are 
transcription factor proteins that bind to specific regions on DNA called silencers and 
negatively regulate gene expression (Maston, Evans, & Green, 2006). Methylation of 
these binding sites can inhibit the binding of these repressors, wherein an increase in 
transcription of the gene would be the result (Medvedeva et al., 2014). We did a brief 
survey on possible transcription factors binding to the DDB1 promoter region using the 
UCSC Genome browser, where we used the ENCODE regulation track to look for 
chromatin immunoprecipitation or ChIP-seq-validated binding sites for transcription 
factors, and this is shown in Figure 4.5. The transcription start site for DDB1 is at the co-
ordinate chr11:61109938-61109939, as obtained from the UCSC Table browser’s 
SwitchGear TSS track under ‘Regulation’ for the human genome assembly hg19. 
 Among the transcription factors indicated by the red arrow in Figure 4.5, there 
were 18 factors found to bind the promoter of DDB1 that are known repressors. These are 
ZNF274 (O'Leary et al., 2015; Yano et al., 2000), CBX3 (UniProt_Consortium, 2018), 
RCOR1 which is a repressor for neuron-specific genes in non-neuronal cells 
(UniProt_Consortium, 2018), IRF1 (Nguyen, Teskey, Lin, & Hiscott, 1999; 
UniProt_Consortium, 2018; Xie et al., 2003), BCLAF1 (Kasof, Goyal, & White, 1999), 
EP300 (Snowden, Anderson, Webster, & Perkins, 2000), TRIM28, also known as KAP-1 
(Friedman et al., 1996), MAZ (Bossone, Asselin, Patel, & Marcu, 1992), SP1 (though 
mostly an activator, has also been identified as a repressor) (Zaid, Hodny, Li, & Nelson, 
2001), HDAC2-a major transcriptional repressor protein via histone deacetylation (Kong, 
Fang, Li, Fang, & Xu, 2009; R. Liu et al., 2009), PML (N. Martin et al., 2012; Mu, Chin, 




Hai, 1994), REST (Chong et al., 1995; Lunyak et al., 2002; Mulligan et al., 2008), MAX 
(Comino-Méndez et al., 2015; Hurlin et al., 1995), NR2F2 (K. Chu & Zingg, 1997),  
ZBTB7A (C.-j. Liu et al., 2004), E2F-6 (Trimarchi et al., 1998) and CEBPB (Narayanan 
et al., 2004; S.-H. Park et al., 2010). This suggests that the promoter region of DDB1 is a 
highly regulated region having binding sites for multiple repressor proteins. This is an 
interesting future direction that could be pursued, where repressor binding to NER genes 
and the possible inhibition of their DNA binding ability due to methylation could be 








Figure 4.5 Map for the region assessed for promoter-level methylation of DDB1, based on the definition by RnBeads, obtained from the 
UCSC Genome Browser. The pink arrow denotes the direction of transcription of DDB1. Grey and black horizontal bars under the track 
‘Transcriptional Factor ChIP-seq from ENCODE with Factor Motifs’ denote the putative binding site for the respective DNA binding 
transcription factor indicated on the left of each bar. Green spots on these gray/black horizontal bars indicate the sites with the highest score for 




The map for ERCC5, on the contrary, for the region that came up differentially 
methylated among the High: Low pair, only one factor binding to the region. Moreover, 
this region seemed to be rather an intronic segment for a fusion gene BIVM-ERCC1, that 
codes for a fusion protein which retains structural similarity to proteins coded by both 
these individual genes. It would be an interesting question as to why this region was 
defined as the promoter region for ERCC5 by RnBeads, as we could not find a 
transcription start site at this region using SwitchGear TSS track of the UCSC Genome 
browser. The only transcription factor binding to this region, CTCF, is a zinc-finger 
protein and also a known repressor of transcription (Figure 4.6). 
CpG sites on genes are considered ‘mutation hotspots’ and this is due to the 
cytosines and methylated cytosines being prone to spontaneous deamination, which leads 
to uracil in case of cytosines, and thymine in case of methyl cytosines (Walsh & Xu, 
2006). Now, presence of thymine is harder to detect as thymine is a usual component of 
DNA. However, uracil is not found in DNA, and therefore is a major mutagenic event 
which is repaired by the base excision repair pathway (Pearl, 2000; Wood, Mitchell, 
Sgouros, & Lindahl, 2001). A good example of this is TP53, a gene frequently mutated in 
tumors, as 49% of germline mutations and 24% of somatic mutations commonly known 
in this gene are a G:C to A:T transition (Walsh & Xu, 2006). Also, gene-level 
methylation showed differential methylation for 10 out of 20 NER genes in the Low: 
Low pair, while only 3 were found to be differentially methylated between the High: Low 
pair. A hypothesis that a low repair signature might be a methylation enabler could be 
tested for in future studies. DNA repair has been shown to have a role in methylation 




development of malignancy (Schär & Fritsch, 2011). It is possible that a low functional 
repair capacity is unable to correct the aberrant methylation occurring in tumors, similar 
to what we see in our Low: Low pair where we see a higher number of genes 
differentially methylated than the High: Low pair. A normal repair capacity in the NTA 
of the High: Low pair might help in maintaining the fidelity of methylation patterns, until 
the DNA repair capacity is lost in its tumor. This interesting hypothesis could be tested 







Figure 4.6 Map for the region assessed for promoter-level methylation of DDB1, based on the definition by RnBeads, obtained from the 
UCSC Genome Browser. Grey horizontal bars under the track ‘Transcriptional Factor ChIP-seq from ENCODE with Factor Motifs’ denote the 






 Variant calling results on the pairs showed that there are more shared variants in 
the Low: Low pair (24) than in the High: Low pair (11). This is consistent with our 
expected observations and the known fact that a low repair capacity enables the 
accumulation of mutations (Hanahan & Weinberg, 2000). The two variants in the NER 
genes, which are also known SNP’s, that were common to a low NER capacity signature 
(which means present in the Low: Low pair and in the tumor of the High: Low) were 
seen in XPD/ERCC2 (rs238406) and in XPG/ERCC5 (rs1047768) (Table 4.11 and 4.15). 
Both these variants have been studied in literature for having an association with an 
altered response to platinum-based chemotherapeutic agents like cisplatin. However, no 
change in amino acid was predicted to occur in the downstream protein composition of 
XPD or XPG in any of these three lines that manifested a low DNA repair capacity, and 
therefore is unlikely that these two variants might be behind the downregulation of the 
NER pathway. An interesting observation in the Low: Low pair was the presence of one 
variant, also a known SNP rs13181, in XPD/ERCC2 that has a homozygous genotype as 
well as caused a downstream amino acid change in the XPD protein. This SNP has been 
implicated in XP as well in associations with the risk of a number of cancer types, 
including breast cancer (Table 4.11). It is possible that the low NER capacity in the Low: 
Low pair (for this particular patient) could be a result of this variant if this were a true 
XPD mutation. However, this is a known SNP with a minor allele frequency ranging 
from 23.66% to 33.08% and therefore, a chance of this SNP being a mutation and causing 





 Associations of SNPs with disease risks have shown conflicting results in the 
literature, as these associations might just be statistical artifacts and their true biological 
impact needs to be verified. For example, the aforementioned SNP in ERCC2 (rs13181), 
which we have seen in our Low: Low pair, has been shown to reduce breast cancer risk 
whereas patients the mutant genotype for this SNP have been associated with a lower 
likelihood of hormone receptor positivity (J. Li et al., 2008). Another large study found 
no association of 3 SNPs in ERCC2 with breast cancer risk (Kuschel et al., 2005). 
Finally, yet another study on 321 patients and their age-matched controls did not show 
any significant association of polymorphisms in XPC, XPD, XPG and XPF genes 
(Jorgensen et al., 2007). Therefore, caution needs to be exercised while making decisions 
to study these SNPs in terms of disease risk and its prediction. 
4.5 Conclusion and Summary 
 Our study calls for further evaluation of mechanism of transcriptional regulation 
of the NER pathway, as methylation or single nucleotide variation do not seem to 
completely explain the downregulation seen in multiple NER genes along with a low 
functional NER capacity. DDB1 was found to be a putative study subject for methylation 
of its promoter region in our pairs, and the activity of repressors binding to this region 
might explain the differential methylation we observed in our pairs. Treating these pairs 
with 5-azacytidine and then measuring restoration of gene expression will help 
understand if methylation is, in fact, the regulator at the promoter site of genes found 
differentially methylated among our cell line pairs. Alternatively, future studies will 
include the investigation of the role of small inhibitory non-coding RNA molecules, 




showed a putative miRNA candidate that regulates some of the genes in the NER 
pathway using late stage cell lines and also showed a change in functional NER capacity 
(As Sobeai, 2017). Future studies will involve miRNA profiling in these cell line pairs 
and molecular studies to observe their effect on the regulation of transcription and 






















Mutations in breast cancer and the construction of person-specific maps 
of genetic alterations for breast tumorigenesis 
5.1 Introduction 
 The somatic evolution of cancer is now well established, and numerous models 
have been proposed explaining the progression of cancer. The earliest theories came from 
rodent models which proposed only two stages of tumor development, initiation and 
promotion (Berenblum & Shubik, 1947; Fujiki et al., 2013; Mottram, 1944). It was later 
shown that cancer follows three major stages, tumor initiation, promotion and 
progression. The specific events or mutations that lead to phenotypic transformation of 
the cells from normal to malignant are deemed as driver events, and they mainly aim at 
altering genomic stability. Loss of genomic stability is a hallmark of most cancers 
(Hanahan & Weinberg, 2000). This in turn allows the accumulation of further somatic 
mutations, known as passenger mutations or events, thus leading to the formation of a 
full-blown tumor (Vogelstein et al., 2013). 
 Certain genetic models for carcinogenesis have laid the framework for delineating 
the steps that the cells of a normal tissue undergo at the genetic level towards their 
transformation to neoplasia. The earliest multistep model was established for colorectal 
cancer by Vogelstein and colleagues in 1953 (Vogelstein & Kinzler, 1993). Similar 




esophageal carcinoma, and for breast cancer as well (Bieche & Lidereau, 1995; Gregson 
et al., 2016). These models show the loss of function or altered function of important 
tumor suppressor genes like TP53 and APC (Figure 2.13 and 2.14). Breast cancer, being 
a heterogenous disease, does not always follow the linearity of steps mentioned in this 
model. Moreover, the driver events are tumor- and individual- specific and therefore it is 
difficult to have one conclusive model for mammary carcinogenesis. 
 The field cancerization theory showed the importance of studying the 
histopathologically normal tissue adjacent to the tumor to find the changes that the tissue 
undergoes during transformation (Heaphy et al., 2009; Rivenbark & Coleman, 2012; 
Stern et al., 2002; Trujillo et al., 2011). Here, we chose to study possible mutations in the 
coding regions of a list of genes known to play important roles in tumorigenesis, 
especially of the breast, using RNA sequencing performed on our Low: Low and High: 
Low pairs of early stage tumor lines and their matched non-tumor adjacent lines. Most of 
the genes in their list were chosen as they have been shown (by ChIP-seq experiments) to 
bind to the promoter regions of the 20 canonical NER genes based on Factorbook Motif’s 
161 transcription factor binding sites database from the ENCODE Consortium. These 
include E1F1, GABPA, E2F1, E2F4, E2F6, BRCA1, ELF1, YY1, MAX, USF1, SP1, 
SP4, EGR1, RUNX3, MYC, PHF8, FOXA1, TEAD4, JUND, STAT1 and ZNF143. The 
remainder of the genes in our list are important genes with respect to cancer, especially of 
the breast. These genes, along with their functions are listed in Table 5.1. We therefore 
aimed to establish a temporal scheme of alterations or our own “Vogelsteinogram” in 




Table 5.1 List and functions of genes with their protein products evaluated for the presence of mutations by variant calling on 
RNA sequencing data in the High: Low and the Low: Low pairs. * indicates the NER genes the respective protein has been found 
to interact with as a transcription factor. This was based on the maps of 5’ ends for the NER genes obtained from the UCSC Genome 
browser with ENCODE Factorbook Motif track denoting transcription factor binding sites based on validation from ChIP-seq 
experiments. The gene and protein functions have been obtained from GeneCards, an online database (Safran et al., 2010), the entries 
in which are based on the reference column. 
 
Protein Name Gene 
Name 
Function and role in cancer NER genes this protein 
interacts with as a 
transcription factor* 
Reference 
HER2 ERBB2 Belongs to Epidermal growth factor (EGF) family of 
receptor tyrosine kinases. Found overexpressed in 
20-30% of breast cancers, and mutations in this are 
involved in breast tumorigenesis 
- (Herter-Sprie, Greulich, & 
Wong, 2013) 
p53 TP53 Tumor suppressor protein frequently mutated in 
cancers including breast cancer 
- (Walerych, Napoli, 
Collavin, & Del Sal, 2012) 
BRCA1 BRCA1 Involved in double strand break repair, mutation 
causes increase in breast cancer and ovarian cancer 
risk 
CCNH, XPC (Antoniou et al., 2003; 
Petrucelli, Daly, & 
Feldman, 2010) 
c-FOS FOS Nuclear phosphoprotein that forms a complex with 
the JUN/AP-1 transcription factor complex. 
Important in cell growth and differentiation; also, a 
proto-oncogene  
- (Pandey, Liu, Cooper, & 
Mulder, 2012) 
JUND JUND Component of the AP-1 transcription factor 
complex; also, a proto-oncogene 
DDB1, RPA3, ERCC1, 
RAD23B, ERCC1 
(Caffarel et al., 2008) 
CHK1 CHEK1 Belongs to the Serine/Threonine protein kinase 
family. Plays an important role in cell cycle arrest 
for DNA damage repair. Found overexpressed in 
breast cancer 
- (Al-Kaabi et al., 2015; 
Albiges et al., 2014) 
CHK2 CHEK2 Belongs to the Serine/Threonine protein kinase 
family. Plays an important role in cell cycle arrest 
for DNA damage repair. Found overexpressed in 
breast cancer; mutations predispose to breast cancer 





Protein Name Gene 
Name 
Function and role in cancer NER genes this protein 
interacts with as a 
transcription factor* 
Reference 
p21; CDN1A CDKN1A Inhibitor of cyclin dependent kinases; regulate cell 
cycle and cell proliferation in response to DNA 
damage. Mutations implicated in bladder cancer 
- (Yang Liu & 
Kwiatkowski, 2015) 
EGR1 EGR1 Nuclear protein belonging to the C2H2 zinc finger 
protein family of early growth receptors. Has a 
tumor suppressor role and is a transcriptional 
regulator  
DDB2, GTF2H3, ERCC6, 
DDB1, GTF2H4, CCNH, 
ERCC3, ERCC8, 
RAD23B, ERCC1 
(C. Liu, Rangnekar, 
Adamson, & Mercola, 
1998; Wei, Wu, Gong, & 
Pei, 2017) 
p16; CDN2A CDKN2A Inhibitor of cyclin dependent kinases CDK4 and 
CDK6. Mutations are implicated in melanoma, 
pancreatic cancer and breast cancer susceptibility  
- (Borg et al., 2000; 
Dębniak et al., 2005) 
RAD21 RAD21 Nuclear phosphor-protein involved in double strand 
break repair. Mutation in this gene causes Cornelia 
de Lange syndrome 
- (Deardorff et al., 2012) 
PALB2; 
FANCN 
PALB2 Partner and localizer of BRCA2; protein involved in 
double strand break. Associated with Pancreatic 
cancer and Fanconi Anemia 
- (Jones et al., 2009) 
RAD51C RAD51C Involved in homologous recombination repair 
pathway. Mutations have been associated with breast 
and ovarian cancer, Fanconi Anemia 
- (Meindl et al., 2010; J.-Y. 
Park et al., 2014; 
Thompson et al., 2012) 
ER ALPHA ESR1 Proteins forming the estrogen receptor. Mutations 
causes resistance to estrogen, thereby causing female 
developmental abnormalities like delay in puberty, 
osteoporosis and unfused epiphyses 
- (Bernard et al., 2016; 
Quaynor et al., 2013) 
E2F1 E2F1 Codes for the retinoblastoma-associated protein. 
E2F family of transcription factors; important in cell 
cycle regulation and the activity of tumor 
suppressors. Mutation associated with 
mesothelioma, colorectal cancer, diabetes mellitus 
and Sjogren’s syndrome 
GTF2H3, DDB2, 
GTF2H4, XPA, ERCC8, 
CCNH, RAD23B 
(Lopes-Ramos et al., 
2017; Salam et al., 2004; 




Protein Name Gene 
Name 
Function and role in cancer NER genes this protein 
interacts with as a 
transcription factor* 
Reference 
TERT TERT Codes for the reverse transcriptase component of 
telomerase enzyme which maintains telomere 
length. Mutations haven been implicated in aplastic 
anemia, melanoma, dyskeratosis congenita and 
pulmonary fibrosis 
- (Armanios et al., 2005; 
Horn et al., 2013; J. Liang 
et al., 2006; Tsakiri et al., 
2007) 
MYC MYC Nuclear phosphoprotein playing an important role in 
cell cycle progression, apoptosis and transformation. 
A proto-oncogene binding to the VEGF promoter 
thereby promoting angiogenesis. Mutation 
associated with Burkitt lymphoma 
ERCC6, GTF2H3, RPA3, 
GTF2H4, ERCC3, 
ERCC8, RAD23B 
(K. Bhatia et al., 1993) 
MAX MAX Myc-associated factor X-member of the leucine 
zipper family of transcription factors. Acts as an 
activator by complexing with MYC, whereas a 
complex of MAX with MAZ is a transcriptional 
repressor. Mutation associated with 
pheochromocytoma 
DDB2, ERCC6, GTF2H3, 
DDB1, RPA3,, ERCC4, 
GTF2H4, ERCC8, 
RAD23B 
(Comino-Méndez et al., 
2011) 
MAZ MAZ Myc-associated zinc finger protein with dual roles in 
transcription initiation and termination. Functions as 
a transcriptional activator as well as repressor 
DDB1, GTF2H4, CCNH, 
ERCC3, RAD23B 
(Bossone et al., 1992) 
ELK1 ELK1 Belongs to the ETS family of transcription factors; 
binds to the serum response elements on the 
promoter of proto-oncogenes like FOS; 
transcriptional activator 
- (Pastorcic & Das, 2003) 
ELF1 ELF1 Belongs to the ETS family of transcription factor; 
encodes for a E26 transformation related 
transcription factor; acts as a transcriptional 
activator  
ERCC6, GTF2H2, 
ERCC4, CCNH, ERCC3 
(J.-Y. Cho et al., 2004; H. 
Song et al., 2009) 
RUNX3 RUNX3 Member of the runt domain containing family of 
transcription factors; transcriptional activator or 
GTF2H3, RPA3, 
RAD23B ERCC1 




Protein Name Gene 
Name 
Function and role in cancer NER genes this protein 
interacts with as a 
transcription factor* 
Reference 
repressor; functions as a tumor suppressor in 
conjunction with ATBF1 
TEAD4 TEAD4 Member of the transcription enhancer factor family 
of transcription factors; belongs to the Hippo 
signaling pathway that is involved in tumor 
suppression functions 
DDB1, ERCC3, RAD23B, 
ERCC1 
(W. Wu et al., 2009; H. 
Zhang et al., 2009) 
YY1 YY1 Transcription factor belonging to the GLI-Kruppel 
family of zinc finger proteins; transcriptional 
repressor as well as activator; shown to have a role 
in homologous recombination 
DDB2, GTF2H3, ERCC4, 
XPA, ERCC8, RAD23B, 
XPC, CDK7, RPA1 
(Y. Shi, Seto, Chang, & 
Shenk, 1991; Siednienko 
et al., 2011; S. Wu et al., 
2007) 
RAD21 RAD21 Cleavable component of the cohesion complex, 
involved in cohesion of sister chromatids during cell 
cycle, DNA double strand break repair and apoptosis 
- (McKay et al., 1996) 
USF1 USF1 Ubiquitous upstream stimulatory factor 1; 
transcription factor that is a member of the leucine 
zipper family proteins; mainly functions as a 
transcriptional activator 
DDB2, ERCC6, DDB1 (Gregor, Sawadogo, & 
Roeder, 1990; Z. Ma, 
Jhun, Jung, & Oh, 2008) 
FOXA1 FOXA1 Belongs to the forkhead family of DNA binding 
proteins; transcriptional activators for liver-specific 
proteins; involved in cell cycle regulation by 
activation of CDKN1B along with BRCA1; 
associated with ER+ breast cancers 
ERCC6, ERCC8 (Laganière et al., 2005; 
Williamson et al., 2006) 
ZNF 143 ZNF143 Zinc finger protein 143, functions as a 
transcriptional activator of the gene for 
selenocysteine tRNA 
ERCC1, XPC (Kubota, Yokota, Yanagi, 
& Yura, 2000) 
SP1 SP1 Zinc finger protein that binds to GC-rich regions on 
promoters of genes; regulates cell growth and 
differentiation, proliferation, chromatin remodeling, 
DNA damage response and apoptosis. Mutations 
cause Huntington’s disease 
GTF2H3, ERCC2, DDB2, 
GTF2H4, CCNH, ERRC8, 
RAD23B 
(M.-C. Hsu, Chang, & 
Hung, 2006; Olofsson, 





Protein Name Gene 
Name 
Function and role in cancer NER genes this protein 
interacts with as a 
transcription factor* 
Reference 
SP4 SP4 Transcription factor that binds to GC regions on 
promoters of genes; a probable transcriptional 
activator 
DDB2, GTF2H3, 
GTF2H4, XPA, CCNH, 
RAD23B, ERCC2 
(Davis Jr, Chen, Ile, & 
Tew, 2003; Hagen, 
Dennig, Preiß, Beato, & 
Suske, 1995) 
STAT1 STAT1 Signal transducer and activator of transcription 1; 
transcription activators that modulate cellular 
responses to interferons, cytokines and growth 
factors; has tumor suppressive functions 
DDB2, RAD23B, ERCC1 (Chapat et al., 2013; K. 
Chen et al., 2017) 
ATM ATM ATM serine threonine kinase that activates cell cycle 
checkpoints and is a DNA damage sensor. 
Phosphorylates important proteins involved in DNA 
damage signaling and repair like BRCA1, p53, 
RAD21, CHEK2, etc. Mutations cause Ataxia 
Telangiectasia 
- (Canman et al., 1998; 
Herbig, Jobling, Chen, 
Chen, & Sedivy, 2004) 
ATR ATR ATR Serine/threonine kinase that activates cell cycle 
checkpoints and is a DNA damage sensor. 
Phosphorylates important proteins involved in DNA 
repair like BRCA1, p53, RAD21, CHEK1, MCM2 
etc. 
- (Cimprich, Shin, Keith, & 
Schreiber, 1996; Haahr et 
al., 2016; Tibbetts et al., 
1999) 
FANCD2 FANCD2 Fanconi Anemia Complementation Group D2; 
Maintains chromosomal stability and promotes 
accurate pairing of homologs during meiosis, 
involved in double strand break repair and 
associated with the disease Fanconi Anemia 
- (Jin et al., 2003; Taniguchi 
et al., 2002) 
E2F4 E2F4 E2F transcription factor 4; controls cell cycle 




(Beijersbergen et al., 
1994; Rubin, Gall, Zheng, 
& Pavletich, 2005) 
E2F6 E2F6 E2F transcription factor-6; involved in cell cycle 
regulation, has a transcriptional suppressing role via 
the recruitment of a chromatin remodeling complex 
ERCC6, DDB2, ERCC4, 
RAD23B 




Protein Name Gene 
Name 
Function and role in cancer NER genes this protein 
interacts with as a 
transcription factor* 
Reference 
GABPA GABPA GA binding transcription factor protein subunit 
alpha; binds to purine (GA) rich DNA regions and 




GTF2H4, XPA, CCNH, 
ERCC3 
(Reiff et al., 2014) 
PHF8 PHF8 PHD finger protein 8; an X-linked gene coding for a 
histone demethylase that has important functions in 
cell cycle progression, rDNA transcription and brain 
development 
ERCC6, ERCC2, ERCC4, 
XPA, CCNH, ERCC3, 
ERCC8, RAD23B 
(Jihui Qiu et al., 2010; 







 Total RNA isolation was performed using Qiagen’s miRNeasy mini kit according 
to manufacturer’s protocol (as described in Chapter 3). RNA sequencing was performed 
on the cell line pairs in triplicate for each cell line at the Hussman Institute for Human 
Genomics at the University of Miami (as described in Chapter 3) and data analysis of the 
sequencing output was performed as described in Chapter 4. Alignment of reads was 
performed using 3 aligners, GSNAP, HISAT and BWA to gain consensus on the called 
variants and to eliminate artifacts. Variant calling was performed using SAMTools in 
Partek Flowâ, as described in Chapter 4. The GTF file for the gene list in Table 5.1 was 
obtained from the UCSC Table browser (hg38). This was used to filter and include only 
the variants overlapping our genes of interest. Venn Diagrams were constructed using 
Partek Genomics Suiteâ to find variants shared and not shared between the Low: Low 
pair of cell lines, JL NTAL-37 and JL BTL-37, as well as the High: Low pair of cell 
lines, JL NTAL-47 and JL BTL-47. 
5.3 Results 
5.3.1 Variants in the Low: Low pair of cell lines 
 Upon performing variant calling and getting consensus variants using 3 aligners 
as well as a consensus between 3 replicates for each cell line, a total of 55 variants were 
discovered in JL-NTAL-37 and 48 in JL BTL-37. Venn diagrams constructed for the 
variants in this pair showed 44 shared variants among JL NTAL-37 and JL BTL-37 
(Figure 5.1). The characteristics of the variants and the genes they were found in are 
listed in Table 5.2. Shared missense mutations were found in CHECK1, ELF1, TP53 and 




found in ERBB2 with a heterozygous mutant phenotype (Table 5.2). There were 5 
unknown variants found that were shared in the Low: Low pair which were the results of 
indels seen in SP1 (2), ELF1, YY1 and RAD21. No amino acid change was predicted for 
these indels. 
 Among variants not shared in between the Low: Low pair of cell lines, 11 variants 
were seen only in JL NTAL-37. One of these variants was the result of a missense 
mutation in BRCA1 gene with a heterozygous mutant genotype (Table 5.3). In JL BTL-
37, 4 variants were found that were not shared with JL NTAL-37. One unknown variant 
resulting from an indel was also found in ELF1 in the line JL BTL-37. However, none of 







Figure 5.1 Venn diagram showing number of variants in the list of genes in the Low: Low 
pair of cell lines, JL NTAL-37 (= 3) and JL BTL-37 (n = 3). The gray shaded area in the 
middle of the Venn diagram indicates number of variants shared between JL NTAL-37 and JL 
BTL-37 (44). The pink area denotes number of variants just in JL BTL-37 (4) and the green area 
indicates variants only in JL NTAL-37 (11) 




Table 5.2 Characteristics of shared variants between JL NTAL-37 and JL BTL-37, the Low: Low pair. The rows in red indicate variants that 
have a homozygous genotype and showed an amino acid (AA) change. 
Gene No. Of 
Variants 
No. of known 
variants  
No. of variants that showed 
AA change 
Zygosity of variants causing the 
AA change 
USF1 1 1 - - 
ATM 2 2 - - 
CHEK1 1 1 1 (rs506504) Homozygous 
SP1 3 1 - - 
ELF1 4 3 2 (rs1056820; rs7799) Both homozygous  
YY1 4 3 - - 
MAX 8 8 - - 
MAZ 2 2 - - 
ERBB2 1 1 1 (rs1058808) Heterozygous 
TP53 1 1 1 (rs1042522) Homozygous 
JUND 1 1 - - 
STAT1 1 1 - - 
ATR 2 2 1 (rs2227928) Homozygous 
ESR1 1 1 - - 
CDKN1A 7 7 - - 
CDKN2A 1 1 - - 





Table 5.3 Variants present only in the NTA line of the Low: Low pair, JL NTAL-37, and not shared with JL BTL-37. The orange variant is 
also present in the NTA of the High: Low pair, JL NTAL-47 
Gene No. Of 
Variants 
No. of known 
variants  
No. of variants that showed 
AA change 
Zygosity of variants causing the 
AA change 
ATM 2 2 - - 
ELF1 1 1 - - 
YY1 1 1 - - 
BRCA1 1 1 1 (rs1799966) Heterozygous  
E2F1 1 1 - - 
ATR 2 2 - - 
SP4 2 2 - - 
 
Table 5.4 Variants present only in the tumor line of the Low: Low pair, JL BTL-37, and not shared with JL NTAL-37 
Gene No. Of 
Variants 
No. of known 
variants  
No. of variants that showed 
AA change 
Zygosity of variants causing the 
AA change 
ELF1 1 - - - 
SP1 1 1 - - 
CDKN1A 1 1 - - 





5.3.2 Variants in the High: Low pair of cell lines 
A total of 44 variants were discovered each in JL-NTAL-47 and in JL BTL-47. 
Venn diagrams constructed for the variants in this pair showed 25 shared variants among 
JL NTAL-47 and JL BTL-47 (Figure 5.2). The characteristics of the variants and the 
genes they were found in are listed in Table 5.5. Shared missense mutations were found 
in ELF1, ERBB2 and TP53 and all three showed a heterozygous mutant genotype. 
Among variants not shared in between the High: Low pair of cell lines, 19 
variants were seen only in JL NTAL-47. Among the 19 variants, two had amino acid 
changes. One of these variants was the result of a missense mutation in BRCA1 gene 
with a heterozygous mutant genotype, where the other missense mutation was seen in the 
E2F1 gene, and the variant showed a heterozygous phenotype as well (Table 5.6). There 
were 19 variants found exclusively in JL BTL-47 as well, that were not shared with JL 
NTAL-47. Among these, two were the results of missense mutations each in the genes 
SP1 and ATR. The variant in ATR had a homozygous mutant genotype, whereas the one 











Figure 5.2 Venn diagram showing number of variants in the list of genes in the Low: Low 
pair of cell lines, JL NTAL-47 (n = 3) and JL BTL-47 (n = 3). The gray shaded area in the 
middle of the Venn diagram indicates number of variants shared between JL NTAL-47 and JL 
BTL-47 (25). The pink area denotes number of variants just in JL BTL-47 (19) and the green area 
indicates variants only in JL NTAL-47 (19).




Table 5.5 Characteristics of shared variants between JL NTAL-47 and JL BTL-47, the Low: Low pair.  
Gene No. Of 
Variants 
No. of known 
variants  
No. of variants that showed 
AA change 
Zygosity of variants causing the 
AA change 
ELF1 3 3 2 (rs1056820; rs7799) Both heterozygous mutants 
YY1 3 3 -  
MAX 5 5 -  
MAZ 1 1 -  
ERBB2 1 1 1 (rs1058808) Heterozygous 
TP53 1 1 1 (rs1042522) Heterozygous  
JUND 1 1 -  
ATR 3 3 -  
ESR1 1 1 - - 
CDKN1A 2 2 -  
CDKN2A 1 1 -  




Table 5.6 Variants present only in the NTA line of the High: Low pair, JL NTAL-47, and not shared with JL BTL-47. The orange variant is 
also present in the NTA of the Low: Low pair, JL NTAL-37 
 
Gene No. Of 
Variants 
No. of known 
variants  
No. of variants that showed 
AA change 
Zygosity of variants causing 
the AA change 
USF1 1 1 - - 
SP1 1 - - - 
ELF1 1 1 - - 
MAX 1 1 - - 
MAZ 2 2 - - 
BRCA1 2 2 1 (rs1799966) Heterozygous  
JUND 1 - - - 
E2F6 1 1 - - 
STAT1 5 4 - - 
E2F1 1 1 1 (rs3213176) Heterozygous 
ATR 1 1 - - 
SP4 1 1 - - 








Table 5.7 Variants present only in the tumor line of the High: Low pair, JL BTL-47, and not shared with JL NTAL-47. The rows in red 






Gene No. Of 
Variants 
No. of known 
variants  
No. of variants that showed 
AA change 
Zygosity of variants causing the 
AA change 
SP1 3 2 1 (rs200394677) Heterozygous  
ELF1 1 1 - - 
YY1 3 3 - - 
MAZ 1 1 - - 
ERBB2 1 - - - 
STAT1 3 3 - - 
ATR 1 1 1 (rs2227928) Homozygous  




5.4 Discussion  
 Variant calling on the list of important genes in breast cancer revealed some 
interesting findings. First, the Low: Low pair of cell lines had more shared variants (44) 
compared to those between the High: Low pair (25). This suggests that the low DNA 
repair of the NTA for that pair is a mutation enabler. This theory goes with the fact that 
loss in DNA repair mechanisms enables the accumulation of mutations and is a major 
hallmark of cancer (Hanahan & Weinberg, 2000).  
 Among the shared mutations in the Low: Low pair of cell lines, CHEK1, ELF1, 
TP53 and ATR showed a homozygous mutant phenotype resulting from missense 
mutations in those genes and ERBB2 showed a heterogenous mutant phenotype, also 
resulting from a missense mutation in the gene. All these genes have important 
implications in cancer. Mutations in CHEK1, TP53 and ERBB2 have all been associated 
with breast cancer (Table 5.1). ATR activates CHK1 and p53 proteins by 
phosphorylation, thereby also playing an important role in maintenance of genomic 
stability. ATR and CHK1 are being explored as therapeutic targets for cancer, and 
inhibitors for these proteins are being tested (Z. Qiu, Oleinick, & Zhang, 2017). 
 An interesting finding was missense mutations in BRCA1 in both NTA lines, but 
not the tumor lines of the Low: Low as well as the High: Low pairs (Table 5.4 and 5.7). 
Both these NTA lines derived from histopathologically normal tissue adjacent to the 
tumor from two different patients containing the same missense mutation in BRCA1 
indicates that both these women might be carriers for a germline BRCA1 mutation, but 
somehow clonal selection led to the disappearance of this mutation. This is a common 




unfavorable mutations disappear in clonal evolution of cells, and this process is also 
called negative selection of mutations (Goyal et al., 2012; Martincorena et al., 2017). 
 Another interesting finding was the presence of a specific ATR missense mutation 
in all the cell lines with a low repair signature, i.e., JL BTL-37, JL NTAL-37 and JL 
BTL-47. This resulted in a specific known variant in the ATR transcripts, which hasn’t 
been widely studied in literature. However, ATR has been known to promote NER, and is 
required for global genomic repair in cells (Auclair, Rouget, Affar, & Drobetsky, 2008; 
Musich, Li, & Zou, 2017; Shell et al., 2009). Therefore, ATR could be investigated in 
future studies as the master regulator of NER in our early stage breast tumor cell lines 
and also in their matched NTA lines where the repair capacity is low as well. 
 We therefore propose our own multistep model for breast carcinogenesis, 
explaining the clonal expansion of cells harboring abnormal alterations. This model 
emphasizes the field cancerization theories that have been put forth for a number of 
cancer types. Starting from the first mutation that a cell sustains on its path to 
tumorigenesis, there is subsequent proliferation of these cells. This leads to accumulation 
of further step-wise mutations and accumulation of these in populations of cells that are 
now spread out throughout the tissue of origin but are still morphologically and 
histopathologically normal. The final morphology-altering mutation then leads to the 
formation of the first tumor cell, and its clonal expansion leads to the formation of the 
tumor mass (Figure5.3). Based on the mutations found in this chapter as well as the 
methylation analysis and variant calling on NER genes, person specific maps of the 




explain the drivers or master regulators as well as passenger events in breast 






Figure 5.3 The Latimer multistep model for breast tumorigenesis. The green cell in the first panel is the first to sustain an abnormal mutation 
(or mutation like event) which clonally expands to generate a population of these cells. One of these gets another mutation (orange cell) and 
subsequent proliferation and accumulation of mutations takes place until the final mutation alters the phenotype of the cell making it neoplastic 
(blue cell with the large nucleus). This cell clonally expands to generate the tumor mass, thereby leaving behind multiple clonally selected 





Summary and Conclusions 
 In the present thesis, we have identified and studied cell line pairs representing 2 
varieties of non-tumor adjacent breast with their matched early stage breast tumor in 
terms of their ability to perform Nucleotide Excision Repair. Previous studies identified 
Low: Low and the High: Low groups of matched NTA-tumor pairs. The NER capacity 
for tumors was lower than that of breast reduction explants for all early stage tumors and 
that of the NTA was similar to the tumors for the Low: Low pairs. However, NER 
capacity was higher than breast reduction for the High: Low pairs while that of the 
tumors were lower than breast reduction explants. We were able to identify representative 
cell line pairs for each of these groups, where JL NTAL-37 and JL BTL-37 represented 
the Low: Low pair of NTA-tumor lines, and JL NTAL-47 and JL BTL-47 represented 
High: Low pair of cell lines. We performed in-depth molecular analyses on these cell line 
pairs to be able to understand the mechanism of regulation of the NER pathway in these 
specific cell line pairs, with an ultimate aim of establishing a temporal scheme of breast 
cancer with respect to NER.   
 In chapter 3 I show gene expression analyses by microarray and its validation by 
RNA sequencing showed that the expression profiles of the 20 canonical NER genes 
were consistent with their functional repair capacity as measured by the UDS assay. In 
the Low: Low pair, most of the 20 NER genes via microarray analyses (15/20) and none 




However, in the High: Low pair, most of the 20 NER genes via microarray (13/20) as 
well as RNA sequencing (16/20) showed a significantly higher expression in the NTA 
line compared to the tumor line. Therefore, the functional NER capacity of these cell line 
pairs was seen to be consistent with their NER gene expression pattern and these lines 
were deemed to be excellent representatives to study the mechanism of transcriptional 
regulation of the NER pathway. Protein expression consistent with gene expression in the 
NER pathway was not completed for these 2 pairs of cell lines but will be ongoing in the 
laboratory. 
 Differential expression of multiple genes in the pathway indicated an epigenetic 
mechanism of regulation in this pathway. My work in the present study (Chapter 5) 
confirmed the absence of frameshift or nonsense mutations (truncating mutations) in the 
NER genes in these 4 cell lines. The previous work of Dr. As Sobeai in our laboratory 
confirmed that key NER proteins were expressed at the RNA and protein levels similarly, 
in other breast cancer cell lines, so that transcriptional regulation or pre-translational 
regulation seemed to be the most likely possibilities. Finally, the consistent low 
expression of NER genes in the 19 different stage I tumors (As Sobeai, 2017; Johnson, 
2006; Latimer et al., 2010) was also indicative of an epigenetic regulation of the NER 
genes in breast cancer. 
 In Chapter 4, we therefore explored the mechanism of DNA methylation as a 
transcriptional regulator of the NER pathway. DNA methylation was our choice of a 
possible mechanism because previous work in the laboratory showed the 20 NER genes 
to be rich in CpG islands in their promoter regions and also that the expression of 3 genes 




2006).  We performed methylation profiling on our High: Low and Low: Low call line 
pairs using the MethylationEPIC array and did not see any significant correlations among 
gene expression and methylation for our cell line pairs and the control breast reduction 
line JL BRL-6.  
However, upon looking at promoter-level methylation, DDB1 stood out 
significantly differentially methylated among both pairs of cell lines, with the NTA line 
having a higher methylation level than the tumor line of both pairs for DDB1. This is 
exactly the inverse of the expected trend of methylation on DDB1 in the High: Low pair, 
as the expression of DDB1 is higher in the NTA line than the tumor line. In the Low: 
Low pair, DDB1 shows no difference in expression but a significant difference in its 
promoter methylation. The inverse trend of methylation of DDB1 in the High: Low pair 
suggests a possible role of the inhibition of transcriptional repressor binding to the 
promoter region of DDB1. This calls for confirmation of the promoter methylation of 
DDB1and its role in transcriptional regulation in future studies. ERCC5 in the High: Low 
pair and DDB2 and RPA2 in the Low: Low pair showed differential methylation, 
whereas there was no difference in expression of these genes in these pair of cell lines. 
Future studies with a larger sample size could be performed in order to validate these 
findings although confirmation with the proteins encoded by these genes must first be 
performed.  If the proteins do not reflect the gene expression in these early stage breast 
cancer lines and matching NTAL cell lines, there is little point in going any further with 
studies of methylation because the foundation of this work is based on NER function.  
Some protein expression correlation with RNA expression was seen preliminarily with 




 One possible explanation for the lack of correlation between any of the NER 
genes and the methylation patterns (analyzed at the promoter level, gene level and CpG 
island level) is that methylation is not the mechanism by which NER gene and protein 
expression is regulated. It is also possible based on the data generated in As Sobeai, 2017 
that the regulation is not at the transcriptional level but rather pre-translational due to 
elements like microRNAs.  It is also possible that some NER genes are regulated by 
methylation while others are regulated post transcriptionally and pre-translationally but 
these data (Chapter 4) show no agreement with previous Azacytidine experiments that 
did not point to DDB1 or ERCC5.  
In addition to the methylation analyses on whole genes, promoter regions and 
individual CpG sites in the NER genes, we looked for known binding sites of 
transcriptional factors, common to 2 or more NER genes, that might be differentially 
methylated. The promoter regions for these genes as a whole, that contained these 
binding sites, were not differentially methylated, but a more exhaustive examination is 
needed (see appendix for the maps of these promoter regions for all 20 NER genes).  
These binding sites were surveyed in the promoter regions (1500 bp upstream and 500 bp 
downstream of the transcriptional start site). 
 RNA sequencing, primarily performed for validation of gene expression results, 
also allowed us to look for known and unknown single nucleotide variants which might 
be related to putative mutations, within the exons of our 20 canonical NER genes in 
Chapter 4. Although SNP analysis is designed to be performed on large populations, we 
used this analysis to correlate to a known NER phenotype. A future goal is to add more 




matched samples) to these analyses to utilize SNP variant analysis in a more conventional 
way.  This study done in great molecular detail on 2 cases of breast cancer, did however 
identify several important markers such as an ATR variant (shared among only the Low 
repairing samples) that will be followed up in future work.  
In Chapter 5 we examined the transcription factors that were shown to have 
binding sites and were common among at least 3 of the 20 NER genes. Only the most 
stringent evidence of binding was used as a criterion to select that transcription factor.  
Some of these transcription factors were oncogene or tumor suppressor gene related. In 
addition to these factors, a selection of other important oncogenes and tumor suppressor 
genes (with no known direct connection to NER) that have been shown to play a role in 
breast cancer were also examined.  The presence of single nucleotide variants within 
these genes was explored with an aim to find possible associations with mutations. The 
variants were also annotated to see if they were already known as single nucleotide 
polymorphisms (SNPs) in the dbSNP database.  
The words “mutations” and “SNPs” are often used interchangeably in the 2nd 
generation sequencing literature and it is often difficult to distinguish one from the other 
from a small-scale study, as SNPs are more of a population characteristic that represent a 
viable change in the DNA sequence and mutations are defined based on their rarity in a 
given population and are sometimes associated with a phenotype. We therefore confined 
our study to the definition of variants, where we variants that were known as well as 
unknown in literature, and some of these known variants caused downstream changes in 




variants). These are summarized in Chapter 5, and the most important ones are 
summarized in Table 6.1. 
 One of the most notable variants discovered in this study was the ATR gene, 
which is a nodal gene that regulates DNA damage signaling and repair. This particular 
variant was seen in all the cell lines that had a low functional NER capacity, namely JL 
BTL-37, JL NTAL-37 and JL BTL-47, but not in JL NTAL-47 that had NER capacity 
higher than the tumors and similar to the normal breast reduction line. This variant might 
be specific to a low repair signature, thus emphasizing the possible importance of the 
ATR gene in the regulation of NER. ATR phosphorylates important tumor suppressor 
proteins like CHK1 and CHK2, and we also saw a missense variant in CHEK1 gene. This 
variant was shared in the Low: Low pair of cell lines (Table 6.1) (Figure 6.2). Therefore, 
ATR is a putative candidate that can be studied further as a master regulator of the NER 
pathway in our samples.   
Another interesting finding in our variant calling results on the cell line pairs was 
a missense variant in BRCA1 that had a heterozygous genotype (Table 6.1). This variant 
was found in both the NTA lines, JL NTAL-37 as well as JL NTAL-47, but not in the 
tumor lines. A possible explanation would be loss of heterozygosity at the specific locus 
of the variant found in BRCA1. Loss of heterozygosity in the BRCA1 and 2 genes has 
been known as one of the driver events in cancer and has also been shown to be a 
frequent occurrence in breast cancer (Locke et al., 2006; Maxwell et al., 2017). Future 
studies will include confirmation of this possibility via DNA sequencing and copy 




 Missense variants in ERCC2, ERCC5 and ERCC6 were found frequently, shared 
between both the Low: Low and the High: Low pair of cell lines. All these known 
variants have been associated with risks of cancer, with the cancer prone disease XP, as 
well as with Cockayne Syndrome (Table 6.1). SNP association studies with disease and a 
phenotype are generally done with large sample sizes and hence, future studies will 
involve the investigation of the presence of these particular variants in breast tumors and 
their adjacent normal tissues from The Cancer Genome Atlas database. 
 
Figure 6.1 The ATM and ATR pathway of DNA damage signaling and response. ATM 
(Ataxia Telangiectasia mutated) and ATR (ATM and RAD3 related) proteins are damage sensors 
that activate CHK1 and CHK2, which are both serine/threonine kinases. This initiates a DNA 
damage response and cessation of replication upon sensing helix distortion, and single and double 




of cancer. Mutations in ATM, ATR, Chk1 and Chk2 are therefore drivers of carcinogenesis in 
many cancers, including the breast. Reprinted with permission (Ashwell & Zabludoff, 2008). 
 
 Finally, taking into consideration our findings in chapter 4 and 5, we constructed 
person-specific maps delineating the alterations that were shared between the paired cell 
lines, and also the ones that were found exclusively in the tumor or NTA line. The map 
for the Low: Low pair is shown in Figure 6.4 and that for the High: Low pair is shown in 
Figure 6.5. Future studies with a higher sample size will help validate these findings and 
enable us to select the most important alterations to find the etiology of early stage breast 
cancer.  
We are the first group to investigate the role of NER in early stage breast cancer 
and its involvement in tumorigenesis by studying the matched non-tumor adjacent breast 
by measuring direct functional NER capacity and the expression of the canonical NER 
genes. Candidate genes identified in our study will be focused on in future studies in 
order to find marker genes and proteins that could give an insight into the regulation of 

























Figure 6.2 Summary Venn diagrams for visualization of the genes involved in shared alterations between the pair of cell lines used in this 
dissertation. Panel A consists of genes involved in the shared changes in the Low: Low pair (JL NTAL-37 and JL BTL-37) and Panel B is for the 


































































Figure 6.3 Summary Venn diagrams for visualization of the genes involved in shared alterations between cell lines used in this dissertation. 
Panel A consists of genes involved in the shared changes in the NTA lines (JL NTAL-37 and JL NTAL-47) and Panel B is for the genes involved 















































Figure 6.4 Summary Venn diagrams for visualization of the genes involved in shared alterations between cell lines used in this dissertation. 
The shaded area in the middle consists of genes involved in the shared changes in all the lines that showed low functional NER capacity (JL 















Table 6.1 Summary of important shared changes between the cell line pairs belonging to the Low: Low and High: Low groups 
respectively. This table shows that certain variants are shared between each pair are also present in the other cell line pair and might 
indicate universality, which could be verified by future studies on a larger sample size. The variants in bold lettering indicate 
candidates for further studies that are of priority. Blue indicates either the cell line in which the alteration was seen or clinical 
association or a specific notation of the alteration seen with regards to the particular gene. 
 Low: Low High: Low 
JL NTAL-37 JL BTL-37 JL NTAL-47 JL BTL-47 
Low: Low 
 
JL NTAL-37 ERCC2 (rs1799793)- ­ BC, 
Pros. Can., Platinum tox; XP 
ATR (rs2227928) 





rs9514067)- XP, ­ Platinum 
tox 
ERCC6 (rs4253072) 
ERCC2 (rs13181) -­ BC, 
NSCLC, Osteosarc.; XP 
Differential promoter 
methylation for DDB1 (JL 
NTAL-37 ­) 
DDB2 (JL BTL-37 ­ )and 








rs9514067) - XP, ­ 
Platinum tox 
ERCC6 (rs4253072) 
JL BTL-37 ATR (rs2227928), 





rs9514067) - XP, ­ Platinum 
tox 
GTF2H3 (rs1051793) ERCC5 (rs9514066; 
rs9514067) - XP, ­ 
Platinum tox 
ERCC6 (rs4253072) 







 Low: Low High: Low 
JL NTAL-37 JL BTL-37 JL NTAL-47 JL BTL-47 
ERCC6 (rs4253072), ERCC2 
(rs13181) -­ BC, NSCLC, 
Osteosarc.; XP, Differential 
promoter methylation for 
DDB1 (JL NTAL-37 ­), 
DDB2 (JL BTL-37 ­ )and 
RPA2 (JL BTL-37 ­) 
High: Low 
 
JL NTAL-47 BRCA1 (rs1799966)  
ERCC2 (rs13181) -­ BC, 
NSCLC, Osteosarc.; XP 
ERCC5 (rs9514066; 




rs17655)- XP, ­ 
gastric, lung, colorectal, 












methylation for DDB1 
and ERCC5 (JL 
NTAL-37 ­) 
 












 Low: Low High: Low 
JL NTAL-37 JL BTL-37 JL NTAL-47 JL BTL-47 
Differential promoter 
methylation for DDB1 
and ERCC5 (JL NTAL-















Figure 6.5 Map of genetic changes for the patient from which the Low: Low pair of cell lines were derived. The red oval shapes denote 
places from where our tumor and NTA tissues were theoretically sampled. Missense variants found in this chapter in important cancer genes along 
with those found in chapter 4 in the NER genes are included in this person-specific map. Important promoter methylation differences found with 
the help of methylation arrays are also included in this map to make it comprehensive. This map differs from the map of changes for the High: 
Low pair, with the exception of a few commonalities, like a missense variant in ATR, loss of promoter methylation in DDB1, and missense 
variants in TP53, ELF1, ERBB2 that are shared and one in BRCA that is lost en route to the tumor. 
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Need further evidence with more 
sample pairs for: 
 
Loss of heterozygosity for 
BRCA1 
Loss of promoter methylation 
for DDB1, gain of promoter 


















Figure 6.6 Map of genetic changes for the patient from which the High: Low pair of cell lines were derived. The red oval shapes denote 
places from where our tumor and NTA tissues were theoretically sampled. Mutations found in this chapter in important cancer genes along with 
those found in chapter 4 in the NER genes are included in this person-specific map. Important promoter methylation differences found with the 
help of methylation arrays are also included in this map to make it comprehensive. This map differs from the map of changes for the Low: Low 
pair, with the exception of a few commonalities, like mutations in ATR, loss of promoter methylation in DDB1, and missense mutations in TP53, 
ELF1, ERBB2 that are shared and one in BRCA that is lost en route to the tumor. 
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Appendix A: R code used for analysis of data from the MethylationEPIC arrays 
using RnBeads 
library(RnBeads) 
data.dir <- "~/Desktop/Manasi/All IDAT files/Analysis excluding 
BRL2" 
idat.dir <- file.path(data.dir) 
sample.annotation <- file.path(data.dir, 
"Sample_Sheet_NoBRL2.csv") 
analysis.dir <- "~/Desktop/Manasi/All IDAT files/Analysis 
excluding BRL2" 
report.dir <- file.path(analysis.dir, "RnBeadsreport_Feb192018") 
rnb.options(identifiers.column="Sample_Name") 
data.source <- c(idat.dir, sample.annotation) 
result <- rnb.run.import(data.source=data.source, 
data.type="infinium.idat.dir", dir.reports=report.dir) 
rnb.set <- result$rnb.set 
rnb.run.qc(rnb.set, report.dir) 
any.bad.p.val <- apply(dpval(rnb.set)>0.01, 1, any) 
rnb.set3 <- remove.sites(rnb.set, any.bad.p.val) 
rnb.set3_p_cont <- rnb.execute.context.removal(rnb.set3)$dataset 








rnb.set.norm <- rnb.execute.normalization(rnb.set6_var, 
method="bmiq") 
rnb.get.annotation("genes", assembly = "hg19") 
rnb.get.annotation("promoters", assembly = "hg19") 





Ner_genes <- c("XPA", "ERCC3", "XPC", "ERCC2", "DDB2", "ERCC4", 
"ERCC1", "ERCC5", "ERCC6", "ERCC8", "RPA1", "RPA2", "RPA3", 





















Appendix B: Maps for promoter regions for the 20 NER genes using UCSC Genome browser (defined in the analysis of data 
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